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1.1. Hodgkin lymphoma- an overview 
Introduction 
Hodgkin lymphoma (HL) is a malignant disease which accounts for around 30% of 
all lymphomas (WHO 2001 ). The disease is characterised by the presence of 
Hodgkin and Reed-Sternberg (HRS) cells, the proposed malignant cells of the 
disease, in a polymorphous cellular background. The presence of these cells 
within an appropriate cellular background is necessary for the diagnosis of HL as 
Reed-Sternberg-like cells are also found in other conditions (Strum et al., 1970). A 
striking feature of this disease is the scarcity of the malignant cells usually less 
than 1 % within the tumour mass. The rarity of these cells has made 
characterisation of this disease a difficult task for researchers. Advances in 
molecular techniques over the last decade have enabled HL research to move 
forward substantially as will be discussed in subsequent sections of this thesis. 
The disease was first described in 1832 by Thomas Hodgkin after a study involving 
the examination of seven lesions of the lymphatic glands and spleen (Hodgkin 
1832). The term Hodgkin's disease (HD) was applied some 30 years later 
following examination of cases for clinical and gross pathological findings (Wilks 
1865). The histology of HD was first described by Sternberg in 1898 and detailed 
further by Reed in 1902 (Sternberg 1898;Reed 1902). The authors described the 
large bi-lobed or multinucleated cells which are characteristic of the disease. Both 
also believed the disease was infectious in nature; Sternberg proposed a 
Mycobacterial infection and Reed some other unknown agent. In more recent 
years the characterisation of the HRS cells as being derived from pre-apoptotic 
germinal centre B-cells has led to this disease entity being named HL as opposed 
to HD but these terms are synonymous (Kuppers et al., 1994;Kuppers and 
Rajewsky 1998). 
Around 90% of HL patients are cured from the disease however treatment 
strategies lead to late complications in long term survivors (Draube et al., 2006). 
These include secondary malignancies, loss of fertility, cardiovascular and lung 11 
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diseases (Ng and Mauch 2004). Although the cure rate is high in HL some patients 
still have a poor prognosis; therefore, an improvement in cure rate and reduction in 
long term toxicity is desirable and perhaps attainable if novel treatment strategies 
can be employed (Connors 2005). 
1.2. Classification of HL 
HL is subdivided into two distint entities know as classical HL (cHL) and Nodular 
Lymphocyte-Predominant HL (NLPHL) (Harris et al., 1994). The World Health 
Organisation has classified cHL further into 4 subtypes based on the 'Revised 
European-American Classfication of Lymphoid neoplasms'. These are nodular 
sclerosis (NS), mixed cellularity (MC), lymphocyte-rich classical (LRC) and 
lymphocyte depleted (LD) HL. (Harris et al., 1994;WHO 2001 ). The descriptive 
features of NLPHL and cHL are given below thus highlighting the distinction 
between these disease entities; however, the focus of this thesis is on cHL. 
Nodular Lymphocyte Predominance HL 
NLPHL accounts for around 5% of all HLs. Sites of presentation include the 
axillary, cervical or inguinal lymph nodes. Involvement of the spleen, mediastinum 
or bone marrow is rare (WHO 2001 ). This very distinctive subtype is characterised 
by the presence of " popcorn" or lymphocytic and/or histiocytic (L&H) cells and 
these neoplastic B-cells are scattered in nodular or nodular and diffuse infiltrates 
containing histiocytes and small lymphocytes. In the majority of cases the L&H 
cells are positive for CD20, CD79a, Ki-67, BCL6 and CD45 (WHO 2001 ). A large 
proportion of cases are also CD75 positive (Anagnostopoulos et al., 2000). In 
contrast to cHL, the L&H cells are generally CD15, TARC (CCL17) and CD30 
negative although CD30 positivity is sometimes present (WHO 2001 ). A 
characteristic feature is that CD3+ and CD57 + T cells surround most of the L&H 
cells. The transcription factor Oct 2 is expressed in L&H cells in conjunction with 
its co-actvator BOB.1 (Laumen et al., 2000;Stein et al., 2001 ). Oct 2 and BOB.1 
12 
Introduction 
may be useful in the differential diagnosis between NLPHL and cHL as tumour 
cells in cHL cases do not co-express these proteins. Identical immunoglobulin (lg) 
gene rearragements can be detected in the L&H cells from a given case and 
analysis of the lg heavy chain variable regions shows evidence of ongoing somatic 
hypermutation. lg mRNA transcripts are detectable and rearrangements appear 
functional in the majority of L&H cells (Marafioti et al., 1997;Kuppers et al., 1998). 
The postulated cell of origin in NLPHL is the germinal centre 8-cell at the 
centroblastic stage of differentiation. In contrast to a proportion of cHL cases, the 
L&H cells of NLPHL show no evidence of latent Epstein-Barr virus (EBV) infection 
(Anagnostopoulos et al., 2000). NLPHL is a relatively indolent disease compared 
with cHL (Orlandi et al., 1997). 
Classical HL 
cHL accounts for 95% of all Hls. The common sites of presentation in the lymph 
nodes are the cervical region followed by the mediastinal, axillary and paraaortic 
regions. Mediastinal involvement is frequently associated with the NS subtype 
whereas in the MC subtype abdominal and splenic involvement are relatively more 
common. In 40% of patients constitutional 'B' symptoms including tiredness, 
weight loss, fever and night sweats are also present (Selby and McElwain 1987). 
The neoplastic tissue in all subtypes of cHL is composed of mononuclear HRS 
cells in a polymorphous cellular background. This background contains 
lymphocytes, histiocytes, plasma cells, neutrophils, fibroblasts, collagen fibres and 
eosinophils. The HRS cells in cHL have identical genetic and immunophenotypic 
features, however, the characteristics of the infiltrate, the morphology of the HRS 
cells and association with EBV differ between the subtypes (WHO 2001 ). The 
characteristic immunophenotype of the HRS cell is CD30+ in virtually all cases 
(Stein et al., 1981 ;Stein et al., 1985) and CD15+ in the majority of cases (Stein et 
al., 1981 ;Stein et al., 1982). CD20 can be detected in around 40% of cases but 
this is variable and only a minority of neoplastic cells are positive. J chain is 
consistently negative as is CD75 and macrophage specific markers. CD80, CD86, 13 
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CCL17 and FSCN1 (dendritic cells), MUM1 (plasma cells) and GATA-3 and T-bet 
(T-cells) are also detected (Re et al., 2005;Atayar et al., 2005). Generally CD45 is 
negative and the B-cell associated antigen CD79a is rarely detected on the HRS 
cells. 
B-cell specific activator protein, which is a product of the PAX5 gene, has been 
detected in the majority of cases in most studies (Foss et al., 1999). This B-cell 
commitment and maintenance transcription factor is present even though most 
typical B-cell genes are down regulated in HRS cells (Schwering et al., 2003b). 
Another regulator of the B-cell specific gene expression programme, E2A, is also 
usually expressed by HRS cells but most of its target genes are not expressed 
(Hertel et al., 2002;Mathas et al., 2006). Detection of the transcription factor Oct2 
and/or its co-activator BOB.1 is absent (Stein et al., 2001 ). A recent study showed 
expression of MAL, a gene overexpressed in mediastinal (thymic) large B-cell 
lymphoma in a proportion of cHL cases; expression correlated with the NS subtype 
of the disease and poor prognosis (Hsi et al., 2006). MAL mRNA was originally 
identified during T-cell development and encodes a proteolipid believed to 
participate in membrane microdomains transport machinery, stabilization and 
signal transduction (Gopie-Bergman et al., 2002). 
The HRS cells of cHL overexpress a variety of cytokines and chemokines which 
may enable them to create their own microenvironment and subsequently increase 
their growth and survival (Skinnider and Mak 2002). Expression of Interleukin (IL)-
2, IL-5, IL-6, IL-7, IL-9, IL 10, IL-13 and IL 13 receptor, transforming growth factor-13 
(TGF-13), lymphotaxin-a, granulocyte macrophage colony-stimulating factor, eotaxin 
and CCL 17 can be detected (Kadin et al., 1990;Samoszuk and Nansen 
1990;Herbst et al., 1996;Kapp et al., 1999;Teruya-Feldstein et al., 1999;van den 
Berg et al., 1999;Jones et al., 2000;Skinnider et al., 2001 ). The increased 
expression of eotaxin may partially explain the presence of many eosinophils within 
some HL tumours (Teruya-Feldstein et al., 1999) and the fibrosis seen may be due 
to TGF-13 (Kadin et al., 1990). A recent report suggests that IL-9 is related to the 
14 
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presence of eosinophils and mast cells in HL and is important in inflammatory 
infiltrate formation (Glimelius et al., 2006). 
HRS cells also express a number of molecules which are important for T-helper 
(Th) cell-B cell interaction. The T-cell infiltrate which consists primarily of Th2 cells, 
surrounding the HRS cells may result from increased expression of CCL 17 (van 
den Berg et al., 1999). These T cells often rosette around the HRS cells and may 
be contributing to an environment that favours survival of the HRS cells. The recent 
demonstration of an abudance of regulatory T-cells in HL, which induce an 
immunosuppressive environment, may explain the ineffective clearance of HRS 
cells by the immune system (Marshall et al., 2004). In addition, attraction of 
lymphocytic subsets to the HRS cell micro environment by chemokines may lead to 
differences in the distinctive subtypes of HL (Poppema and van den Berg 
2000;Maggio et al., 2002). 
Studies of oncogenes and tumour suppressor genes in the pathogenesis of cHL 
have been hampered by the scarcity of the HRS cells within a tumour mass. 
Advances in microdissection techniques and molecular analyses have enabled a 
more comprehensive investigation of the HRS cells. Investigation for 
translocations of the proto-oncogenes bcl-2 and bcl-6 showed that they are rarely 
detected in HRS cells (Gravel et al., 1998;Seitz et al., 2001 ). Only few cases 
showed mutations of the tumour suppressor p53 (Montesinos-Rongen et al., 1999). 
Chromosomal gains have been demonstrated in cHL frequently involving 2p, 9p, 
12q, 16p, 17q and 20q with a loss of 13q (Joos et al., 2003;Chui et al., 2003). The 
proposed target genes of 2p, 9p and 12q are c-REL, JAK2 and MDM2 respectively 
(Kupper et al., 2001 ;Joos et al., 2003). The nuclear localisation of c-REL 
correlates with the gain of 2p and this may be contributory to constitutive NF-KB in 
cHL (Barth et al., 2003). 
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1.3. Origin of the HRS cell 
For many years the origin of the HRS cell was unknown. Earlier studies 
attempting to clarify if HRS cells were of lymphocytic origin, used both polymerase 
chain reaction (PCR) and Southern blot analysis to analyse DNA extracted from 
whole HL tumour tissue and gave inconclusive results (Gledhill et al., 1990;Tamaru 
et al., 1994;Manzanal et al., 1995;Orazi et al., 1995;Yatabe et al., 1996;al Saati et 
al., 1997). Micromanipulation of HRS cells from frozen tissue sections and 
subsequent lg gene PCR showed that the HRS cells were clonal B-cells (Kuppers 
et al., 1994;Kanzler et al., 1996a). The number of HL cases in these studies was 
small although a larger study confirmed these findings (Kanzler et al., 1996b). The 
detection of mutations rendering the lg genes non functional and the high number 
of somatic mutations led to the conclusion that the HRS cells were derived from 
pre-apoptotic GC 8-cells. HRS cells do not express B-cell receptor (BCR) which 
would signal cell death in normal 8-cells. The HRS cells do survive the germinal 
centre reaction and are therefore resisting apoptosis (Marafioti et al., 2000). 
Despite a 8-cell origin downregulation of 8-lineage specific gene expression has 
been demonstrated in HRS cells (Schwering et al., 2003b). This loss of B-cell 
phenotype may help explain the survival of HRS cells without a BCR as discussed 
further in section 1.9. 
Two studies also describe the rare detection of T-cell receptor gene 
rearrangements in cHL and conclude that the disease can infrequently exist as a T­
cell lymphoma (Seitz et al., 2000;Muschen et al., 2000a). 
1.4. Epstein-Barr virus 
Biology of EBV 
Epstein-Barr virus (EBV) is a human B-lymphotropic herpesvirus which is carried in 
a persistent state by over 90% of the world population. The virus was originally 16 
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identified in cultured lymphoblasts derived from Burkitt's lymphomas (BLs) of 
African patients (EPSTEIN et al., 1964). Primary infection generally occurs in early 
childhood and is asymptomatic. Late exposure and primary infection of the virus in 
adolescence or young adulthood results in the onset of infectious mononucleosis 
(IM)/glandular fever in approximately 25% of cases (Crawford et al., 2006). 
EBV is a y herpesvirus and all members of this subfamily of herpesviruses have 
the ability to replicate in lymphoid cells in vitro. There are two distinct phases of 
the herpesvirus lifestyle known as lytic and latent phases. In the lytic cycle, viral 
particles are produced and the host cell DNA protein synthesis can be shut of 
leading to host cell death (Wagner and Roizman 1969). The ability to establish a 
latent infection, in which a limited number of viral genes are expressed, is 
characteristic of herpesviruses. 
EBV latent gene expression 
In B-cells three patterns of expression of the EBV latent proteins have been 
described, designated Lat I, Lat II and Lat Ill. In Lat I only the EBV nuclear antigen 
(EBNA)-1 protein is expressed. In Lat 11, both EBNA-1 and the latent membrane 
proteins (LMPs) are expressed and in Lat Ill all of the EBV latent gene products are 
present (Rowe et al., 1992). Various malignancies have been associated with 
different patterns of EBV gene expression. Lat I expression is seen in BL (Rowe et 
al., 1992) whereas Lat Ill latency is generally observed in lymphomas in 
immunosuppressed persons and lymphoblastoid cell lines (Young et al., 1989). In 
undifferentiated nasopharyngeal carcinoma an intermediate pattern or Lat II is 
described (Young et al., 1988). 
Mechanisms of HRS cell survival in EBV-associated HL 
EBV is detected in and localised to the HRS cells in a proportion of HL patients, 
which varies in relation to geographical local (Armstrong et al., 1992;Jarrett et al., 
1996). EBV detected in HL lesions is clonal indicating infection and expansion of a 
single cell (Weiss et al., 1987;Jarrett et al., 1991 ;Pallesen et al., 1991 a). These 17 
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cases are deemed EBV-associated (Armstrong et al., 1992). The latent gene 
products EBNA1, LMP1 and LMP2 are expressed with a lack of EBNA 2 giving a 
Lat II pattern of expression (Pallesen et al., 1991 a). 
It is now widely accepted that EBV is involved in the pathogenesis of the EBV­
associated cases of HL (IARC 1997). The EBV LMP-1 is expressed in these cases 
and LMP-1 has been shown to transform rodent fibroblasts in vitro. It is therefore 
likely that this major transforming protein of EBV is involved in the transformation of 
HRS cells. A key function of LMP-1 is it mimics an activated CD40 receptor 
leading to activation of the transcription factor NF-KB (Kilger et al., 1998). 
Expression of LMP-1 in the EBV-associated cases of HL is therefore an additional 
method of NF-KB activation (Eliopoulos et al., 2003). NF-KB is discussed further in 
section 1.5. The expression of LMP2a by EBV may also play a role in the rescue 
of HRS cells by mimicking a BCR. The survival of LMP2a transgenic B-cells has 
been demonstrated in the absence of a BCR (Caldwell et al., 1998;Casola et al., 
2004). Three independent studies have also recently demonstrated that EBV has 
the ability to rescue BCR-deficient germinal centre B-cells from apoptosis (Mancao 
et al., 2005;Chaganti et al., 2005;Bechtel et al., 2005). These studies add 
substantial support to the idea that EBV plays a role in rescuing HRS cells, or their 
precursors, from apoptosis in germinal centres. 
1.5. Other mechanisms of HRS cell survival 
The exact mechanism responsible for the survival of the HRS cells in cHL is still 
unclear however a number of factors are known to be involved in their rescue from 
apoptosis. 
De-regulated expression of inhibitors of apoptosis (IAP) family members may 
confer apoptosis resistance in HL. The HRS cells of cHL co express CD95 (Apo-
1/FAS) and CD95L (Metkar et al., 1999;Verbeke et al., 2001 ). Apoptosis of normal 
18 
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GC B cells is in part due to CD95 signalling (Liu et al., 1997); however, HRS cells 
appear resistant to CD95 mediated apoptosis (Re et al., 2000). In a small number 
of cases this can be explained by the presence of CD95 gene mutations (Muschen 
et al., 2000b). A more frequent scenario is likely to be the inhibition of CD95 
signalling by cFLIP expression in HRS cells (Mathas et al., 2004). HRS have also 
been shown to express the X-linked inhibitor of apoptosis (XIAP), which inhibits 
activation of caspase-3 mediated cell death (Kashkar et al., 2003). Expression of 
clAP1, clAP2 (Zheng et al., 2004) and survivin (Garcia et al., 2003) have also been 
demonstrated to a variable extent in HL cell lines and primary tissue. A more 
recent study found that clAP2 is expressed in the HRS cells in 20 of 23 cases of 
cHL cases by in situ hybridisation and that this inhibitor of caspase 3 is inducible by 
CD30 stimulation. The authors further suggest that clAP2 contributes to apoptosis 
resistance in HRS cells and that newly developed IAP inhibitors may be beneficial 
for the treatment of patients with cHL (Durkop et al., 2006). 
NF-KB is a transcription factor that regulates the expression of many effector 
molecules including growth factors, cytokines and anti-apoptotic proteins in 
response to ligation of surface receptors. It is now widely accepted that 
constitutive activation of NF-KB in the HRS cells plays a critical role in escape from 
apoptosis. Both cFLIP and XIAP are NF-KB target genes and therefore constitutive 
NF-KB activity in HRS cells may well be responsible for the anti-apoptotic 
phenotype of the HRS cells (Re et al., 2005). There are several mechanisms of 
activation of NF-KB in cHL which include LMP-1 expression, c-REL amplification, 
IKBa mutation/deletion and constitutive CD30 signalling (Emmerich et al., 
1999;Horie et al., 2002;Joos et al., 2003;Emmerich et al., 2003;Grimm et al., 
2005;Osborne et al., 2005;Uchihara et al., 2006). In addition to CD30, CD40 
(Gruss et al., 1994) and RANK (Fiumara et al., 2001) are two other members of the 
TNF receptor family that are expressed on HRS cells and may be contributory in 
HRS cell survival by activating NF-KB. Future studies on the exact mechanisms of 
NF-KB activation in cHL are important for both our understanding of disease 
pathogenesis and the development of novel therapies. 
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The overexpression of particular cytokines and chemokines in HL has been 
discussed above. Notably both IL 13 and IL 13 receptor are expressed by HRS cells 
and this appears to result in autocrine proliferation (Kapp et al., 1999). Functional 
experiments from HRS cells lines have confirmed the importance of IL-13 as an 
autocrine growth factor in HL (Skinnider and Mak 2002;Trieu et al., 2004). There is 
increasing evidence that loss of function of suppressor of cytokine signalling 
(SOCS)-1 is involved in the progression of several cancers (Rottapel et al., 
2002;Sutherland et al., 2004). More recently a specific function of STAT3, SOCS1 
and SOCS3 in the proliferation and survival of cHL cells has been reported (Baus 
and Pfitzner 2006). They stated that downregulation of STAT3 by siRNA 
expression decreased cell proliferation and induced apoptosis. Overexpression of 
SOCS1 and SOCS3 resulted in a proliferation arrest of cells with limited 
endogenous amount of these negative regulators, but not in cells that already 
express high amounts of SOCS1 and SOCS3. In addition, SOCS1 mutations have 
been detected in the HRS cells of 8/19 cHL samples and it has been suggested 
that this defective tumour suppressor is triggering an oncogenic pathway in HL 
(Baus and Pfitzner 2006). 
The transmembrane receptor Notch 1 when activated initiates expression of 
multiple genes in the nucleus of the cell. Notch1 is expressed at high levels in the 
HRS cells of cHL but is absent in normal B-cells. Triggering of Notch 1 in HL 
derived cell lines initiates a strong proliferation signal indicating that this may be 
involved in maintaining the HRS cells in vivo (Jundt et al., 2002a). 
Deregulation of receptor tyrosine kinases (RTKs) is frequently involved in 
transformation (Blume-Jensen and Hunter 2001 ). In a recent study, 6 different 
RTKs were shown to be expressed and activated in the tumour cells of cHL, 
particularly in the NS subtype. The authors suggest that the use of tyrosine kinase 
inhibitors may be of therapeutic use in these cases (Renne et al., 2005). 
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Introduction 
Early epidemiological studies show a bimodal age incidence curve for HL although 
the age specific incidence peaks occur in different age groups in different situations 
(MacMahon 1966). Differences in age-specific incidence curves led to the 
suggestion that at least three epidemiological patterns of HL exist (Correa and 
O'Conor 1971 ). 
In developing countries the first peak of the bimodal curve occurs in childhood, 
there is a decrease in incidence in the third decade and a second peak occurs in 
older age groups. In developed countries, there is a low incidence in childhood, 
but this increases with age resulting in a pronounced peak in young adulthood (15-
34 years). The incidence declines in the fourth decade and in older years a 
gradual increase or plateau is observed (McKinney et al., 1989;Glaser and Swartz 
1990). An intermediate pattern is found in rural areas of developed countries, in 
central Europe and in the southern United States (Correa and O'Conor 
1971 ;Alexander et al., 1991 a). 
NSHL has a unimodal age incidence and accounts for the young adult peak seen 
in developed countries. In early childhood, NSHL is relatively less common. The 
other subtypes, in particular MCHL show an increasing incidence with age (Glaser 
and Swartz 1990 ;Alexander et al., 1991 a). 
Several hypotheses have been suggested to explain the epidemiological features 
of HL. MacMahon observed that different age groups 0-14 years, 15-34 years and 
50 years and over, had different features of the disease associated with the age at 
onset. He therefore proposed that HL was a heterogeneous condition and that the 
three groups had different aetiologies (MacMahon 1966). Epidemiological studies 
have since confirmed that the risk factors for the young adult and older age groups 
differ giving rise to a "two disease" hypothesis (Correa and O'Conor 
1971 ;Gutensohn 1982 ;Alexander et al., 1991 a). 
21 
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Another not mutually exclusive model exists that suggests that HL results from 
delayed exposure to a common infectious agent. Epidemiological studies have 
shown an increased risk of developing HL in individuals with a high socio-economic 
status in childhood (Alexander et al., 1991 b). It had been suggested that persons 
lacking early social contact may have escaped infection with common childhood 
infections until later in life (Gutensohn and Cole 1977). An extension of this model 
suggested that HL in childhood in developing countries and young adult cases in 
developed countries are caused by the same infectious agents(s) (Correa and 
O'Conor 1971 ;Gutensohn and Cole 1981 ). This theory has not been substantiated 
in subsequent studies (Macfarlane et al., 1995). It was shown that the risk ratios of 
HL tended to be lower for men who had experienced various common contagious 
diseases in childhood (Paffenbarger et al., 1977). Another study supports this 
previous evidence that early exposure to infection protects against HL although 
adds that a previous history of infectious mononucleosis (IM) increases subsequent 
risk (Alexander et al., 2000). It has now been shown that children who attend 
nursery school and day care seem to have a decreased risk of developing young 
adult HL, most likely due to childhood exposure to common infections, and the 
subsequent maturation of cellular immunity. This finding supports the delayed 
infection model of HL aetiology in young adults but also introduces the determinant 
of age at infection (Chang et al., 2004). 
EBV and the epidemiology of HL 
Since EBV was associated with a proportion of HL cases it appeared plausible that 
this may be the infectious agent that would fit the model proposed by Gutensohn 
and Cole as described above. However, early studies showed that EBV was not 
associated with young adult cases when compared to other age groups (Jarrett et 
al., 1991 ). EBV is therefore not the agent responsible for the young adult 
incidence peak seen in developed countries. Based on the above epidemiological 
data it is this group of HL patients which is of particular interest when looking for 
other infectious aetiologies. 
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Further studies have clarified the link between EBV status and age at diagnosis. 
UK data from young and older adults support the idea that these two groups have 
different aetiologies (Armstrong et al., 1993;Armstrong et al., 1998a). Paediatric 
cases from different geographical locales were also shown to be EBV-associated, 
particularly with children under 1 O years of age. These data led to the proposal of 
a "three disease model" which supported MacMahons original theory (MacMahon 
1966). The first group comprises paediatric cases (particularly under 1 O years) 
which are EBV-associated and often of the MC subtype; the second group is also 
EBV-associated and is found in older adults mainly with MC subtype; the third 
group are non EBV-associated and comprise mostly young adults of the NS 
subtype. 
Infectious mononucleosis and HL 
Evidence from two population based studies has help clarify the relationship 
between EBV and HL (Alexander et al., 2000;Alexander et al., 2003). Previous 
studies had shown that young adults who had a past history of IM were three times 
more likely to develop HL (Gutensohn and Cole 1980). The findings from 
Alexander et al confirmed that in general, IM is associated with an increased risk of 
developing HL. Prior IM also confers an·� additional risk of developing EBV­
associated HL in young adults (Alexander et al., 2000). In these cases it is 
believed that the IM and EBV-associated disease are causally linked (IARC 1997). 
One study failed to confirm these findings and reported a dissociation between IM 
history and EBV-positivity, in that almost all of the cases with a history of IM were 
EBV-negative (Sleckman et al., 1998). In support of the majority of the literature an 
association between IM-related EBV infection and the EBV-positive subgroup of 
HL was subsequently reported as likely in young adults (Hjalgrim et al., 2003). 
These data have suggested a "four disease model" (Jarrett 2002). The fourth 
entity described encompasses EBV-associated cases following delayed infection 
with EBV. The model consists of three EBV-associated groups and one group that 
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is non- EBY-associated. The EBV-associated peak in the 15-34 year age group 
(young adults) represents cases that are associated with delayed exposure to EBV. 
1.7. Other viruses and cHL 
The exact transforming event in the EBV-negative cases remains unsolved. It has 
been suggested that a hit-and-run scenario involving EBV is possible. There is 
persuasive epidemiological evidence that infectious agent(s) are involved in young 
adult HL in developed countries (section 1.6.). Likely candidates are ubiquitous 
viruses that infect individuals at older ages in developed countries in comparison 
with developing countries. Members of the polyomavirus and herpesvirus family fit 
into this category. No evidence of the polyomaviruses LPV, JC, BK and SV40 
viruses was detected in DNA from HL cases (Armstrong et al., 1998b;MacKenzie et 
al., 2003). Cytomegalovirus, human herpesvirus (HHV)-6, -7 and -8 have not been 
consistently detected within HL lesions however HHV-6 and -7 are frequently 
detected at low copy number presumably in bystander cells (Jarrett et al., 
1988;Gledhill et al., 1991 ;Torelli et al., 1991 ;Khan et al., 1993;Secchiero et al., 
1998;Berneman et al., 1998;Cozen et al., 1998;Armstrong et al., 1998b). 
The measles virus has also been implicated as a candidate virus in a proportion of 
HL cases (Benharroch et al., 2003). These results however remain controversial 
and have not been confirmed (our unpublished data and personal communication 
R.Kuppers). 
A tentative link has also been suggested between TT viruses and HL. The 
hypothesis proposed by the authors leaves many questions unanswered. Further 
investigative studies on the role of TTVs in HL may help clarify these observations 
(zur Hausen and de Villiers 2005). 
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The aetiology of cHL is still not completely understood however a combination of 
both genetic and environmental factors are implicated. A familial predisposition is 
most evident in monozygotic twins where the co-twin has a risk of developing HL 
which is 99 times higher than that shown for dizygotic twins (Mack et al., 1995). 
Ethnic variation is also observed in the incidence of HL which is also supportive of 
a genetic predisposition (Glaser and Jarrett 1996;Glaser and Hsu 2002). The 
genetic predisposition appears in part related to immune function in HL with a 
number of HLA associations having been reported (Hors and Dausset 1983;Taylor 
et al., 1999;Alexander et al., 2001 ;Harty et al., 2002). The role of specific HLA 
alleles and haplotypes is however not clearly defined in HL and because of linkage 
disequilibrium in the HLA region any association may not be causal. 
The most notable environmental factor in the pathogenesis of HL is EBV. Recent 
studies have shown that genotypic markers in HLA class I and HLA class Ill are 
associated with HL susceptibility. Detection of specific microsatellite markers in the 
HLA class I region is associated with EBV-positive HL. This suggests that the 
presentation of EBV-derived peptides could be important in the pathogenesis of 
EBV-positive HL (Diepstra et al., 2005). Further mapping of the HLA regions is 
essential to identify susceptible loci in HL and the role of antigen presentation in 
the disease pathogenesis (Poppema 2005). 
1.9. Gene expression studies in HL 
A number of studies have attempted to determine the overall gene expression 
profile of HRS cells, the majority of which have used cHL-derived cell lines (Kapp 
et al., 1999;van den Berg et al., 1999;van den Berg et al., 2000;Kuppers et al., 
2003;van den Berg et al., 2003;Schwering et al., 2003a;Schwering et al., 
2003b;Janz et al., 2006;Staber et al., 2006) or whole cHL tissue (Devilard et al., 
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2002;Sanchez-Aguilera et al., 2006). Two studies have used isolated HRS cells to 
perform gene expression profiling of cHL (Gossman et al., 1999;Karube et al., 
2006). 
The first study to use single HRS cells for a global gene expression profiling 
sequenced a large number of expressed sequence tags however the tag profile 
was a mixture between cHL and NLPHL cells which differ significantly in 
expression profile (Gossman et al., 1999). The expression profile generated 
supported a B-cell lineage for HRS cells, but subsequent studies have shed doubt 
on whether the 'primary tumour' cells were bona fide HRS cells. 
The use of the serial analysis of gene expression (SAGE) technique demonstrated 
the extremely high expression of the chemokine CCL 17 from HRS cells and 
highlighted the possible role it may have in attracting Th2 cells to the surrounding 
infiltrate (van den Berg et al., 1999). In a subsequent SAGE study the B-cell 
receptor inducible gene BIC was identified in all subtypes of HL (van den Berg et 
al., 2003) which led to the investigation and detection of the mature microRNA-155 
in HL cell lines and tissue samples (Kluiver et al., 2005). 
In comprehensive studies using SAGE and DNA microarrays the loss of the B­
lineage specific gene expression program was demonstrated in the HRS cells of 
cHL (Kuppers et al., 2003;Schwering et al., 2003a;Schwering et al., 2003b). Down 
regulation of these genes affect multiple pathways in B-cells including BCR 
signalling . As the B-cell transcriptional activator PAX5 is expressed in most HRS 
cells and many of its target genes are down regulated the authors checked for 
mutations of PAX5 in HL cell lines without success. There are a number of 
mechanisms that may explain the lack of B-cell phenotype in HRS cells; the 
expression of LMP2A in EBV-positive cHL cases (Portis et al., 2003); the down 
regulation of B cell transcription factors (Stein et al., 2001 ;Jundt et al., 2002b); 
overexpression of the proteins ABF-1 and ld2 which downregulate B-cell specific 
genes although induce other lineage markers in HRS cells (Mathas et al., 2006) 
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and gene silencing by methylation of 8-cell specific genes (Ushmorov et al. , 2006). 
This lack of B-cell identity may help explain the survival of HRS cells lacking a 
BCR. 
In an additional study using microarrays on 4 HL cell lines, twenty seven genes 
previously not shown to be expressed in HRS cells were aberrantly expressed, 
among which were GATA-3, ABF1, EAR3 and Nrf3 (Kuppers et al., 2003). These 
newly identified genes may be involved in the pathogenesis of HL and could 
represent novel diagnostic markers that may be considered as therapy targets. In 
a recent gene expression study of cytokines and chemokines from microdissected 
primary HRS cells high expression of IL-11 receptor a was detected (Karube et al., 
2006). IL-11 receptor is known to activate the JAK/STAT pathway and therefore 
may be associated with a maligant phenotype. 
Further gene expression studies are required using primary HRS cell material to 
clarify the complex gene expression profile of HRS cells in cHL and perhaps 
identify candidates involved in the disease pathogenesis. 
1.10. Thesis overview 
The mechanisms of transformation in HL are still not completely understood 
however advances over the last decade in micromanipulation of HRS cells and 
advanced molecular techniques have enabled more understanding and 
characterisation of this complex lymphoma. Unravelling the transformation process 
and key elements involved in the disease may lead to new and improved treatment 
strategies in the future. 
Chapter 2 discusses the significance of EBV DNA that is present in the serum of 
EBV-associated cases of HL and compares this with the non-associated cases and 
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normal healthy controls. The relevance of the results as a prognostic marker is 
also evaluated. 
Chapter 3 looks at the "hit and run" hypothesis suggested for the role of EBV in the 
non-EBV-associated cases of the disease. It has also been suggested that 
integrated fragments of the normally episomal EBV genome may persist in EBV­
negative cases. This study aims to tackle these points comprehensively using a 
combined serologic and molecular approach. 
Chapters 4 and 5 describe the use of degenerate PCR strategies for the 
investigation of known and novel herpesviruses and polyomaviruses that may be 
present in cHL DNA. Implications for the EBV-negative cases of cHL are 
discussed. Following on from this Chapter 6 covers molecular methods for virus 
discovery encompassing those techniques employed in chapters 4 and 5 and 
dicussing other molecular techniques that may be useful for the investigation of 
viral contaminants in vaccines. These techniques are relevant for the investigation 
of possible viral involvement in cHL. 
Chapter 7 discusses the SAGE procedure for the investigation of relevant gene 
expression in cHL using enriched HRS cell populations from primary cHL material. 
The main aim of this study was to identify genes that are differentially expressed 
between HRS cells and their 'normal' counterpart. An additional aim was to 
investigate gene expression differences between EBV-positive and EBV-negative 
cHL. 
Chapter 8 summarises the results obtained in this thesis and discusses the 
significance of these findings in the current cHL research field. Future experiments 
are highlighted and novel research strategies explored. 
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DNA from malignant cells is present in the serum/plasma of cancer patients and 
DNA from this source is amenable to analysis by polymerase chain reaction (PCR). 
In the present study we evaluated whether Epstein-Barr virus (EBV) DNA is 
present in the serum of patients with EBV-associated Hodgkin's disease (HD). 
Using conventional PCR, EBV DNA was detected in serum from 30/33 patients 
with EBV-associated Hodgkin's disease but only in 6/26 patients with non-EBV­
associated disease (p<0.001 ). Samples from healthy individuals were negative 
and only 5/12 infectious mononucleosis samples were positive. Real-time 
quantitative PCR was subsequently employed to determine the concentration of 
EBV DNA present in serum; among positive samples the level ranged from 1 to 
705 copies per 125 µI of serum. Post-treatment samples from 5/14 cases with 
EBV-associated Hodgkin's disease contained detectable EBV DNA; analysis of this 
small group of cases suggests that positivity in post-treatment samples correlates 
with risk factors indicative of a poor prognosis. Overall, the results are consistent 
with the notion that DNA from Reed-Sternberg cells is present in the serum of HD 
patients, and further suggest that serum EBV should be evaluated as a prognostic 
marker. 
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Introduction 
For several decades it has been known that patients with cancer and autoimmune 
disease have increased amounts of DNA in serum and plasma relative to healthy 
individuals (Leon et al., 1 977;Steinman 1 979). The polymerase chain reaction 
(PCR) has been used to analyse DNA sequences from these sources. It has been 
possible to detect mutations of oncogenes, such as ras, in the plasma of cancer 
patients (Vasioukhin et al., 1 994;Anker et al., 1 997), and loss of heterozygosity has 
been demonstrated in serum and plasma samples from patients with head and 
neck tumours (Nawroz et al., 1 996) and small cell lung carcinoma (Chen et al., 
1 996). The results of the latter analyses indicate that the DNA present in the 
serum/plasma of cancer patients is largely derived from tumour cells. Such studies 
suggest that the analysis of serum or plasma DNA may be useful diagnostically 
and also, more importantly, in the clinical follow-up of cancer patients. 
In the present study we addressed whether genomes from the Epstein-Barr virus 
(EBV) could be detected in the serum of patients from Hodgkin's disease (HD). 
EBV is detectable in Reed-Sternberg cells, the tumour cells in HD, in around one 
third of HD cases in western countries and is thought to play a role in disease 
pathogenesis in these cases (Armstrong et al., 1 992;Jarrett et al., 1 996). The 
ability to detect EBV DNA in serum samples from patients with EBV-associated HD 
could prove useful in both clinical and epidemiological studies. 
Materials and Methods 
Case and sample selection: Serum samples from 80 patients with HD, 20 
patients with clinical symptoms of infectious mononucleosis and lgM antibodies to 
EBV, and 1 5  healthy individuals were assayed for the presence of EBV genomes. 
HD cases were selected on the basis of EBV status of lesions and the availability 
of pre-treatment serum. The series included samples from 42 cases of EBV-31 
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associated and 38 cases of non-EBV-associated HD. Plasma and serum samples 
were collected prospectively from a further 6 HD patients in order to compare DNA 
extracted from these two sources. 
DNA extraction: DNA was extracted from 500 µI aliquots of pre-treatment serum 
or plasma which had been stored at -80°C. DNA extraction was performed using 
the Blood & Cell Culture DNA Mini Kit (Qiagen, Crawley, UK) but with minor 
modifications to the manufacturer's instructions. Briefly, 500 µI of G2 lysis buffer 
and 25 µI of protease were added to the serum sample and the reaction was 
incubated for 20 minutes at 56°C. Subsequent steps were performed according to 
the supplier's protocol and samples were resuspended in either 30 µI (for 
conventional PCR) or 60 µI (for quantitative PCR) H20. 
Conventional polymerase chain reaction: Initially, EBV PCR was carried out 
using primers derived from the BamHI W repeat sequence of EBV as previously 
described (Deacon et al., 1991 ;Armstrong et al., 1992). Twenty five microlitres of 
DNA corresponding to 417 µI of serum were assayed in a 50 µI PCR reaction 
containing 200 µM nucleotides, 1 µM each primer and 1.5 mM MgCl2 • A negative 
water control was assayed after every 2 samples, and a positive control consisting 
of 100 ng of DNA from the EBV-positive cell line Raji was included in each assay. 
Thermal cycling was performed on a Perkin Elmer Thermal Cycler (Perkin Elmer 
Biosystems, Warrington, UK) using the following conditions: initial denaturation at 
95°C for 5 min, followed by 40 cycles of ramping to 94 °C over 1 min; 94 °C for 30 
sec; cooling to 55 °C over 2 min; 55 °C for 1 0 sec; heating to 72 °C over 1 min; 72 
°C for 30 sec, followed by a final extension step at 72 °C for 7 min. PCR products 
were analysed by electrophoresis on 8% polyacrylamide gels followed by 
electroblotting and hybridisation with a 32P-labelled EBV BamHI W probe (Arrand et 
al., 1981 ). 
Since the primers used in this assay are derived from a region of the EBV genome 
which is repeated a variable number of times, this assay cannot be used to 
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quantitate EBV copy number. However, in order to obtain a rough estimate of 
assay sensitivity, we tested serial 10-fold dilutions of DNA from the Raji cell line. 
Samples containing 100 ng to 1 pg DNA were assayed; since this cell line is 
estimated to contain 50 EBV genomes per cell this corresponds to 7.5 x 105 to 7.5 
copies of EBV. Six replicates of the highest dilution were assayed. 
Post-treatment samples from 16 of the patients with EBV-associated disease were 
also tested using the conventional PCR assay. Clinical data including age, sex, 
stage at presentation, prognostic index (Proctor et al., 1991 ), haemoglobin, and 
occurrence of relapse were compared for cases scoring negative and positive. 
Quantitative polymerase chain reaction: In later experiments we used real-time 
quantitative PCR to determine the amount of EBV DNA present in serum samples. 
TaqMan® methodology was used and samples were analysed using an ABI 
Prism® 7700 Sequence Detection System (Perkin Elmer Biosystems, Warrington, 
UK). Primers and probe were derived from the EBV polymerase gene and 
designed using the Primer Express™ software programme (Perkin Elmer 
Biosystems, Warrington, UK). 
5' primer: AGT CCT TCT TGG CTA GTC TGT TGA C 
3' primer: CTT TGG CGC GGA TCC TC 
Probe: CAT CAA GAA GCT GCT GGC GGC C 
In order to optimise the assay and determine the sensitivity, replicates of 10-fold 
dilutions of Raji DNA containing from 7 .5 x 105 to 0.075 genomes per reaction were 
tested; six replicates of each of the three highest dilutions were assayed. Samples 
containing human herpesviruses 6, 7 and 8 were analysed to verify specificity. 
Samples from 46 cases of HD (26 EBV-associated, 20 non-EBV-associated), were 
investigated using the quantitative PCR; 25 of these cases had been analysed 
using the conventional assay. For comparison, samples from an additional 8 cases 
33 
Chapter 2 
of IM and samples from 9 of the healthy controls were assayed. In these 
experiments, 15 µI of DNA template, corresponding to 125 µI of serum were used. 
Reactions were performed using TaqMan® Universal PCR Master Mix (Perkin 
Elmer Biosystems, Warrington, UK) in a final volume of 50 µI with primers and 
probe at a concentration of 50 nM and 200 nM respectively. Following initial 
incubations at 50°C for 2 min and 95°C for 1 0 min, 40 cycles of thermal cycling at 
95 °C for 15 sec and 60°C for 60 sec were performed. Replicate dilutions of Raji 
DNA estimated to contain 7.5 x 105 to 7.5 copies were included in each assay and 
at least one negative control was included for every two samples. 
In 16 of the EBV-associated HD cases, the number of EBV-infected cells in the 
peripheral blood was known (G. Khan, unpublished results). The viral load in these 
cases was therefore compared with the concentration of EBV genomic sequences 
in serum. 
Determination of EBV status: EBV status of HD lesions had been determined 
previously using EBV EBER in situ hybridisation, but repeat analyses were carried 
out on selected cases using a commercially available kit (Novacastro, Newcastle­
upon-Tyne, UK). The integrity of the RNA in tissue sections from these cases was 
assessed using fluorescein-conjugated poly dT probes (Novacastro, Newcastle­
upon-Tyne, UK), and expression of the EBV LMP-1 protein was investigated using 
a cocktail of monoclonal antibodies (CS1-4) essentially as described previously 
(Rowe et al., 1987;Armstrong et al., 1992). 
DNase digestion of fractionated samples: In order to determine whether EBV 
genomes detected in serum from HD patients were present as naked DNA or as 
virus particles the following experiment was performed. A known positive serum 
sample was analysed alongside supernatant from the 895-8 cell line, which was 
included as a positive control for the presence of EBV virions. Samples (500 µI) 
were clarified by low-speed centrifugation and filtration and virus pelleted by 
ultracentrifugation at 50,000 rpm for 60 min in a TLA-120.1 rotor in a Beckman 
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Optima TLX Ultracentrifuge (Beckman Instruments Inc., High Wycombe, UK). The 
resulting supernatant was divided into 2 aliquots and the pellet resuspended in an 
equivalent volume of PBS. DNase 1 (Boehringer Mannheim, Lewes, UK) was 
added to one of the supernatant samples and the resuspended pellet at a final 
concentration of 1 mg/ml and reactions incubated at room temperature for 1 hour. 
EDT A was added to stop the reaction and DNA extraction and quantitative PCR 
were performed as described above. 
Comparison of serum and plasma: In experiments designed to compare DNA 
extracted from serum and plasma, �-globin primers were used. Initially samples 
from six cases were compared using a conventional PCR assay which amplifies a 
fragment of 119 bp, essentially as previously described (Saiki et al., 1988). 
Reaction conditions and controls were as described for the conventional EBV PCR 
except that only 12.5 µI of the DNA sample were used per reaction. In later 
experiments, quantitative PCR was performed on samples from 5 of the cases, 
using the reaction conditions described above for the EBV TaqMan® assay but 
with the following primers and probe: 
5' primer: GGC AAC CCT AAG GTG AAG GC 
3' primer: GGT GAG CCA GGC CAT CAC TA 
probe: CAT GGC AAG AAA GTG CTC GGT GCC T 
Statistical Analysis: Statistical analyses were performed using the package 
Minitab® (PA, USA). 
Results 
Analysis of pre-treatment samples using conventional PCR: Serum samples 
were initially analysed for the presence of EBV genomes using a conventional PCR 
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assay and the results are shown in Table 1 and Figure 1. This assay is not 
quantitative but is sensitive because it amplifies a repeat sequence; in dilution 
experiments we obtained positive results in 2 of 6 samples estimated to contain 7.5 
copies of the EBV genome, while lower dilutions were all positive. Serum samples 
from 30 of the 33 cases of EBV-associated HD were positive in this assay; in 27 of 
the 30 positive samples amplification products were clearly detectable on ethidium 
bromide-stained gels. Repeat samples obtained following treatment were available 
from 2 of the cases which were originally negative; both were positive in the 
second assay suggesting that failure to detect EBV genomes in the original sample 
may have occurred for technical reasons. Samples from 6 of the 26 non-EBV­
associated cases were also positive; products were visible on ethidium bromide­
stained gels in only 4 cases, and in only 1 case (case 3543) was the PCR product 
visualised on the stained gel of similar intensity to the products from the majority of 
EBV-associated cases. There was, therefore, a highly significant correlation 
between the EBV status of lesions and the ability to detect EBV DNA in serum 
(Pearson product moment correlation coefficient = 0.691, p<0.001 ). Samples from 
5 cases of infectious mononucleosis were also positive but none of the 15 samples 
from healthy individuals gave rise to positive results (Table 1 ). 
Analysis of post-treatment samples using conventional PCR: EBV PCR was 
performed on post-treatment serum samples from 14 EBV-associated patients who 
had positive pre-treatment samples. The mean time between samples was 67 
weeks and the mean time of follow-up was 90 weeks. Samples from 5 cases were 
positive following treatment whereas 9 were negative (Table 2). There was no 
significant difference in the time between samples or the time of clinical follow-up 
between the 2 groups of cases. Only one patient relapsed (case 1 ); this patient 
had detectable EBV genomic sequences in serum at the time of the second sample 
and was the case with the longest follow-up time. EBV DNA was detectable in 
serum 6 months before clinical relapse. Cases in which EBV genomic sequences 
were detectable at the time of the second sample were more likely to have a higher 
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prognostic index (p<0.05, 2 sample t-test), a lower haemoglobin (p<0.01 ) and to 
present at advanced stage. 
Quantitative PCR: The above results suggested that a quantitative PCR assay 
might prove useful in the clinical follow-up of patients and in the differentiation of 
EBV-associated from non-associated HD cases. We therefore developed a real­
time quantitative PCR assay using TaqMan® methodology (Perkin Elmer 
Biosystems). In this system the PCR reaction contains conventional primers and a 
probe labelled with reporter and quencher molecules. During specific amplification 
the probe is cleaved causing separation of reporter and quencher molecules and 
emission of fluorescence. Fluorescent intensity increases in direct proportion to 
the amount of specific amplified product and cycle-by-cycle changes are 
measured. Results are scored during the exponential phase of the reaction when 
the fluorescence emission is proportional to the input number of template copies. 
Data are initially expressed as Ct values; the Ct corresponds to the cycle number 
at which the amplification plot for a given sample crosses the threshold, which is 
normally set at the point where the fluorescent signal equals ten times the standard 
deviation of background fluorescence. Ct values were recorded for the serum 
samples, and dilutions of DNA from the Raji cell line were used to produce a 
standard curve [log 1 O (initial copy number) plotted against Ct value]. This allowed 
us to extrapolate the concentration of EBV genomes in samples. 
In optimisation experiments and in the experimental assays we consistently 
obtained a positive result when 1 pg of Raji DNA, estimated to contain 7.5 EBV 
genomes, was included as template. Occasional positive results were obtained 
(�2/6 replicates positive) when 0.1 pg Raji DNA (0.75 copies) were assayed but 
higher dilutions were always negative (data not shown). The assay was clearly 




Serum samples from 46 cases of HD were analysed using the quantitative assay; 
duplicate results were available for 36 cases and in these cases the mean value 
was taken as the final result {Table 3 and Figure 2). Of the 26 samples from EBV­
associated cases, 18 were positive with genome concentrations ranging from <7.5 
to 705 copies per 125 µI of serum. One sample from an EBV-associated case 
which scored negative in the conventional assay was positive with a mean copy 
number of 12 genomes per 125 µI serum. Two of the twenty samples from non­
EBV-associated cases gave rise to positive results; 1 of these was estimated to 
contain only 1 copy of the EBV genome per 125 µI serum. The second sample had 
a mean EBV copy number of 41 and was derived from the same serum donation 
as the sample which gave a robust signal in the conventional PCR (case 3543). 
Three additional samples, derived from non-EBV-associated cases, which gave 
positive results in the conventional assay were negative in the quantitative assay. 
Samples from 4 of the 8 IM patients were positive using the TaqMan® assay and 
the two highest copy numbers (750 and 1950 genomes/125 µI serum) were 
obtained from this group. None of the samples from healthy individuals was 
positive. 
For 16 cases of EBV-associated HD, the concentration of EBV genomes in serum 
was compared with the EBV viral load in peripheral blood mononuclear cells; no 
correlation was observed between these 2 results. 
Cases with discrepant results: Three cases had clear positive staining of Reed­
Sternberg cells in the EBER in situ hybridisation assay but negative results in the 
initial serum PCR. All 3 of these cases, however, had detectable EBV DNA in 
serum at some stage during the course of these experiments - one was positive in 
the TaqMan® assay and the remaining two had positive post-treatment samples. 
The EBER and poly dT assays were repeated and LMP-1 immunohistochemistry 
performed on the 6 cases which were positive in the serum assay but negative on 
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in situ hybridisation. Further EBV analyses were negative in all cases, consistent 
with the original result, however scattered positive bystander cells were visible in all 
of these cases following EBER in situ hybridisation. 
Sensitivity to DNase digestion: In order to determine the physical state of the 
EBV genomes, we subjected a known positive sample to ultracentrifugation and 
DNase digestion. EBV DNA was not amplified from the pelleted material or from 
the DNase-digested supernatant, but was detected in the non-digested 
supernatant sample; this result indicates that the EBV DNA is present as naked 
DNA and not in virions. EBV sequences were amplified from the DNase-digested, 
pelleted material from the 895-8 supernatant confirming the presence of virions in 
this sample. 
Comparison of serum and plasma: DNA extracted from plasma and serum was 
compared in cases from which matched samples were available. Both 
conventional and quantitative �-globin PCR assays were used. On ethidium 
bromide-stained gels 6/6 of the serum samples were positive compared to only 2/6 
of the plasma samples. The results of the TaqMan® assay (Figure 3) confirmed 
that the serum samples were the better source of DNA. 
Discussion 
Our results add to a growing body of data indicating that serum samples from 
cancer patients provide a useful source of DNA suitable for molecular analyses. In 
the present study, EBV DNA was detected in the majority of serum samples from 
patients with EBV-associated HD but was infrequently detected in samples from 
non-EBV-associated cases. Two assay systems were used to detect viral DNA. 
Initially we screened samples using conventional PCR and primers derived from a 
repetitive sequence within the EBV genome. EBV was detected in serum samples 
from 30/33 (>90%) HD patients with EBV-associated disease but in only 6/26 
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cases of non-EBV-associated disease; furthermore there was a suggestion that the 
amount of EBV DNA was lower in the latter cases. We therefore developed a real­
time quantitative PCR assay using TaqMan® methodology. The TaqMan® assay 
was more sensitive than the conventional PCR, however, we used a smaller 
volume of serum in this analysis and this resulted in a lower overall positivity rate: 
18/26 samples from EBV-associated and 2/20 samples from non-associated cases 
scored positive. Although the amount of EBV DNA detected in the non-EBV­
associated cases was low, the TaqMan® assay did not enable us to cleanly 
separate the two groups of cases on a quantitative basis. 
Several published studies have also detected EBV DNA in serum or plasma from 
individuals with EBV-associated malignancies. Laroche et al. (1995) obtained 
positive results from 9/13 cases of AIDS-related non-Hodgkin's lymphoma using 
the equivalent of <1 0µI serum and a PCR assay based on the EBV BamHI W 
repeat sequence. Mutirangura et al. (1998) reported the detection of EBV genomic 
sequences in serum samples from 13/42 patients with nasopharyngeal carcinoma, 
an EBV-associated carcinoma, using a conventional PCR assay similar to that 
used in the present study except that a slightly smaller serum sample (300 µI) was 
assayed and PCR primers were derived from single copy, rather than repeat, 
sequence. EBV DNA was detected in serum from 4/7 patients with 
nasopharyngeal carcinoma and 2/7 HD patients in a study by Fontan et al. (1998); 
in this report technical details of the PCR reaction and the EBV status of the HD 
patients were not given. Taken together, these results suggest that EBV DNA is 
present in the serum of patients with a range of EBV-associated malignancies. 
Using quantitative PCR, we estimated that positive samples from EBV-associated 
HD cases contained from <7.5 to 705 EBV genomes per 125 µI of serum. The low 
concentration of EBV DNA present in many cases highlights the importance of 
assaying a sufficiently large volume of serum, and most probably explains 
differences in detection rates in these studies. We recommend that DNA extracted 
from at least 500 µI of serum should be used in future experiments. 
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We also detected EBV DNA in serum samples from patients with infectious 
mononucleosis, a benign, usually self-limiting disease associated with primary EBV 
infection. Approximately half of these samples scored positive and the two 
samples with the highest EBV genome concentration were from this group. 
Precise clinical data were not available from this convenience sample but it is 
possible that EBV copy number relates to disease stage. Previous studies of 
infectious mononucleosis have detected EBV sequences in the serum of the 
majority of cases (Yamamoto et al., 1995;Laroche et al., 1995;Fontan et al., 1998) 
and detection rates have varied in acute and convalescent samples (Yamamoto et 
al., 1995). In contrast to the situation in HD (see below), EBV DNA in infectious 
mononucleosis is present in viral particles as well as free DNA (Gan et al., 
1994;Yamamoto et al., 1995). In the present study, and in over 200 cases 
reported in the literature, EBV has not been detected in the serum or plasma of 
healthy individuals (Yamamoto et al., 1995;Laroche et al., 1995;Fontan et al., 
1998;Mutirangura et al., 1998), therefore the detection of EBV in these samples is 
suggestive of EBV-associated disease. 
In EBV-associated HD, EBV genomes are present in Reed-Sternberg cells and in 
B-cells persistently infected with this virus. EBV infection in both cell types is latent 
and, although rare Reed-Sternberg cells in a small number of cases may support 
abortive replication (Pallesen et al., 1991 b;Brousset et al., 1993), there is no 
evidence of productive infection. However, in order to rule out the possibility that 
serum samples from HD cases contain EBV virions, we investigated whether the 
EBV DNA was present in pelleted material and was resistant to DNase digestion. 
The results confirmed that the viral genomes were present as free DNA and not in 
viral particles. 
The correlation between the EBV status of HD lesions and the ability to detect EBV 
DNA in serum suggests that Reed-Sternberg cells are the most likely source of the 
viral DNA. However, EBV was detected in serum samples from occasional cases 
of non-EBV-associated disease. In all of these cases scattered lymphocytes in 
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lymph node biopsies were EBV-positive, raising the possibility that latently infected 
B-cells could be the source of the viral DNA. We therefore compared the 
concentration of EBV DNA in serum with the frequency of EBV-infected cells within 
peripheral blood mononuclear cells (data not shown). No correlation was 
observed, suggesting that in most cases the serum EBV is derived from infected 
Reed-Sternberg cells. In order to substantiate this, it is essential to be able to 
differentiate between EBV genomes present in Reed-Sternberg cells and those in 
latently infected 8-cells by analysing polymorphic regions of the viral genome. 
Although we are collecting samples to perform this analysis, we have not identified 
an informative case. Support for the idea that Reed-Sternberg cells are usually the 
source of the EBV DNA is provided by Kornacker et al. (1999) who recently 
demonstrated identical immunoglobulin gene rearrangements in biopsy and serum 
samples from a HD patient (Kornacker et al., 1999). 
Post-treatment samples from 14 cases with EBV-associated HD and a positive pre­
treatment sample were tested using the conventional assay and 5 were positive. 
Cases with EBV DNA detectable in post-treatment samples had higher prognostic 
indices, lower haemoglobin values and presented with stage 3 or 4 disease (Table 
2). The single patient who relapsed had EBV DNA detectable in serum 6 months 
before clinical relapse. The number of cases included in this analysis was small 
and the time of follow-up short, however the results suggest that this assay may be 
useful as a prognostic marker and should be investigated as a predictor of relapse. 
Future studies will include analysis of sequential samples using the quantitative 
PCR assay. 
Previous studies have used DNA extracted from serum or plasma and also crude 
samples in PCR assays (Chen et al., 1996;Nawroz et al., 1996;Lo et al., 1997). 
Serum was initially chosen for our analyses because samples were available, and 
DNA extraction was performed in order to increase the size of the sample to be 
assayed. We subsequently performed a small comparative study and the results 
suggested that serum is superior to plasma as a source of DNA. 
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Overall, our results suggest that EBV DNA is detectable in most, if not all, patients 
with EBV-associated HD. In contrast, EBV DNA is infrequently found in serum 
from non-EBV-associated cases and, in this study, was never detected in samples 
from healthy individuals. This assay could prove useful in epidemiological studies 
and in the clinical follow-up of patients with EBV-associated HD and other EBV­
associated malignancies. 
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Table 2. Analysis of post-treatment samples using conventional PCR 
Case Age Sex Stage Prognostic Hb Follow Interval Serum EBV 
Index up between PCR 
weeks sam les 
1 *  25 M 4 0.8 8.9 1 52 1 23 + 
2 54 M 4 0.7 9.7 1 1 5 1 1 5 + 
3 25 M 4 0.6 9.9 48 35 + 
4 21 M 4 0.6 1 0.9 41 21 + 
5 20 F 3 0.6 1 0.6  45 45 + 
6# 63 M 3 0.6 1 0.2 1 1 2  98 
7 26 F 3 0.5 1 1 .4 1 36 1 36 
8 1 9  M 3 0.3 1 4.0 1 27 77 
9 32 M 4 0.3 1 3.8 1 03 74 
1 0  1 9  M 3 NK 1 5.2 NK 66 
1 1  35 M 2 0.2 1 5 .3 49 1 6  
1 2  36 M 3 0.7 1 0.3 48 29 
1 3  36 F 2 0.5 1 1 .5 NK 43 
1 4  24 M 2 0.6 1 1 .3 99 53 
Comparison of clinical data between cases with positive and negative post-treatment samples; all cases 
included in this analysis had positive pre-treatment samples. *Case 1 was the only patient who 
relapsed; #case 6 died from unrelated causes during follow-up; Hb, haemoglobin; NK, not known. 
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Table 3. Detection of EBV genomes in serum using TaqMan® PCR1 
Group Number Result 
Negative Positive 
Copies/1 25µI serum 
<7.5 7.5-74 >75 
EBV-associated HD 26 8 2 1 2  4 
Non-EBV-associated HD 20 1 8  1 1 0 
Infectious mononucleosis 8 4 0 2 2 
Healthy individuals 9 9 0 0 0 
1The majority of samples were analysed in duplicate and mean values were 
taken as the final result. HD, Hodgkin's disease. 
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♦ 1 39 bp 
M 1 2 3 4 5 6 7 8 C 
Figure 1 .  Detection of EBV genomes in serum using conventional PCR. Ethidium 
bromide-stained gel showing representative results using the conventional PCR assay. 
M, DNA size marker - Hae I l l-digested <l>X1 74 DNA; C, positive control, DNA from Raji 
cell line; samples were from: EBV-associated Hodgkin's disease, lanes 1 ,  2, 5 and 7; 
non-EBV-associated Hodgkin's disease, lanes 4 and 8; healthy individuals, lanes 3 and 
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Figure 2. Detection of EBV genomes using TaqMan® PCR. For each sample, the 
change in fluorescence intensity (dRn) is plotted against cycle number. The result is 
scored as the cycle number (Ct) at which the amplification plot crosses the threshold. 
Panel A) analysis of replicates of ten-fold dilutions of DNA from the Raji cell l ine. 
Samples were estimated to contain 750,000 to 7.5 copies of the EBV genome. Six 
replicates of the two highest dilutions and three replicates of lower dilutions were 
assayed and the Ct values used to construct a standard curve. Panel B) analysis of six 
representative serum samples from EBV-associated HD cases. Following extrapolation 
from the standard curve generated from A), these samples were recorded as containing 
750, 1 95, 1 01 ,  58, 1 2  and 3 copies of the EBV genome. Note that the figures given in 
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Figure 3. Detection of p-globin DNA sequences in serum and plasma.Analysis of 
serum and plasma samples from six cases of Hodgkin's disease using TaqMan® 
PCR. For each sample, the change in fluorescence intensity (dRn) is plotted against cycle 
number. The result is scored as the cycle number (Ct) at which the amplification plot 
crosses the threshold. Panel A) DNA extracted from serum and panel B) DNA extracted 
from plasma. All of the 5 serum samples were positive in this assay whereas only 3 of the 
plasma samples were positive and these had higher Ct values (lower concentration of �­
globin DNA) than the serum samples. 
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The Epstein-Barr virus (EBV) is associated with a proportion of Hodgkin lymphoma 
(HL) cases and this association is believed to be causal. The aetiology of cases 
lacking EBV in the tumour cells (EBV HRS-ve), which make up the majority of 
cases in western countries, is obscure. It has been suggested that EBV may also 
cause these tumours by using a hit-and-run mechanism. Support for this idea 
comes from the finding that most young adult patients, who are likely to have a 
good immune response to EBV, have EBV HRS-ve HL. We investigated this 
possibility using a combined serological and molecular approach. Analysis of EBV 
seroprevalence rates in an epidemiological study of young adult HL revealed that 
cases with EBV HRS-ve HL were more likely to be EBV seronegative than controls. 
Furthermore, additional studies clearly showed that some HL patients have never 
been infected by EBV. Quantitative PCR was used to look for the presence of 
deleted EBV genomes in a series of adult cases with EBV HRS+ve and EBV HRS­
ve HL. Subgenomic fragments were detected in equimolar proportions. This 
study, therefore, found no evidence to support the idea that a hit-and-run 
mechanism involving EBV plays a role in the pathogenesis of HL. 
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Introduction 
The Epstein-Barr virus (EBV) is associated with a proportion of cases of Hodgkin 
lymphoma (HL), and this association is believed to be causal (Jarrett et al., 
1 996;IARC 1 997). In EBV-associated cases, viral genomes are detected in 
Hodgkin and Reed-Sternberg (HRS) cells, the tumour cells in HL, and EBV latent 
gene products are expressed (Jarrett 2002). The latter include the EBER RNAs 
and EBNA 1 ,  LMP1  and LMP2 proteins; both LMP1  and 2 are postulated to play a 
role in disease pathogenesis (Jarrett 2002). EBER in situ hybridisation and LMP1  
immunohistochemistry are generally used to determine the EBV status of HL 
tumours, and cases that are positive in these assays are referred to hereafter as 
EBV-associated or EBV HRS+ve. The aetiology of EBV HRS-ve cases remains 
obscure. 
The epidemiology of HL  suggests that it is a heterogeneous condition and the term 
HL most probably embraces more than one aetiological entity. Consideration of 
differences in age-specific incidence patterns, along with risk factor data and the 
distribution of histological subtypes, suggests that HL in children, young adults ( 15-
34 years) and older adults (�50 years) have different aetiologies (MacMahon 
1966). For the young adults, it has been further suggested that delayed exposure 
to a common childhood pathogen may play a role in disease pathogenesis 
(Gutensohn and Cole 1980;Gutensohn and Cole 1 981 ). 
In developed countries, EBV is associated with around one third of cases, but in 
developing countries this proportion can be much higher (Jarrett et al., 1 996;Glaser 
and Jarrett 1 996;Glaser et al., 1 997). Within individual geographical locales, there 
is also a suggestion that EBV HRS+ve HL is associated with lower socio-economic 
status and greater material deprivation (Flavell et al., 1 999;Grufferman et al., 
2001 ). There are proportionately fewer EBV-associated cases in the young adult 
age group compared to the childhood and older adult age groups (Armstrong et al., 
1 998a). The age incidence curve for non-EBV-associated cases in the UK is 
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unimodal with an incidence peak between the ages of 15-34 years. In contrast, for 
EBV-associated cases the curve is much flatter with the suggestion of a peak in 
young adults aged 15-24 years and a second peak in  older adults. Males 
outnumber females among EBV HRS+ve cases, and a sign ificantly higher 
proportion of mixed cellularity (MCHL) compared to nodular sclerosis (NSHL) 
cases are EBV-associated (Jarrett et al., 1996;Glaser et al., 1997). 
The suggestion that EBV is causally associated with a larger proportion of HL 
cases but is using a hit-and-run mechanism in cases classified as EBV HRS-ve, 
has been discussed (Ambinder 2000). Proponents of this idea suggest that EBV 
HRS-ve patients have a good immune response to EBV, since these individuals 
are generally young and from socio-economically advantaged backgrounds, and 
are therefore able to clear the virus from tumour cells. Although there is no 
example of hit-and-run oncogenesis in a natural setting, such mechanisms are 
difficult to disprove. 
It has also been suggested that integrated fragments of the normally episomal EBV 
genome may persist in EBV HRS-ve cases. Defective, i ntegrated and rearranged 
EBV genomes have been detected in sporadic Burkitt's lymphoma providing 
precedent for this scenario (Razzouk et al., 1996). We previously performed a 
Southern blot study using large probes spanning the EBV genome but found no 
evidence that defective or integrated EBV genomes are a frequent occurrence in 
HL (Byron Cox, data not shown). Similarly, Staratschek-Jox and colleagues found 
no evidence for persistent i ntegrated fragments in LMP1-negative classical HL 
using in situ hybridisation (Staratschek-Jox et al., 2000). Recently Gan and 
colleagues adopted a different approach in the investigation of a series of 
paediatric HL tumours; using PCR they specifically looked for rearranged 
heterogeneous (het) EBV DNA with a configuration known as WZhet (Gan et al., 
2002). In almost one third of cases, including 8/24 cases negative by EBER in situ 
hybridisation, rearranged genomes were detected. This rearrangement juxtaposes 
BamHI W and Z fragments of the EBV genome and leads to constitutive 
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expression of the BZLF1 protein. Expression of this immediate early protein can 
lead to loss of EBV genomes in vitro and it has therefore been suggested that 
infection with rearranged WZhet genomes might lead to loss of episomal DNA from 
infected tumour cells in vivo (Takada et al., 1992;Gan et al., 2002). 
Many studies have shown a concordance between expression of EBER RNA and 
LMP1 protein in HRS cells (Armstrong et al., 1992). In the investigation of >300 HL 
cases in our laboratory using both EBER in situ hybridisation and LMP1 
immunohistochemistry we have only rarely identified cases with discordant results 
(usually EBER-positive, LMP1-negative), and have largely attributed discrepancies 
to sample quality. However, we recently identified a case of HL, described here, in 
which HRS cells clearly expressed LMP1 but not EBER (Figure 1 ). This prompted 
us to revisit the possibility that deleted or rearranged EBV genomes may be 
present in HRS cells in HL and that EBV may use a hit-and-run mechanism in HL. 
Using serological methods, we looked for evidence that EBV-seronegative 
individuals are under-represented among HL patients and using quantitative PCR 
(qPCR) we have looked for evidence of defective and rearranged EBV genomes. 
Materials and Methods 
Serological study: Serum samples were collected as part of a UK population­
based, case-control study of HL in young adults (Alexander et al., 2000;Alexander 
et al., 2001 ). Cases were aged 16-24 years at diagnosis and controls were 
matched on gender, year of birth and county of residence. EBV status of tumours 
was determined for most cases but only those with confirmed EBV HRS-ve HL are 
included in our study. 
Antibodies against EBV viral capsid antigen (VCA) and early antigen (EA) were 
detected using indirect immunofluorescence assays (IFAs) as previously described 
(Henle and Henle 1973;Long et al., 1974). Serum samples were screened at an 
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initial dilution of 1 : 1 0 and positive samples were diluted 2-fold until an end titer 
(reciprocal of serum dilution at which specific immunofluorescence was last seen) 
was reached. Results of a comparison between EBV HRS+ve and HRS-ve cases 
have been reported previously (Alexander et al., 2001 ). In order to confirm that 
samples negative in the IFAs were truly negative, available serum samples, diluted 
1 : 1 00, were screened for lgG antibodies to EBV nuclear antigens (EBNA) using a 
commercially available kit (ETI-EBNA-G, Diasorin s.r.l., Saluggia, Italy). 
Statistical analyses compared results from the EBV HRS-ve HL cases with controls 
in three ways. First, the proportion of EBV seronegative cases in the two groups 
was compared. Secondly, results of EBV VCA and EA assays were grouped into 4 
categories of approximately equal size according to antibody titre (Table 1 ). The 
grouped data were then subjected to contingency table analysis with and without 
stratification for sex. Thirdly, antibody titres were compared using the Wilcoxon 
test. 
EBER in situ hybridisation and LMP1 immunohistochemistry: Both assays 
were carried out on sections of routinely fixed, paraffin-embedded material. The 
EBER in situ hybridisation assay utilised a commercially available probe (Vector 
Laboratories, Peterborough, UK) and hybridisation kit (Dake Ltd., Cambridgeshire, 
UK). Following antigen retrieval, the CS1 -4 cocktail of monoclonal antibodies 
(Dake Ltd.) was used to detect the presence of LMP1 . Positive reactivity was 
detected using the ABC technique incorporating DAB as the chromogenic 
substrate (Vector Laboratories). 
PCR and nucleotide sequencing: qPCR assays detecting sequences spanning 
the EBV genome were used to determine whether a) we could detect deletions in 
EBV genomes present in EBV HRS+ve tumours and b) we could detect remnants 
of EBV genomes in EBV HRS-ve tumours. DNA was extracted from diagnostic 
biopsies from 30 cases of classical HL (CHL) [Table 2] using proteinase K 
digestion and extraction with organic solvents (Trainor et al., 1 982). qPCR was 
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performed using TaqMan® methodology (Applied Biosystems, Warrington, UK) 
and the primer probe sets listed in Table 3. Repeat samples from 8 cases were 
investigated. Reactions were performed in a total volume of 50 µI and included 1 
µg of DNA, each primer at 50 nM (except BamHI e3 assay where 3' primer was 
300 nM),  probe at 200 nM, and TaqMan® Universal PCR Mastermix (Applied 
Biosystems). For three cases ( 1 3 ,  1 7  and 2 1 )  there was insufficient DNA to 
perform analysis using the BamHI H assay. Amplification and analysis were 
performed on an ABI PRISM™ 7700 Sequence Detection System (Applied 
Biosystems) using the default thermal cycling parameters for 40 cycles (Gallagher 
et al., 1 999). Dilutions of DNA from the Raji cell line were used as a positive 
control in all assays except the BamHI e3 assay; EBV genomes in the Raji cell line 
are deleted in this region and therefore DNA from the JiJoye cell line was used as 
the positive control. Negative controls, containing water instead of template DNA,  
were included in a 1 :2  ratio with test samples. 
An additional TaqMan™ was designed specifically to detect rearranged EBV 
genomes of the WZhet configuration. Primers and probe (minor groove binding , 
Applied Biosystems) are shown in Table 3 and reaction conditions were as above . 
DNA from the cell line P3HR1  clone 5, kindly provided by John Sixbey, was used 
as a positive control. 
Conventional PCR was carried out using primers derived from the EBV LMP1 gene 
(Table 3) and primers spanning the WZhet rearrangement (Gan et al., 2002). A 
Taq DNA Polymerase kit (Qiagen , Crawley , UK) with buffer containing 1 .5 mM 
MgCl2 and 200 µM nucleotides (Amersham Pharmacia Biotech , Buckinghamshire , 
UK) was used and thermal cycling conditions were as previously described 
(Gallagher et al., 1 999). Positive and negative controls were as described above. 
Products from the LMP1 PCR were sequenced, either directly or following cloning 
using a PCR®4 TOPO TA cloning kit (lnvitrogen, Groningen, The Netherlands). 
Cycle sequencing was performed using the Big Dye™ Terminator kit v2.0 (Applied 
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Biosystems) followed by analysis on an ABI PRISM™ 310 Genetic Analyzer 
(Applied Biosystems). Products from the conventional WZhet PCR were subjected 
to electrophoresis on 8% polyacrylamide gels followed by electroblotting and 
hybridisation with a BamHI W probe, labelled with [a-32P]dCTP using a rediprime™ 
kit (Amersham Pharmacia Biotech). 
Case 31:  Case 31 was a 37 year old, female patient with NSHL. Both fresh, viably 
stored and fixed material were available from her diagnostic biopsy. Sections of 
the fixed material were subjected to EBER in situ hybridisation and LMP1 
immunohistochemistry and used in PCR experiments. Microdissection was also 
performed in order to obtain regions of paraffin-embedded sections containing 
clusters of HRS cells. CD15-labelled MiniMACS magnetic beads (Miltenyi Biotec 
Ltd., Surrey, UK) were used to enrich HRS cells from a cell suspension prepared 
from the fresh sample; the level of enrichment was assessed by flow cytometry on 
an EPICS Elite flow cytometer (Coulter Electronics Ltd., High Wycombe, UK). 
qPCR assays for EBV and �-globin were carried out on: DNA extracted from the 
fresh biopsy; lysates of cell fractions obtained in the MiniMACS experiment; 
extracts obtained from paraffin sections by boiling for 30 minutes in lysis buffer 
(Tris HCI 10 mM, NP40 0.45% v/v, Tween 20 0.45% v/v); and similarly prepared 
extracts of HRS cells obtained by microdissection. 
Results 
Serological analysis:  Results were available from 72 cases of EBV HRS-ve HL 
and 103 controls. We first compared the proportion of seronegative samples in the 
2 groups. Negative results for both EBV VGA and EA antibodies were obtained for 
16 of 72 cases, including 13 of 64 classical HL cases and 12 of 103 controls. "All 
HL" and classical HL cases were therefore more likely to be EBV-seronegative 
than controls and differences are statistically significant (p = 0.02 and 0.05, 
respectively, using Fisher's exact). Differences are focused in the younger age 56 
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group (<20 years), the more affluent, firstborn children and subjects with just one 
sibling and are evident in both sexes. 
Sera giving negative results in both IFA assays were subsequently screened for 
antibodies to EBNA; all of the 14 HL and 11 control samples tested were negative 
in this assay, providing robust evidence of EBV seronegativity. 
The contingency table analysis of the IFA results grouped by titre shows similar 
distributions for the EBV HRS-ve cases and controls, especially for EA (Pearson's 
chi-square values exceeded 0.15 and linear trend chi-square p-values exceeded 
0.6) [Table 1]. Similarities persist following stratification by sex. The Mann­
Whitney tests, examining actual titres, indicate slightly lower VCA and EA levels in 
the controls but this does not approach statistical significance (p=0.53 and 0.85, 
respectively). 
PCR and sequence analysis: DNA extracted from tumour samples from 30 HL 
cases was investigated using 7 EBV qPCR assays. Results are expressed as Ct 
values, the cycle number at which the amplification plot crosses a threshold value, 
which are inversely proportional to the amount of target DNA. A Ct value of 40 
indicates a negative result. Results for the 30 cases were ranked according to the 
Ct value obtained in the EBV pol assay, the qPCR assay routinely used for EBV 
detection in our laboratory. Results for the pol assay were then compared with 
results from each of the other assays in a pairwise fashion and outliers were 
identified (Figure 2). This method of comparison is subject to fewer sources of 
error than the comparison of absolute copy numbers, and gave consistent results 
when repeat sampling of individual samples was performed. 
Generally there was a good correlation between the results of the various EBV 
assays, although correlation was less good at low viral copy numbers (Ct values 
above 35) where chance-sampling differences are likely. The EBER and BamHI 
e3 assays were less sensitive than the other tests, giving higher Ct values; this 
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most probably reflects the length and GC content of the amplimer sequences. The 
BamHI W assay detects a repetitive sequence of variable copy number and, as 
anticipated, this assay was marginally more sensitive than other assays. There 
was no absolutely clear value that distinguished EBV HRS+ve and HRS-ve cases, 
although all EBV HRS+ve cases had Cts below 30 in the pol assay and gave 
positive results in all of the assays. 
In the ori P assay, one sample (case 3) had a higher than expected Ct, suggesting 
that the amplimer sequence in this case was deleted or contained a sequence 
polymorphism (Figure 2b). There was insufficient DNA from this case to allow 
further exploration of these possibilities. Several samples (from cases 1, 2, 5, 12 
and 13) gave unexpectedly high Ct values in the LMP1 assay (Figure 2f). 
Conventional primers were designed to amplify a region of the LMP1 gene 
surrounding the qPCR amplimer; samples from cases 1 , 2, 5 and 12 were amplified 
and PCR products sequenced. Identical sequence polymorphisms, involving one 
nucleotide in the 5' primer and two nucleotides in the 3' primer (Table 3), were 
identified in the qPCR sequence. These polymorphisms have been previously 
reported in LMP1 sequences deposited in public databases. A modified 3' primer 
was designed (Table 3), incorporating two of the base substitutions, and the 
samples were reanalysed; the polymorphism in the 5' primer is at position 3 and is 
therefore less likely to affect PCR efficiency. Ct values in the modified assay were 
all lower than in the original assay confirming that the initial results were due to 
polymorphic, and not deleted, sequences. 
The presence of rearranged EBV genomes was investigated using TaqMan™ and 
conventional PCR. DNA from the positive control, P3HR1 clone 5, gave rise to 
clear positive results in both assays but none of the 30 adult HL samples was 
positive, even following long exposures of Southern blots (Figure 3). 
Case 31 : EBER in situ hybridisation, performed on the diagnostic biopsy, showed 
positive staining of scattered lymphocytes and also a cluster of cells that appeared 
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to reside within a germinal centre (Figure 1 ). HRS cells were negative in this 
assay. In contrast, there was clear staining of the HRS cells following 
immunohistochemical staining using the LMP1 antibodies (Figure 1 ). Both assays 
gave identical results on repeat staining. To confirm that the HRS cells were EBV­
positive, we enriched HRS cells using CD15 MiniMACS magnetic beads and 
examined the starting sample and CD15-enriched fraction using the pol and �­
globin qPCR assays. Following normalisation for levels of the �-globin gene, the 
CD15-enriched fraction contained 7.2-fold more EBV genomes than the starting 
sample, consistent with the presence of EBV genomes within HRS cells. Similarly, 
HRS cell clusters microdissected from paraffin sections were positive in the EBV 
pol qPCR. 
We next attempted to determine whether the lack of EBER expression by HRS 
cells was due to a defective EBV genome or downregulation at the transcriptional 
level. qPCR assays for EBER and pol were performed on a small sample of DNA 
from the CD15-enriched cell fraction and DNA extracted from paraffin sections. 
Although Ct values obtained in the EBER assay were high (36.3 and 37 
respectively) compared to those obtained using the pol assay (29.3 and 30.3, 
respectively) these results were consistent with those of other samples in the 
ranked comparison. 
Discussion 
EBV is thought to play a causative role in the pathogenesis of EBV HRS+ve HL. 
The aetiology of cases lacking EBV genomes in HRS cells is poorly understood, 
but it has been suggested that EBV may use a hit-and-run mechanism in these 
cases. If EBV is truly responsible for all HL, then all cases should show evidence 
of infection by EBV. We investigated this possibility by performing EBV VCA and 
EA serology on a population-based series of young adult cases. EBV seronegative 
cases of HL were identified and there was no evidence that seronegative subjects 59 
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were under-represented in EBV HRS-ve HL. In contrast, EBV HRS-ve cases were 
significantly more likely to be EBV seronegative than controls; we have previously 
reported that these cases had experienced fewer childhood infections than their 
matched controls and the above finding provides further evidence of lack of 
exposure to infectious agents during childhood (Alexander et al., 2001 ). For EBV 
seropositive subjects, antibody titres were similar in cases and controls. 
Serological assays for VGA and EA provide good tests for EBV infection; however, 
as an additional measure we investigated samples that were negative for VGA and 
EA antibodies using an EBNA ELISA. All of the !FA-negative samples were also 
negative for anti-EBNA lgG. 
There are rare examples of individuals who are EBV-seronegative but from whom 
virus can be recovered from peripheral blood. We therefore looked for additional 
evidence for lack of EBV infection in HL. In a recent study, performed in our 
laboratory, we evaluated the frequency of EBV-infected cells in the peripheral 
blood of HL cases. Three patients were EBV seronegative and had no detectable 
EBV in any of 20 aliquots of 2x105 peripheral blood mononuclear cells (Khan et al., 
2002). In an additional study we failed to detect EBV-specific cytotoxic T-cell 
responses in an EBV seronegative HL patient (Chapman et al., 2001 ). These 
studies provide robust evidence that some HL patients have never been infected 
by EBV. Thus, EBV is not the sole aetiological agent in HL. 
We investigated a HL biopsy in which the tumour cells expressed LMP1 protein but 
were EBER negative. Further analysis using qPCR suggested that the lack of 
EBER RNA expression was not due to deletion of the EBER gene in this case. 
Expression of LMP1 is essential for transformation of B-cells by EBV, and LMP1 is 
postulated to play a crucial role in the survival of EBV+ve HRS cells by mimicking a 
constitutively active CD40 receptor (Kieff and Rickinson 2001 ;Jarrett 2002). The 
function of EBER RNAs is less clear; EBER expression is not required for B-cell 
transformation (Swaminathan et al., 1991 ), but recent studies suggest that EBER 
RNAs may play some role in oncogenesis (Komano et al., 1999;Yamamoto et al., 
60 
Hodgkin lymphoma and EBV 
2000). Analysis of case 31 indicates that continued expression of EBER 
transcripts is not necessary for maintenance of the transformed phenotype in HRS 
cells. Although expression of EBER RNAs is generally considered a hallmark of 
latent EBV infection, lack of EBER expression has been described in EBV­
associated hepatocellular carcinoma and EBV PCR-positive breast cancers 
(Sugawara et al., 1999;Bonnet et al., 1999). 
To search for defective EBV genomes, we assayed a series of 30 HL samples 
using seven qPCR assays spanning the EBV genome. In this type of analysis, 
Southern blotting has the advantage that probes covering the entire genome can 
be used and restriction fragment length polymorphisms identified; however, this 
technique is often at the limits of sensitivity in the investigation of EBV genomes in 
HL. PCR has the advantage of sensitivity and the TaqMan™ assays used in the 
study facilitated relative quantitation of subgenomic fragments. Results were 
ranked according to the values obtained in the EBV pol gene assay and then 
comparisons with the results for the remaining six assays were performed in a 
pairwise fashion (Figure 2). EBV genomes with polymorphisms in the LMP1 gene 
were clearly identified, thus validating this approach and method of analysis. A 
single sample with a deletion or polymorphism in the ori P region was also 
identified but further analysis of this case was not possible. Comparison of results 
for the other samples suggested that each part of the genome was present at 
approximately equimolar concentrations. There was no evidence of either deletion 
or retention of parts of the genome. We further investigated whether rearranged 
EBV genomes could be detected in adult HL samples using both TaqMan™ and 
conventional PCR. No positive results were obtained, suggesting that loss of EBV 
genomes from HRS cells following infection by EBV virions with rearranged 
genomes is not a frequent event in the pathogenesis of adult HL. 
The aim of this study was to investigate the hypothesis that EBV is causatively 
associated with all, or most, HL cases. The results provide good evidence that 
some patients with HL have never been infected with EBV, thus EBV cannot be 61 
Chapter 3 
associated with all cases. Although we did identify a case of HL in which the 
tumour cells were LMP1-positive but EBER-negative, we found no evidence of 
defective EBV genomes in this case. Analysis of a further 30 cases provided no 
evidence that defective EBV genomes are a feature of HL. Overall, this study 
provides no evidence to support a hit-and-run hypothesis for EBV in HL. 
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Table 1. Serological results 
EBV VCA EBV EA Grouped HL Controls Grouped HL Controls level Number(%) Number(%) level Number(%) Number(%) �40 1 8  (25%) 20 ( 1 9%) Negative 28 (39%) 40 (39%) 80 - 320 8 ( 1 1 %) 25 (24%) 1 0, 20 18 (25%) 22 (2 1%) 640, 1280 26 (36%) 33 (32%) 40 1 0  ( 14%) 1 7 ( 16.5%) > 1280 20 (28%) 25 (24%) �80 16 (22%) 24 (23%) 














1 0  





1 6  
1 7  































1 6  
63 









1 9  


















































NSHL, nodular sclerosis Hodgkin lymphoma; MCHL, mixed cellu larity Hodgkin lymphoma; 
LRCHL, lymphocyte rich classical Hodgkin lymphoma; CHL NOS, classical Hodgkin 
lymphoma not otherwise specified. EBV status refers to the presence (+) or absence (-) of 
EBV in Hodgkin Reed-Sternberg cells as assessed by EBER in situ hybridisation or LMP1  
immunohistochemistry. ND, not done, sections not available; NR, no  result, sections not 
suitable for scoring. 
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Table 3. Primers and probes used in PCR analyses 
PCR assay 
Amplimer positio 
EBV EBER 6629-6795 
EBV ori P 8 104-8 167 
EBV BamHI W 14345-14419 
EBV BamHI H 54424-54498 
EBV BamHI e3 101592-101664 
EBV pol 154828- 154738 
EBV LMPl 168692-1687 60 5 'primer AGGACCT ACGCTGCCCTAGAG Probe AGCCACACACGTCTCCTCCCT AGCAAA 3 'primer AACCACAGACACCGTCCTCAC 5'primer AGGCGCAAGTGTGTGTAATTTGT Probe CTCCAGATCGCAGCAATCGCGC 3'primer GGGCGGGCCAAGATAGG 5'primer CCCCTGGTATAAAGTGGTCCTG Probe AGCTATTTCTGGTCGCATCAGAGCGC 3 'primer CCCTCTTACATTTGTGTGGACTCC 5'primer AGTCGTGTGCATGGAAATGG Probe ACCCTGCATCCTGTGTTGGAGCTAGC 3'primer CGAAAGGCGGAGAGGTGTT 5 'primer TGTCCAGTTCCCTTCTCCCA Probe CCTGTACACCCCGACCCAAAGGG 3 'primer GGTAACTAGAAATCTGAATGCCATTGA 5'primer AGTCCTTCTTGGCTAGTCTGTTGAC Probe CATCAAGAAGCTGCTGGCGGCC 3'primer CTTTGGCGCGGATCCTC 5 'primer TCATCGGTAGCTTGTTGAGGGT Probe ACCACCACGATGACTCCCTCCCG 
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Chapter 3 3'primer EB V LMP 1 variant 3 'primer EBV WZhet EBV LMPl conventional �-globin 5 'primer Probe 3 'primer 5 '  primer 3 '  primer 5 'primer Probe 3 'primer TGGACAACGACACAGTGATGAA TGGACCACGACACACTGATGAA GCAGCAGACATTCATCATTTAGAAA CAGTGGTCCCCCTCC* CAGACAGCAGGCAATTGTCAGT TGGAGTTAGAGTCAGATTCATGGCC TGGTTGATCTCCTTTGGCTCCT GGCAACCCTAAGGTGAAGGC CATGGCAAGAAAGTGCTCGGTGCCT GGTGAGCCAGGCCATCACTA 
Amplimer co-ordinates refer to the complete EBV genomic sequence: GenBank accession number 
V01 555. *Minor groove binding probe. 66 
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a b 
C d 
. . . 
Figure 1 .  In situ analysis of case 31 . Panels a and b: High power view of a cluster of 
Hodgkin and Reed-Sternberg (HRS} cells stained using EBER in situ hybridisation and 
LMP1 immunohistochemistry, respectively. No specific staining is observed in panel a, 
whereas positively staining HRS cells are observed in panel b. Panel c: Low power view 
showing positive staining of a cluster of small cells in the EBER in situ hybridisation 
assay. Panel d: Similar area of section, stained using LMP1 immunohistochemistry, 
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Figure 2. Analysis of qPCR results. qPCR results were ranked according to the Ct 
values obtained in the EBV pol qPCR assay. The result for each sample in this assay 
(square symbols) was compared with the result in each of the other assays (diamond 
symbols): panel a, EBER; panel b, ori P; panel c, BamHI W; panel d, BamHI H; panel e, 
BamHI e3 ; panel f, LMP1 . Samples with values outside the expected range are indicated 
with arrows. 
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• 268 bp 
HI. samples 
2 3 4 5 6 7 8 9 
Figure 3. Rearranged EBV genomes are not detected in adult HL samples. Panel a:  
TaqMan™ analysis of HL samples for the presence of rearranged EBV genomes with the 
WZhet configuration. The positive control is giving rise to a clear positive result with the 
amplification plot crossing the threshold after 24 cycles of amplification. Amplification plots 
from the HL samples do not reach the threshold value. Panel b:  Conventional PCR 
analysis followed by Southern blotting and hybridisation to an EBV BamHI W probe. Lane 
1 ,  case 22; lane 2, negative control; lane 3, case 7; lane 4; case 8; lane 5, negative contro l ;  
lane 6, case 23; lane 7, case 24; lane 8, negative control, lane 9 ;  positive control. The 
positive control is giving rise to a positively hybridising fragment of 268 bp (base pairs), 
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Abstract 
The Epstein-Barr virus (EBV) is associated with a proportion of cases of Hodgkin's 
disease (HD) and this association is believed to be causal. Epidemiological studies 
suggest that an infectious agent is involved in the aetiology of young adult HD, 
however, cases in this age group are less likely to have EBV-associated disease 
than cases diagnosed in early childhood or older adult years. Molecular studies 
have failed to find a consistent association between HD and other candidate 
viruses, and the aetiology of non-EBV-associated cases remains obscure. We 
looked for evidence of herpesvirus infection in samples of non-EBV-associated HD 
using a highly sensitive, degenerate PCR assay. Despite exhaustive sequence 
analysis of PCR products, no novel herpesviruses were identified. These results 
suggest that it is extremely unlikely that a novel herpesvirus is involved in the 
pathogenesis of non-EBV-associated HD. 
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Introduction 
The lymphotropic herpesvirus Epstein-Barr virus (EBV) is associated with a 
proportion of cases of Hodgkin's disease (HD) and this association is believed to 
be causal (IARC 1 997;Jarrett 1 998;Jarrett 2002). In EBV-associated HD 
(EBV+HD) the Reed-Sternberg cells, the tumour cells of HD, are infected by EBV 
and viral genes are expressed (Wu et al., 1 990;Pallesen et al., 1 991 a;Jarrett 1 998). 
Although most Reed-Sternberg cells are derived from germinal centre 8-cells 
(Kuppers and Rajewsky 1 998), they do not express B-cell receptor (BCR) 
complexes and it is not clear how they escape apoptosis, the normal fate of mature 
8-cells lacking BCRs. It is postulated that, in EBV+HD, expression of the EBV 
latent membrane proteins 1 and 2A facilitates survival of Reed-Sternberg cells by 
mimicking CD40 and BCR signalling respectively (Jarrett 2002). 
HD has an unusual age distribution with geographical and ethnic variation in age­
specific incidence patterns (MacMahon 1 966;Correa and O'Conor 1 971 ;Macfarlane 
et al., 1 995;Glaser and Jarrett 1 996). Classically the incidence is described as 
bimodal with incidence peaks occurring in childhood and older adults (>50 years) in 
developing countries, and in young adults (1 5-34 years) and older adults in 
developed countries. In practice, variations on these patterns are observed 
(Macfarlane et al., 1 995;Glaser and Jarrett 1 996). The clinicopathological features 
of HD differ by age at diagnosis (MacMahon 1 966;Glaser and Jarrett 1 996). The 
vast majority of young adult cases have nodular sclerosing HD (HONS) whereas in 
older adults and children the mixed cellularity subtype (HDMC) is relatively more 
common (MacMahon 1 966;Glaser 1 987;McKinney et al., 1 989;Glaser and Jarrett 
1 996). Male cases predominate in childhood and older adult age groups whereas 
there is no significant gender bias among young adults cases (Glaser and Jarrett 
1 996). In 1 966 MacMahon (MacMahon 1 966) suggested that HD in different age 
groups has different aetiologies and subsequent data provide support for this 
hypothesis. Epidemiological studies have consistently found that young adult HD 
cases have risk factors suggesting a high standard of living in early childhood 
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(Gutensohn and Cole 1980;Gutensohn 1982;Glaser 1987;McKinney et al., 
1989;Alexander et al., 1991 a). This has led to the suggestion that HD in this age 
group is caused by delayed exposure to a common infectious agent (Gutensohn 
and Cole 1980). In support of this model, individuals with HD diagnosed in young 
adult life report fewer childhood infections than control groups (Paffenbarger et al., 
1977). 
Many studies have examined the relationship between EBV-association and HD 
occurring in different geographical locales and patient subgroups. In the UK 
around one third of cases are EBV-associated whereas in developing countries this 
proportion is generally much higher (Jarrett et al., 1996;Glaser et al., 
1997;Armstrong et al., 1998a;Jarrett 2002) A greater proportion of HDMC cases 
are EBV-associated compared to HONS cases and this difference has been 
statistically significant in almost every study (Pallesen et al., 1991 a;Jarrett et al., 
1996;Glaser and Jarrett 1996). Among EBV+HD cases, males outnumber females 
whereas gender differences are not significant for non-EBV-associated cases 
(Glaser et al., 1997;Alexander et al., 2000). EBV status also varies significantly 
with age; most cases diagnosed in early childhood and older adult years are 
EBV+HD whereas only a minority (~25% in the UK) of young adults cases are 
EBV-associated (Jarrett et al., 1991 ;Jarrett et al., 1996;Glaser et al., 1997;Jarrett 
2002). Recent evidence suggests that EBV+HD occurring in the young adult age 
group is frequently associated with late exposure to EBV (Alexander et al., 
2000;Alexander et al., 2001 ;Jarrett 2002). 
Based on the above data, we have proposed a four-disease model of HD that 
defines subgroups of cases on the basis of age at diagnosis and EBV status 
(Jarrett 2002). Three groups of EBV+HD cases are recognised along with a single 
group of non-EBV-associated cases; the latter group has a unimodal age 
distribution with a pronounced peak in the young adult age group and a tail 
extending into the older adult age group. Young adult HONS cases typify this 
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group but older cases and HDMC cases are also represented. The aetiology of 
these cases is the subject of the present study. 
Few epidemiological studies of HD have included an analysis of the EBV status of 
lesions and therefore hypotheses of aetiology for non-EBV-associated cases are 
largely based on consideration of young adult cases. One case-control study of 
young adult HD, which did classify cases by EBV status, provides support for the 
idea that non-EBV-associated cases have experienced fewer childhood infectious 
illnesses than controls (Alexander et al., 2000). This suggests that late exposure to 
a common infectious agent may be involved in the pathogenesis of these cases. 
We, and others, have looked for genomes of lymphotropic and/or oncogenic 
viruses other than EBV in HD biopsies with negative results (Jarrett et al., 
1988;Khan et al., 1993;Secchiero et al., 1998;Berneman et al., 1998;Armstrong et 
al., 1998b) and Mackenzie et al., submitted. In particular, there is no evidence for 
involvement of known members of the herpesvirus family including human 
cytomegalovirus (HCMV), human herpesvirus (HHV) -6, HHV-7 and HHV-8. Given 
the epidemiological findings, candidate viruses should be prevalent in the 
population and living conditions should influence age of exposure. Members of the 
herpesvirus family fit these criteria and we therefore reasoned that a hitherto 
unknown herpesvirus might be involved in HD pathogenesis. To test this 
hypothesis we used a degenerate PCR strategy to search for herpesviruses in 
samples of non-EBV-associated HD. We have previously used this methodology 
to look for herpesvirus genomes in clinical samples from human and animal 
species and have shown that our assay is able to detect a wide range of 
herpesvirus genomes, (MacKenzie et al., 2001) and unpublished results. Similar 
methodology has been used by others to identify new members of the herpesvirus 
family (VanDevanter et al., 1996;Rose et al., 1997;Ehlers et al., 1999;Rivadeneira 
et al., 1999;Chmielewicz et al., 2001 ). 
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Materials and Methods 
Sample selection and experimental approach: Two series of HD cases were 
investigated for the presence of herpesvirus genomes using a degenerate PCR 
assay based on conserved regions of the herpesvirus polymerase protein. The 
first series , which comprised 28 non-selected biopsy samples from a single 
institution , was used to determine whether the assay was able to detect EBV in 
EBV+HD cases and thereby validate this experimental approach. At the time of 
analysis the EBV status of these biopsies was not known but was subsequently 
determined by EBV EBER in situ hybridisation (see below). Samples from the first 
series were investigated using a single round of PCR. A second series of 1 7  pre­
selected biopsies was then investigated in order to determine whether hitherto 
unknown herpesvirus genomes are detectable in non-EBV-associated cases. 
Selection criteria were : classical HD  following histological review; non-EBV­
associated on the basis of EBV EBER in situ hybridisation; sufficient available DNA 
(Table 1 ). In order to decrease the likelihood of missing a herpesvirus genome 
with incomplete homology to our primers, the assay was used in a semi-nested 
format in the latter analysis; modification of the primers prior to this analysis also 
resulted in an increase in assay sensitivity. The second case series was also 
screened for known HHVs using specific quantitative PCR (qPCR) assays . 
EBV status: In order to determine the EBV status of Hodgkin's tumours, EBV 
EBER in situ hybridisation analysis was performed on sections of routinely fixed, 
paraffin-embedded material using a commercially available kit (Vector 
Laboratories, Peterborough, UK). Cases were classified as EBV-associated or 
EBV+HD if Reed-Sternberg cells were positive in this assay . The approximate 
number of EBV-positive bystander cells in sections from non-EBV-associated 
cases was also recorded. 
DNA extraction : DNA was extracted from fresh or frozen biopsy samples that had 
been mechanically disrupted using a MediMachine (DAKO, High Wycombe, UK). 
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Proteinase K digestion was followed by extraction with organic solvents and 
ethanol precipitation as previously described (Trainor et al., 1982). 
Degenerate PCR assay for herpesviruses: All the available amino acid 
sequences of herpesvirus polymerases, with the exception of those from fish 
viruses, were aligned and regions of homology identified (Figure 1 ). Primers were 
designed to include all possible coding sequences of three well-conserved 
pentapeptides (Figure 1 ). Clamp sequences were then added to the 5' ends of the 
degenerate sequences; initially clamps consisted of non-viral sequences with a 
specified Tm but in the modified primers (primers 1 A, 1 8 and 2) used in the analysis 
of the second case series clamps were derived from the consensus nucleotide 
sequence of HHV genomes in this region. In order to reduce the degeneracy of 
primer pools, and thereby increase sensitivity, the synthesis of the 5' outer primer 
was split into two (1 A and 1 B) based on differential codon usage of serine. 
Likewise the synthesis of the inner primer was split into two, with primers 3A and 
38 having codons for phenylalanine and valine respectively. Samples were 
assayed with both outer primers sets and a semi-nested analysis was performed in 
the investigation of the second case series. Six separate PCRs were therefore 
performed in the analysis of the latter cases and these have been designated 
PCRs 1-6 (Figure 1, Table 1 ) . 
Extensive optimisation was performed in order to ensure that the assay had 
sufficient sensitivity to detect a single herpesvirus genome present in <1 % of the 
cells in a sample. Reactions included 1 µg of template DNA, 1.8 units of AmpliTaq 
thermostable polymerase, 2 mM MgCl2 and buffer II (all from Applied Biosystems, 
Warrington, UK), 200 µM nucleotides (Amersham Pharmacia Biotech, 
Buckinghamshire, UK), TaqStart antibody (Clontech, Cambridge, UK), and 10% 
glycerol or Q Solution (Qiagen, Crawley, UK). 5' primers were labelled with the 
fluorochrome Fam (Cruachem, Glasgow, UK) and all primers were used at an 
optimised concentration of 4 µM. PCRs were performed in a total volume of 50 µI 
and thermal cycling was performed on a RoboCycler Gradient 96 thermal cycler 
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(Stratagene, Cambridge, UK) or, in the second series of experiments, a GeneAmp 
PCR System 2400 (Applied Biosystems). Cycling conditions were: 94°C for 5 min, 
followed by five cycles of 94°C for 1 min; 44°C for 2 min; 72°C for 3 min, followed 
by 30 (series1 ) or 35 cycles (series 2) of 94°C for 1 min; 55°C for 2 min; 72°C for 3 
min followed by a final extension step at 72°C for 7 min. In semi-nested reactions, 
1 µI of first round product was used as template. Amplification products from both 
first round and nested reactions were analysed on an ABI PRISM™ 31 0 or 31 00 
Genetic Analyzer using GeneScan™ Analysis Software {Applied Biosystems). This 
gave greater sensitivity than conventional gel analysis, and improved resolution of 
fragments allowed better discrimination of non-specific and specific amplification 
products. 
Positive controls consisted of DNA from the EBV-positive cell line Raji; HHV-6-
infected JJhan cells; and a HCMV-infected tissue culture supernatant. Negative 
controls containing water were included after every two samples and placental 
DNA was used to control for non-specificity. 
Nucleotide sequence analysis: Sequence analysis was performed to determine 
the identity of, or further characterise, all PCR products in the anticipated size 
range for herpesvirus products (236 +/- 50 bases). PCR products were gel purified 
and cloned into pCR2.1 using a TA cloning kit (lnvitrogen, Groningen, The 
Netherlands). At least 6 clones derived from each 'positive' PCR product were 
sequenced using universal primers and the Big Dye™ Terminator v2.0 cycle 
sequencing kit (Applied Biosystems), according to the manufacturer's instructions. 
Thermal cycling was performed on a GeneAmp PCR System 2400 {Applied 
Biosystems) and unincorporated fluorescent nucleotides were removed using gel 
filtration (Edge Biosystems Performa DTR gel filtration kits, Vh Bio, Newcastle­
upon-Tyne, UK). Products were analysed on an ABI PRISM™ 31 0 or 31 00 Genetic 
Analyzer (Applied Biosystems). 
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Herpesvirus-specific PCR analysis: The second series of cases was screened 
with qPCR assays for all known HHVs, with the exception of herpes simplex virus 
(HSV) 2, in order to quantify the levels of viral genomes present and to aid 
characterisation of fragments amplified in the degenerate assay . TaqMan® 
methodology (Applied Biosystems) was applied and assays were designed using 
Primer Express™ version 1.0 software (Applied Biosystems); primers and probe 
sequences are shown in Table 2. Reactions included 100 ng of template DNA, 
primers at 50 nM (EBV, HHV-6 variants A and B, HHV-8 and �-globin) or 300 nM, 
probes at 200 nM, and TaqMan® Universal PCR Mastermix (Applied Biosytems) in 
a total volume of 50 µI. Thermal cycling and analysis were performed on an ABI 
PRISM™ 7700 Sequence Detection System (Applied Biosystems) using the default 
thermal cycling parameters. Positive controls included DNA from: clinical samples 
infected with HSV1 and VZV; the Raji cell line ; a HCMV-infected tissue culture 
supernatant ; JJhan cells infected with HHV-6 ; SupT1 cells infected with H HV-7; 
and the BCP-1 cell line (HHV-8). Negative controls containing water in place of 
DNA template were analysed after every two samples. A �-globin assay was used 
to quantify the amount of amplifiable DNA within samples as previously described 
(Gallagher et al., 1999). 
Results 
Analysis of the first series of non-selected HD cases, using the outer primers 1A 
and 2 (PCR 1 ), revealed five samples with clear peaks in the expected size range 
on the electropherogram tracings (Figure 1 c). A further three samples gave rise to 
small peaks in the same size range. Sequence analysis revealed that all of the 
corresponding DNA fragments were derived from EBV. EBER in situ hybridisation 
showed that the five samples with clear positive results were from the only EBV­
associated cases in this series ; EBV was detected in bystander cells in several 
other cases including the three with weak positive results. The EBV-association 
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rate (5/28) in this series was unexpectedly low for non-selected UK samples and 
we can only attribute this to the small sample size. Nevertheless, the results 
clearly demonstrate that this PCR assay can reliably and consistently detect EBV 
genomes present in Reed-Sternberg cells, thus validating this approach for the 
detection of novel herpesviruses in HD. 
Following the analysis of the first case series, the primer clamp sequences and 
assay conditions were modified slightly, see Materials and Methods, to optimise 
sensitivity. In modified format, the semi-nested assay was able to reliably detect 
<100 EBV and HHV-6 genomes and <1000 HHV-7 genomes in a background of 1 
µg DNA (data not shown). In order to look for currently unknown herpesvirus 
genomes, samples from 17 cases of non-EBV-associated, classical HD were 
tested using the semi-nested assay (Figure 1, Table 1 ). One sample was weakly 
positive using the outer primers (1A and 2), however, the majority of samples 
scored 'positive' in at least one of the nested assays (Table 1, Figure 1 d). 
Extensive sequence analysis of these products was carried out, but in all cases 
fragments corresponded to known HHVs. EBV was the most frequently detected 
virus, followed by HHV-6 variant B and HHV-7. As anticipated, there was cross­
reactivity of primer sets (Table 1 ). 
Specific PCR assays for known HHVs were performed on samples from the 
second case series. Samples from 12 cases were positive for one or more 
herpesvirus: EBV (n=5), HHV-6 variant B (n=3) or HHV-7 (n=9). Genome copy 
numbers were extrapolated from standard curves and normalised using the results 
of the �-globin qPCR assay; since it is difficult to determine precise copy numbers, 
results have been categorised into groups containing : no; 1-9; 10-49; 50-99; and 
100-350 herpesvirus genomes/100 ng amplifiable DNA (Table 1 ). One sample 
(case 3) contained a moderate number of HHV-6 variant B genomes (equivalent to 
~1 copy per 45 cells) whereas all other samples contained only a low level of 
herpesvirus genomes. Detection of EBV in PCR assays correlated with detection 
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of EBER RNAs in bystander cells by in situ hybridisation. No samples were 
positive for HSV-1 , VZV, HCMV, HHV-6 variant A or HHV-8. 
In general there was a good correlation between the results of the qPCR and 
degenerate assays. In 6 samples, low level HHV-7 infection was detected by 
qPCR but not by the degenerate PCR; this result was consistent with the known 
sensitivity of the degenerate assay. In 2 samples the degenerate assay failed to 
detect EBV genomes that were detected at low copy number by qPCR. The 
degenerate assay picked up EBV in 4 samples and HHV-6 variant B in 3 samples 
that were negative for these viruses by qPCR. This most probably reflects the fact 
that 1 0-fold more DNA was used in the degenerate assays than in the qPCR, and 
also that the degenerate assay detects EBV and HHV-6 with high sensitivity. In 
two of the latter cases EBV was detected using PCR 5; although this primer 
combination was designed for identification of HHV-6, -7 and related viruses, we 
have previously observed that these primers efficiently amplify EBV. 
Discussion 
The aim of our study was to identify novel herpesvirus genomes in non-EBV­
associated HD using a degenerate PCR strategy. Following validation of the 
experimental approach, a semi-nested PCR assay with the potential to detect all 
herpesvirus genomes of mammals, birds, amphibians and reptiles was used to 
investigate a series of biopsy samples. Herpesvirus pol sequences were amplified 
from the majority of samples tested, however, sequence analysis revealed that all 
were derived from known lymphotropic herpesviruses, namely EBV, HHV-6 and 
HHV-7. No new viruses were detected. 
Quantitative PCR was used in parallel to detect and quantify the levels of known 
HHVs within biopsies. Using this methodology genomes of one or more 
herpesvirus were detected in most samples; HHV-7 was the most frequently 
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detected herpesvirus followed by EBV and HHV-6 variant 8. The level of infection 
by these viruses was low and genome copy numbers were not consistent with 
infection of all Reed-Sternberg cells within lesions. For samples that were EBV­
positive by PCR, EBER in situ hybridisation demonstrated that the virus was 
present in bystander cells and not Reed-Sternberg cells. There was no evidence 
to suggest direct involvement of any of these viruses in the pathogenesis of non­
EBV-associated HD. 
Comparison of the results of degenerate and specific PCR assays, coupled with 
formal assessments of assay sensitivity, underscores the sensitivity of this semi­
nested degenerate PCR approach. The assay clearly has sufficient sensitivity to 
detect infection of Reed-Sternberg cells in HD. In addition, we have demonstrated 
that the assay is able to detect a wide range of herpesvirus genomes in clinical 
samples (this study and unpublished data). Although it is not possible to 
definitively exclude the presence of an unknown herpesvirus, our study suggests 
that it is highly unlikely that another herpesvirus is directly involved in the 
pathogenesis of HD. 
The epidemiological features of young adult HD, coupled with the age distribution 
of EBV-negative HD cases, suggests that an infectious agent is involved in disease 
pathogenesis. A 'hit-and-run' mechanism involving EBV has been suggested 
(Ambinder 2000), however, some patients with HD have never been infected with 
EBV and so this mechanism cannot account for all cases, (Chapman et al., 2001) 
and unpublished results. Future studies should therefore focus on other virus 
families and indirect involvement of infectious agents. 
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Table 1 .  Patient details and PCR results 
Case Sex Age Diagnosis EBV HHV-68 HHV-7 PCR 1 PCR 2 PCR 3 PCR 4 PCR 5 PCR 6 
1 M 42 HDMC - - <50 - - - - HHV-7 -
2 F 24 HDNS - - - - - - - EBV -
HHV-68 
3 F 1 6  HDNS <100 <350 <10 +/- - EBV EBV -
EBV 
4 F 1 9  HDMC - - - - - EBV - - -
5 M 1 9  HDMC <1 0 - - - - - EBV - -
HHV-68 
6 F 25 HDNS - - <50 - - EBV - -
HHV-7 
7 M 20 HDNS - - - - - - - - -
8 F 36 HONS - - - - - - - HHV-68 -
9 M 43 HDMC <50 - <50 - - - - - -
HHV-68 -
10  M 38 HDNS - - <50 - - - -
EBV 
1 1  F 41 HDNS <1 0 - - - - - - - -
12  F 54 cHD <10 - <10  - - EBV EBV EBV -
1 3  M 1 9  HDNS - <10  <50 - - EBV - HHV-68 -
14 M 31  HDNS - - - - - - - - -
1 5  F 1 5  HDNS - - <50 - - - - - -
16 F 46 HDNS - - <1 0 - - - - HHV-7 -
1 7  M 27 HDNS - <10  - - - - - HHV-68 -
M, male; F, female; HDMC, mixed cell ularity Hodgkin's disease; HONS, nodular sclerosis Hodgkin's 
disease; cHD, classical Hodgkin's disease, further subtyping not possible. Positive results in quantitative 
PCR assays are shown. Copy numbers of viral genomes were extrapolated from standard curves and 
normalised using quantitative PCR results for �-globin. Results are grouped according to the number of 
viral genomes per 1 00 ng of amplifiable DNA: -, negative; <1 0 ;  1 -9 genomes; <50; 1 0-49 genomes; 
<1 00; 50-99 genomes; <350, 1 00-349 genomes. The results of the degenerate PCR assays are 
tabulated according to the primer set used (Figure 1 ). Amplification products were analysed using 
GeneScan™ Analysis Software. Sequence analysis was performed whenever a fragment of the 
appropriate size was identified and the identity of the corresponding viral genome(s) is shown; -, 
indicates that no fragments in the expected size range were detected. Since primers 1 A and 1 B and 
also 3A and 38 are very similar, cross-reactivity is apparent particularly when larger numbers of viral 
genomes are present. 
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Table 2. Degenerate primers 
Degenerate primers based on herpesvirus polymerase sequences 1 
Outer primers: 
5' Primer 1 A  
5' Primer 1 B  
3 '  Primer 2 
Inner primers: 
5' Primer 3A 









































GTTTGA TGCCGACCTT AYGGNTTY ACNGG 




























1Degenerate primers. Primers were designed to include 1 4  nucleotides corresponding to a conserved 
pentapeptide motif. A further 1 5  nucleotides, shown in italics, were added to the 5' end of the primers to 
serve as a clamp and increase the overall Tm of the primers. The clamp sequences of the outer primers 
were derived from the consensus nucleotide sequence of the human herpesvirus sequences in this 
region. N=A+G+C+T; Y=C+T; H+A+C+T; R+A+G and D=A+G+T. 2Speclfic primers: The primers 
used in the virus-specific assays are all within the sequence amplified by the outer set of degenerate 
primers. HHV-6A and B, HHV-6 variants A and B respectively. Primer sets for EBV, HHV-6A, -7, -8 
and �-globin have been described previously (Gallagher et al., 1 999;MacKenzie et al., 2001 ). 
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Figure 1 .  Degenerate PCR strategy for the detection of herpesvirus genomes and representative 
results. Panel a) The amino acid sequence of the polymerase proteins of all herpesviruses, where 
available, were aligned and conserved sequences identified. The sequence of three well-conserved 
pentapeptides is shown in single letter amino acid code - these sequences are conserved across all 
herpesviruses, with the exception of fish viruses, although only the human herpesvirus sequences are 
shown. HSV, herpes simplex virus;  VZV, Varicella zoster virus; EBV, Epstein-Barr virus; HCMV, human 
cytomegalovirus; HHV, human herpesvirus. Panel b) Degenerate PCR primers containing 1 4  
nucleotides corresponding to all possible codon usages of the relevant pentapeptides and a 5' clamp 
sequence were synthesised and used in the combinations indicated. The clamp sequences of the outer 
primers (1 A, 1 B and 2) were based on the consensus sequence of the known human herpesviruses in 
this region. To reduce degeneracy and increase sensitivity, the synthesis of primer 1 was split into two 
according to the codon usage for serine. The substitution of methionine for isoleucine in the N-terminal 
peptide does not affect primer design since the first two bases of the respective codons are identical. 
Primer 3 was split into two syntheses with primers 3A and 3B having codons for phenylalanine and 
valine, respectively. PCRs that wil l  preferentially amplify the known human herpesviruses are indicated. 
Panel c) Representative electropherogram showing products from a sample of EBV-associated HD 
amplified with primers 1 A and 2 ( PCR 1 ) .  A clear peak (shaded) is visible in the anticipated size range 
for herpesvirus fragments (533 base pairs) and sequence analysis confirmed that this was EBV. Size 
markers are indicated with an asterisk. Panel d) Electropherogram showing amplification products from 
case 1 7, amplified using PCR 5. A peak is visible (shaded) in the expected size range (236 base pairs) 
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Abstract 
The epidemiology of young adult Hodgkin lymphoma (HL) suggests that delayed 
exposure to a common childhood pathogen may be involved in disease 
pathogenesis. The Epstein-Barr virus (EBV) is associated with a proportion of 
cases but cases of young adult HL in westernised countries are less frequently 
EBV-associated than cases in other age groups and geographical locales. This 
study investigated the possibility that polyomaviruses might be involved in the 
aetiology of HL by analysing a series of 35 cases of classical HL using both 
specific and degenerate PCR assays for polyomavirus genomes. No positive 
results were obtained, indicating that it is highly unlikely that this virus family is 
directly involved in the pathogenesis of HL. 
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Introduction 
The epidemiological features of Hodgkin lymphoma (HL) suggest that an infectious 
agent may be involved in the pathogenesis of this unusual malignancy (Gutensohn 
and Cole 1980). The herpesvirus Epstein-Barr virus (EBV) is associated with a 
proportion of cases and this association is believed to be causal (IARC 1997;Jarrett 
2002). In western countries around one third of all cases are EBV-associated, but 
this proportion varies by geographical locale, age and sex (Jarrett 2002;Jarrett et 
al., 2003). We have suggested a four disease model of HL which divides HL into 
four subgroups on the basis of age, EBV-association and age of exposure to EBV 
(Jarrett 2002). The model includes three EBV-associated subgroups of cases: a 
childhood subgroup accounting for most cases occurring in early childhood; a 
young adult subgroup associated with delayed exposure to EBV; and an older 
adult subgroup, which we speculate is associated with dysregulation of the normal 
equilibrium between host immunity and EBV. The fourth subgroup is non-EBV 
associated and accounts for the majority of cases of HL in western countries. It 
has a unimodal age incidence curve with a peak incidence between the age of 15-
34 years. Most young adult HL cases are included in this group and it is therefore 
likely that the risk factors previously described for young adult cases in developed 
countries apply to this EBV-negative subgroup of cases. 
Risk factors indicative of a high standard of living in early childhood consistently 
show an association with increased risk of developing young adult HL (Gutensohn 
and Cole 1980;Gutensohn 1982;Gutensohn and Shapiro 1982;Glaser 
1987;Alexander et al., 1991 a). It has been inferred from these data that delayed 
exposure to a common infectious agent is involved in disease pathogenesis. In 
support of this, we and others have found that young adults with HL report fewer 
common childhood infections than controls (Paffenbarger et al., 1977;Alexander et 
al., 2000). Societal changes occurring over recent decades are likely to have 
influenced patterns of childhood infections but, consistent with the above 
hypothesis, a recent study found that attendance at nursery school or day care was 9 1  
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associated with a decreased risk of HL (Chang et al., 2004). These data suggest 
that any virus associated with HL is likely to be widespread and infect many or 
most individuals at a young age. Herpesviruses, including EBV, fulfil these criteria; 
however, a previous study from our group using a degenerate PCR assay to detect 
herpesvirus genomes found no evidence for the presence of herpesviruses, other 
than EBV, at a significant level in HL biopsies (Gallagher et al., 2002). 
Polyomaviruses are also widely distributed in nature, infect most individuals at a 
young age and are known to be oncogenic in experimental systems. JC virus 
(JCV) and BK virus (BKV), the two known human polyomaviruses, both establish 
persistent infections and in immunocompromised persons are associated with 
progressive multifocal leukoencephalopathy and urinary tract pathology, 
respectively (Cole and Conzen 2001 ). Both viruses have been associated with 
malignant disease but these associations are controversial. SV40 is a related 
primate virus that does not naturally infect humans but may have been introduced 
into human populations as a result of contamination of polio vaccines in the 1950s 
and early 1960s (Shah and Nathanson 1976). SV40 genomes have been reported 
to be detectable in a high proportion of non-Hodgkin's lymphoma samples in the 
US (Vilchez et al., 2002;Shivapurkar et al., 2002), but we and others have not 
detected this virus in samples from the UK, France and Canada (MacKenzie et al., 
2003;Brousset et al., 2004). Other investigators have detected SV40 genomes in 
an intermediate proportion of lymphoma cases (Martini et al., 1998;Nakatsuka et 
al., 2003). The reasons for these different findings are not clear; geographical 
differences in the administration of infected polio vaccines are unlikely and 
therefore technical factors such as differences in assay sensitivity (McNees et al., 
2005) and the contamination of DNA samples with SV40, particularly the large T 
sequences frequently found in plasmid vectors (Lopez-Rios et al., 2004), would 
seem to be more plausible explanations. 
Volter et al (1997) previously investigated five cases of HL for the presence of 
polyomaviruses using degenerate PCR assays based on well conserved amino 
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acid motifs within the structural protein VP1 (Volter et al., 1997). Negative results 
were obtained but the number of cases examined was small, HL case details were 
not given and the reported assay sensitivities were not sufficient to detect single 
copy genomes present in Hodgkin and Reed-Sternberg (HRS) cells, the tumour 
cells in HL .  
The aim of the present study was to determine whether polyomavirus genomes are 
present within HL tumours. A series of 35 HL  cases was examined using specific 
assays for JCV, BKV and SV40 and also degenerate PCR assays, which have the 
potential to detect novel polyomaviruses. Degenerate assays were based on T 
antigen sequences since defective, integrated genomes lacking T antigen coding 
sequences are unlikely to be associated with transformation (Cole and Conzen 
2001 ). We avoided sequences in the 5' end of the large T gene as SV40 
sequences from this region are present in many cloning vectors and are a potential 
source of PCR contamination (Lopez-Rios et al., 2004). Since the tumour cells in 
HL, the HRS cells, generally constitute 1 % or less of the total cellular mass, we 
aimed to develop assays with the ability to detect a single copy genome present in 
<1 % of the cells in any sample. In addition, the study was limited to cases of 
classical HL  (cHL); nodular lymphocyte predominant HL  was excluded as this 
histological subtype is thought to represent a distinct entity with a different cell of 
origin (Stein 2001 ). 
Materials and Methods 
Clinical Samples: Lymph node biopsy samples from 35 non-selected cases of 
cHL were investigated (Table I); 1 7  cases were part of a previous study examining 
the association between SV40 and lymphoma (MacKenzie et al., 2003). Flow 
cytometric analysis was performed on 29 of these cases in order to determine the 
approximate number of HRS cells in the biopsy samples. Briefly, single cell 
suspensions were incubated with a panel of antibodies including BerH2 (Dako, 
93 
Chapter 5 
Cambridgeshire, UK), which is reactive with CD30, and results analysed on an 
EPICS Elite (Beckman Coulter, High Wycombe, UK). The overall percentage of 
CD30-positive cells was recorded using the number of viable cells as the 
denominator. DNA was extracted from fresh or frozen lymph nodes using either 
proteinase K digestion followed by extraction with organic solvents, or the 
QIAamp® DNA Blood Mini kit (Qiagen, Crawley, UK). The EBV status of tumours 
was determined using EBV EBER in situ hybridisation. Briefly, sections of paraffin­
embedded lymph node biopsies were hybridised with a commercially available 
probe (Vector Laboratories, Peterborough, UK) and reactivity detected using a 
hybridisation kit (Dako). Cases in which the HRS cells were positive are 
designated EBV-associated or EBV-positive. This study was approved by a 
multicentre research ethics committee and samples were assayed in an 
anonymised fashion. 
Quantitative Real-Time PCR analysis: DNA samples (500 ng) were screened 
using quantitative PCR assays for JCV, BKV and SV40, as previously described 
(MacKenzie et al., 2003). We have previously shown that the SV40 assay can 
consistently detect 1 0 copies of SV40 DNA in a background of 1 µg high molecular 
weight DNA (MacKenzie et al., 2003). To determine the sensitivity of the BK and 
JC assays, multiple replicates of dilutions of plasmids carrying the complete JCV 
and BKV genomes were spiked into 1 µg of DNA from the J-JHAN cell line. A 
quantitative PCR assay for �-globin was also performed to confirm that all samples 
contained sufficient amplifiable DNA (Gallagher et al., 1999). Thermal cycling and 
analysis were performed on an ABI PRISM® 7700 Sequence Detection System 
(Applied Biosystems, Warrington, UK). 
Degenerate PCR for Polyomavirus Genomes 
Assay design: Amino acid sequences from all available large T antigen 
sequences were aligned using ClustalW, courtesy of the BCM search launcher 
(http://dot.imgen.bcm.tmc.edu/multi-align/multi-align.html) , and conseNed 
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blocks of amino acids were identified (Figure 1 ). Three peptide motifs were 
selected for design of degenerate primers. The single forward primer was derived 
from the sequence E/DDVKG, which is conserved in all polyomaviruses except the 
Kilham strain of murine polyomavirus. Since codons for E (glutamic acid) and D 
(aspartic acid) have the same nucleotides in positions 1 and 2, both amino acids 
are covered by this primer {Table 2). The conserved sequence VNLE was selected 
for design of the reverse primer; two primers were synthesised with one including 
all nucleotide sequences encoding KVNLE and the other including all those 
encoding PVNLE (Table 2). A third reverse primer, based on the sequence 
TMNEY, was also synthesised (Table 2); although this sequence is not perfectly 
conserved across all polyomaviruses, the resultant primer has low degeneracy (16-
fold) and, therefore, use of this primer was predicted to result in an assay with 
superior sensitivity. Clamp sequences of 15-16 nucleotides were added to the 5' 
end of each primer. These sequences were based on the consensus nucleotide 
sequence at the relevant position of the viral genomes, with some modifications to 
ensure a reasonably high melting temperature (Tm), Primers including clamp 
sequences plus two nucleotides of non-degenerate polyomavirus sequence were 
also synthesised separately for use in second round PCRs (Table 2). The E DVKG 
and CLAMP-EDVKG primers were labelled with FAM and the CLAMP-VNLE primer 
was labelled with H EX; all primers were synthesised by TAG Newcastle Ltd 
(Gateshead, UK). 
Assay specificity and sensitivity: The following templates were used to validate 
the specificity of the assay : SV40 viral DNA (Form 1, lnvitrogen, Paisley, UK); DNA 
from the COS-7 cell line, which contains integrated SV40 (Gluzman 1981 ); D NA 
extracted from cell culture supernatants containing bovine polyomavirus (BPyV); 
and plasmids containing the complete JCV, BKV, lymphotropic papovavirus (LPV) 
and hamster polyomavirus (HaPV) genomes. All samples were assayed in a 
background of 1 µg of DNA from the J-JHAN cell line. In addition, DNA from the 
rabbit papovavirus (strain 443; LGC Promochem, London UK), a known but 95 
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uncharacterised polyomavirus, was tested. DNA was extracted from tissue culture 
supernatants using the QIAamp® UltraSens® Virus Kit (Qiagen). 
Replicates of serial 1 0-fold dilutions, predicted to contain from 1 06 to 1 0  viral 
genomes, of SV40 and BPyV were assayed in a background of high molecular 
weight DNA to determine assay sensitivity. Semi-log dilutions of viral templates 
were used to determine sensitivities in the range 104 - 1 02 viral genomes per µg 
DNA. 
Hodgkin lymphoma samples: Following optimisation and validation of the 
degenerate assays, DNA from the HL biopsies was assayed using each primer set. 
In addition, a second round PCR was performed using the CLAMP primers where 
appropriate (Table 2) . Negative controls, with water replacing the DNA template, 
were included after each sample in order to control for PCR contamination , and J­
JHAN DNA ( 1  µg) was used to control for non-specific amplification. A 
conventional PCR assay for J3-globin, which amplifies a 1 1 0 base pair product, was 
performed on all samples to verify the presence of amplifiable DNA (Saiki et al., 
1 988). 
PCR reaction mixtures contained 1 µg DNA template, 4 µM of each primer, 200 µM 
dNTPs (Amersham Pharmacia Biotech, Buckinghamshire, UK), 1 Ox PCR buffer 
containing 1 .5 mM MgCl2 , 5x a-solution and 1 .25 U HotStarTaq DNA polymerase 
(all from Qiagen). Thermal cycling was performed on a GeneAmp PCR System 
2400 (Applied Biosystems) using the following parameters: 95°C for 1 5  minutes, 
followed by five cycles of 94°C for 60 s; 44°C for 2 minutes; 72°C for 3 minutes, 
followed by 35 cycles of 94°C for 60 s; 55°C for 2 minutes; 72°C for 3 minutes 
followed by a final extension step at 72°C for 7 minutes. Following amplification 
with primer pair EDVKG/KVNLE or EDVKG/PVNLE, 1 µI of first round products 
was subjected to a further 20 cycles of amplification using primers CLAMP-EDVKG 
and CLAMP-VNLE and an annealing temperature of 45°C. Reaction products 
were analysed on an ABI PRISM® 3 10  Genetic Analyzer using GeneScan analysis 
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(Applied Biosystems) as this method gives greater sensitivity and fragment size 
resolution than conventional electrophoresis. 
Nucleotide sequence analysis: Sequence analysis was performed to further 
characterise degenerate PCR products in the anticipated size range for amplicons 
of polyomavirus genomes. Amplification products were cloned using the TOPO 
TM 
TA Cloning® kit (lnvitrogen) and sequencing performed using the Big Dye® 
Terminators v3.1 Cycle Sequencing Kit and an ABI PRISM® 3100 Genetic 
Analyzer (Applied Biosystems). Nucleotide sequences were subjected to blastn 
searches (http://www.ncbi.nlm.nih.gov/BLAST). 
Results 
Flow Cytometry: Single cell suspensions from 29 of the 35 cases were analysed 
by flow cytometry and the results are shown in Table I. In the majority of cases 
(24/29), �1 % of the viable cells were reactive with the BerH2 antibody indicating 
cell surface CD30-positivity; although CD30 staining is not entirely specific to HRS 
cells, the vast majority of CD30-positive cells within HL tumours would be expected 
to be HRS cells. 
Quantitative Real-Time PCR Analysis: HL samples were screened using 
sensitive PCR assays for the known human polyomaviruses JC and BK and the 
primate virus SV40. All samples were negative in these assays despite the 
presence of amplifiable DNA. Analysis of replicate dilutions of plasmids containing 
full length JCV and BKV genomes confirmed that all of these assays could 
consistently detect 1 O copies of viral DNA 
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Degenerate PCR for Polyomavirus Genomes 
Specificity and sensitivity: Degenerate PCR assays based on the large T antigen 
of polyomaviruses were designed and validated. Primers were derived from the 3' 
region of the large T gene and therefore will not amplify the SV40 sequences that 
are most frequently present in cloning vectors (Lopez-Rios et al., 2004). Primer 
pairs had the expected specificities: JCV, BKV, SV40, LPV and HaPV templates 
were amplified using the reverse primer KVNLE, whereas BPyV was amplified 
more efficiently using the PVNLE reverse primer (Figure 2a). JCV, BKV and LPV 
were successfully amplified using the reverse primer TMNEY; despite an imperfect 
sequence match, SV40 was also efficiently amplified using this primer (Figure 2a). 
All amplification products were of the expected size - 146 base pairs for the 
EDVKG/KVNLE or EDVKG/PVNLE assays and 208 base pairs for the 
EDVKG/TMNEY assay. When DNA from the rabbit papovavirus was used as 
template, negative results were obtained using the PVNLE and TMNEY reverse 
primers but a 146 base pair product was generated using the EDVKG/KVNLE 
primer set (Figure 2b). The nucleotide sequence of this amplification product, and 
the predicted translation, were found to have homology with known polyomavirus 
genomes and large T antigens, respectively. The nucleotide sequence has been 
deposited as GenBank accession number AY911513. 
Analysis of serial dilutions of template DNA, in a background of 1 µg of high 
molecular weight DNA, was performed in order to determine assay sensitivity. To 
detect a single copy viral genome present in 1 % of the cells, the assay should be 
able to detect 1 .5 x 103 genomes in a 1 µg DNA sample. Using the EDVKG and 
KVNLE or PVNLE primers, we were able to detect 103·5 genome copies of SV40, 
JCV, BKV and BPyV, but could not consistently detect 103 copies. Using the 
CLAMP primers in a second round reaction, we were able to detect 102·5 SV40 
genomes and 103 BPyV genomes. As predicted, the assay incorporating the 
TM NEY primers was most sensitive having the ability to detect <102 SV40 
genomes. 
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Hodgkin lymphoma samples: DNA samples from 35 cases of cHL were assayed 
using the above degenerate PCR assays for polyomaviruses, on multiple 
occasions. No PCR products in the anticipated size range were detected on 
GeneScan analysis. 
Discussion 
Sensitive, degenerate PCR assays based on the large T antigen of polyomaviruses 
were developed and their specificity and sensitivity were validated using a variety 
of templates. Using this approach, we successfully amplified sequences from the 
rabbit papovavirus, a known virus for which no sequence information was 
available, thus confirming the usefulness of these assays for polyomavirus 
detection. 
Both specific and degenerate PCR assays were used to investigate polyomavirus 
involvement in HL. No positive results were obtained suggesting that it is highly 
unlikely that a polyomavirus is present within all the HRS cells of HL tumours. The 
quantitative assays for SV40, JCV and BKV utilise TaqMan® methodology and are 
therefore very sensitive, having the ability to detect �1 0 copies of the viral genomes 
in a background of 1 µg high molecular weight DNA. Degenerate PCR assays are 
inherently less sensitive, but the least sensitive of the semi-nested assays used in 
this study was able to detect 103 genomes in a DNA sample from the equivalent of 
1.5x105 cells. Since, in the majority of our samples, > 1 % of the cells were reactive 
with CD30 antibodies, this level of sensitivity should be sufficient to detect 
polyomavirus infection of HRS cells. All of the assays utilised in this analysis were 
based on large T sequences and it is therefore unlikely that defective, integrated 
genomes have escaped detection. We cannot exclude the possibility that a small 
proportion of the total HRS cell population is infected by a polyomavirus or the 
existence of a hit-and-run mechanism involving polyomaviruses. However, we 
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believe these results suggest that it is highly unlikely that polyomaviruses are 
directly involved in the transformation of HRS cells in HL. 
The epidemiological features of young adult EBV-negative HL suggest that an 
infectious agent is involved in disease pathogenesis (Gutensohn and Cole 1980). 
Previous studies from our laboratory indicate that herpesviruses are unlikely to be 
directly involved (Gallagher et al., 2002). The inability to detect persistent EBV 
infection in patients with non-EBV-associated HL using multiple methods; the 
finding that young adult HL cases with non-EBV-associated disease are more likely 
to be EBV seronegative than controls; and the lack of defective or rearranged (Gan 
et al., 2002) EBV genomes in HL biopsies from adult cases, all argue against a 'hit 
and run' mechanism in cases classified as 'EBV-negative' using in situ techniques 
(Staratschek-Jox et al., 2000;Gallagher et al., 2003;Knecht and Odermatt 2003). 
This study further suggests that polyomaviruses are not directly implicated. The 
putative virus remains elusive but complementary techniques for virus discovery, 
which do not require any a priori knowledge of the likely agent, need to be explored 
before a direct role for viruses in this disease can be excluded. 
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Table 1 .  Patient details 
Case Sex Age• at Histological EBV status %CD301 
number diagnosis subtype positive 
1 F 24 NSHL Positive 1 
2 M 42 MCHL Negative ND 
3 M 21 NSHL Negative ND 
4 M 63 NSHL Negative ND 
5 F 16  NSHL Negative ND 
6 F 25 NSHL Negative 2 
7 M 36 NSHL Positive 3 
8 M 29 NSHL Positive 2 
9 M 43 MCHL Negative ND 
1 0  M 42 NSHL Positive 3 
1 1  M 38 NSHL Negative 3 
1 2  F 41 NSHL Negative <1 
1 3  M 1 9  MCHL Positive 3 
14  M 1 9  NSHL Negative <1 
1 5  F 1 5  NSHL Positive 
16  M 31 NSHL Negative 2 
17 F 33 HL NOS Positive <1 
1 8  M 31 NSHL Positive <1 
19  F 1 5  NSHL Negative 2 
20 F 46 NSHL Negative 7 
21 M 33 NSHL Negative 5 
22 M 30 NSHL Positive ND 
23 M 27 NSHL Negative 8 
24 F 76 NSHL Negative 3 
25 F 22 NSHL Negative 5 
26 F 1 7  NSHL Negative 4 
27 F 14  NSHL Negative 13  
28 M 37 MCHL Negative 3 
29 M 21 NSHL Positive 6 
30 M 27 NSHL Negative 
31 F 36 NSHL Positive 3 
32 M 23 MCHL Positive 
33 F 22 NSHL Negative 0 
34 F 31 NSHL Negative 
35 F 1 6  NSHL Negative 
F, female; M, male; NSHL, nodular sclerosis Hodgkin lymphoma; MCHL, mixed cellularity 
Hodgkin lymphoma; HL NOS, Hodgkin lymphoma not otherwise specified as further subtyping 
not possible, ND, not done. *Age in years. #%CD30-positive as defined by flow cytometry 
using total viable cells as the denominator. 101 
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Table 2. Degenerate PCR primers for detection of polyomaviruses 
Primers 
Forward Primer EDVKG 
*GTTTA TGGTTGTCTTTGANGA YGTNAARGG 
Reverse Primer KVNLE 
GTTTCGGTGTTTCTTTTCNARRTTNACYTT 
Reverse Primer PVNLE 
GTTTCGGTGTTTCTTITCNARRTTNACNGG 











1 6  
1 
Clamp sequences are shown in italics. N = A +  G + C + T; Y = C + T; and R = A +  G. * FAM­
labelled oligonucleotides; # HEX-labelled oligonucleotide. 
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EDVKG KVNLE TMNEY 
BKV ----- ----- -----
JCV ----- ----- -----
LPV D---- ----- -----
SV4 0 ----- ----- ----F 
HaPV ----- ----- -A---
Py ( Crawford ) ----- ----- -----
Py ( strain A2 ) ----- ----- -----
Py ( strain A3 ) ----- ----- -----
Py ( Ki lham ) -VLAE ----- -s---
BPyV ----- P---- -c---
BFDV - - - -- P---- ---N-
GHPV ----- P---- ---H-
Figure 1 .  Conserved amino acid motifs within the large T antigen of polyomaviruses 
- denotes amino acid identity. BKV, BK virus; JCV, JC virus; LPV, lymphotropic papovavirus; SV40, 
simian virus 40; HaPV, hamster polyomavirus; Py, murine polyomavirus; BPyV, bovine polyomavirus; 
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Figure 2. GeneScan analysis of degenerate PCR products. a) Upper panel : 
amplification of SV40 sequences using primer pair EDKVG and KVNLE. Middle panel: 
amplification of bovine polyomavirus sequences using primer pair EDKVG and PVNLE. 
Lower panel: amplification of SV40 sequences using primer pair EDKVG and TMNEY. b) 
Ampl ification of partial genomic sequence from rabbit papovavirus. Arrows indicate 
specific polyomavirus PCR products; *idicates ROX 350 size marker. 
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The potential use of novel cell substrates from diverse animal species raises 
concerns about the transmission of hitherto unknown viral agents. Viruses that do 
not cause a cytopathic effect in cell culture may escape detection by conventional 
methods and molecular methods may therefore prove useful for screening for 
hitherto unknown viruses. This review describes currently used molecular methods 
for virus discovery, including degenerate PCR assays, representational difference 
analysis and rolling circle amplification, and summarises the advantages and 
disadvantages of each technique. 
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Introduction 
Characterizing potential virus contaminants in vaccines is a complex and 
constantly evolving problem. Contaminants have been associated with the use of 
primary cell substrates and of non-irradiated materials like trypsin and serum. The 
move towards using clonally derived cell lines, irradiated serum and recombinant 
trypsin have been major steps in improving the safety of the new generation of 
vaccines. At the same time there has been renewed interest in cell substrates, 
some of them tumourigenic, from species such as dogs, African green monkeys 
and Syrian hamsters. Of particular concern is that these cells might harbour a 
virus, which while non-pathogenic in the species of origin, might be tumourigenic in 
a human host. Virus infections in these cell substrates may not always be revealed 
by traditional assays that depend on a cytopathic effect, and this has driven the 
need to implement new technologies for virus detection. 
Molecular techniques for virus discovery have been developed over the last ten to 
fifteen years and now have a proven track record. Early attempts to identify novel 
viruses by molecular means lacked sensitivity and specificity but modern 
amplification techniques, such as the polymerase chain reaction (PCR), have 
revolutionised the field of virus discovery. Currently used methods include 
degenerate PCR assays, subtractive hybridisation including representational 
difference analysis (RDA)(Lisitsyn et al., 1993), and the more recently described 
rolling circle amplification (RCA) technique for detection of closed circular DNA 
genomes (Rector et al., 2004b). This review will summarise these techniques and 
their advantages and disadvantages. Additional methodologies, such as screening 
cDNA expression libraries with immune serum, have been successfully used in the 
past (Choo et al., 1989) but are less relevant to the analysis of vaccine cell 
substrates and will not be considered further. 
Degenerate PCR assays: Degenerate or redundant PCR assays utilise pools of 
primers that include most or all of the possible nucleotide sequences encoding a 
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conseNed amino acid motif. They have been used extensively to identify genes 
encoding proteins related to known proteins, for example new members of protein 
families or functional homologues in different species. In the context of virus 
discovery, these assays are used to detect novel viral genomes related to known 
genomes; they are therefore useful for identification of new members of virus 
families or subfamilies. 
The first step in the design of degenerate assays is to identify proteins that are well 
conseNed among different members of a virus family and to perform an alignment 
of all the available amino acid sequences. Conserved blocks of sequence are then 
identified; in our experience conserved pentapeptides are ideal for primer design. 
A degenerate nucleotide sequence, containing all the possible sequences 
encoding the pentapeptide, is then derived from the amino acid sequence. The 
level of degeneracy (i.e., the number of different primers in the primer pool) will 
depend on the number of codons for each of the amino acids. Since sensitivity is 
inversely proportional to degeneracy, it is preferable to select conserved peptides 
that contain amino acids such as methionine, with only one codon, rather than 
amino acids such as serine, with six; unfortunately, this is not always possible. The 
degenerate nucleotide sequence corresponding to a pentapeptide is 14 bases 
long, since the terminal degenerate nucleotide is omitted from the primer. To 
achieve a reasonable level of sensitivity a primer with a degeneracy of 128-fold or 
less is desirable. 
In order to increase PCR efficiency, a non-degenerate clamp sequence is usually 
added to the 5' end of the primer; this facilitates annealing of the primer to PCR 
products generated during the reaction. In our laboratory, the clamp sequence is 
derived from the consensus nucleotide sequence at the relevant position of the 
viral gene, with some modifications to ensure a reasonably high primer Tm. Since 
this clamp sequence has homology to the viral target template, it will stabilise 
primer binding during the early cycles of the PCR. We also usually add the 
sequence GTTT to the 5' ends of primers to ensure optimal cloning efficiency using 108 
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TA cloning methods (Brownstein et al., 1996). The first rounds of thermal cycling 
are performed using a low annealing temperature (e.g., five cycles with annealing 
at 44 °C) to allow the degenerate sequence to anneal to the template and then the 
annealing temperature is raised to facilitate specific amplification of PCR products. 
A similar strategy for degenerate PCR design has been independently developed 
in Tim Rose's laboratory and designated CODEHOP (COnsensus-DEgenerate 
Hybrid Oligonucleotide Primer)(Rose et al., 2003); a software programme is 
available for primer design at http://blocks.fhcrc.org/codehop.html. The main 
difference between this method of primer design and that described above is that 
the clamp sequence is derived from amino acid sequence, using codon 
preferences based on species. 
Degenerate PCR assays are inherently non-specific and lack sensitivity compared 
to conventional PCR assays. Probes are generally not available, therefore positive 
results cannot be confirmed by hybridisation; identification of novel viral sequences 
is therefore dependent on identification of DNA fragments in the anticipated size 
range and subsequent sequence analysis. For these reasons, we prefer to 
analyse PCR products using capillary electrophoresis and GeneScan TM analysis 
(Applied Biosystems, Warrington, UK). This gives improved sensitivity {up to 100-
fold) compared to conventional agarose or polyacrylamide gel electrophoresis, and 
the superior fragment size resolution helps distinguish non-specific amplification 
products, present in control samples, from fragments of interest (Gallagher et al., 
2002). 
The major focus of research in our laboratory is the search for a novel viral agent in 
Hodgkin lymphoma (Jarrett 2002). This malignancy presents many challenges as 
the malignant cells are fragile, difficult to purify and scarce, usually representing 
less than 1 % of the total cells in the tumour. In order to detect viral genomes 
present in the malignant cells our degenerate PCR assays have to be able to 
detect a single copy genome present in 1 % of the sample. Since 1 µg of tumour 109 
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DNA is generally used as template in our assays, we aim to detect 1.5x103 viral 
genomes within a background of high molecular weight DNA. The epidemiology of 
Hodgkin lymphoma suggests that the disease may result from delayed infection 
with a common infectious agent. We have therefore focused our efforts on the 
search for new members of virus families that are widespread in the human 
population and infect most individuals at a young age. For these reasons, we have 
designed degenerate PCR assays for detection of herpesviruses and 
polyomaviruses, as described below. 
PCR assays for detection of herpesvirus genomes: Degenerate PCR assays 
have been used successfully to identify many new members of the herpesvirus 
family (Ehlers et al., 1999;Rivadeneira et al., 1999). Assays are generally based 
on the polymerase and glycoprotein B proteins, as these are well conserved across 
family members. Alignment of the available polymerase sequences reveals 
several blocks of amino acid sequence that are well conserved in all herpesviruses, 
with the exception of the fish viruses (Fig. 1 ). We have designed an assay based 
on the YPSII and IYGDT amino acid motifs (Fig. 1 ); although YPSII is not 
absolutely conserved, the substitution of the final isoleucine (I) with methionine (M) 
does not affect the primer design. Since 144 primers are required to cover all 
possible nucleotide sequences encoding the pentapeptide YPSII, we have split the 
synthesis of this primer into two in order to maintain sensitivity . An internal primer, 
based on the YGF/VTG motif, allows the assay to be run in a semi-nested format 
(Fig. 1 ); again, the synthesis of this primer has been split into two, with one primer 
covering the codon usage of phenylalanine (F) and the other valine (V). Clamp 
sequences have been added to the 5' ends of the primers, essentially as described 
above (Table 1 ) . 
This assay is extremely sensitive and robust (MacKenzie et al., 2001 ;Gallagher et 
al., 2002). Using the outer primer sets we can detect 103 copies of a herpesvirus 
genome present in a background of 1 µg DNA and this sensitivity increases to <102 
copies using the semi-nested primers. We have validated the assay using a wide 110 
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range of templates (Fig. 1 ), and have amplified pol gene sequences from porcine 
cytomegalovirus, a known virus for which no sequence was available at the time of 
analysis. The assay is relatively simple to perform and can therefore be used for 
screening purposes. Similar assays have been used by other laboratories to 
identify novel herpesvirus sequences in a wide range of animal species including 
non-human primates, pigs, and turtles (Quackenbush et al., 1998;Ehlers et al., 
1999;Rivadeneira et al., 1999). Novel herpesvirus sequences were not detected in 
DNA samples from Hodgkin lymphoma biopsies using this approach (Gallagher et 
al., 2002). 
PCR assays for detection of polyomavirus genomes: Polyomaviruses have well 
conserved amino acid sequences, particularly in the gene encoding the virus 
capsid protein VP1 (Volter et al., 1998). However, tumours associated with 
polyomaviruses frequently contain integrated viral genomes which have lost these 
sequences, although the gene encoding the T antigen is retained. We therefore 
elected to design an assay based on the large T antigen, which is less well 
conserved than the structural proteins. Sequences from SV40, particularly those at 
the 5' end of the large T gene, are frequently included in plasmid vectors and 
contamination of DNA samples with these vectors can lead to false positive results 
in PCR assays for SV40 and related viruses (Lopez-Rios et al., 2004). It is 
therefore prudent to avoid the 5' part of the T antigen gene when designing 
primers. 
Alignment of the available large T antigen sequences did not reveal any conserved 
pentapeptides although there were several tetrapeptides that were conserved 
across all viruses, with the exception of the Kilham strain of mouse polyomavirus 
(Fig. 2). We selected the E/DDVKG motif for design of the 5' primer, since codons 
for E (glutamatic acid) and D (aspartic acid) only differ at the third position, and the 
VNLE motif for design of the 3' primer. Synthesis of the latter primer was split into 
two, with separate primers covering KVNLE and PVNLE (Fig. 2). An additional 3' 
primer derived from the amino acid sequence TMNEY was also synthesised; 111 
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although this sequence is not conserved in all polyomaviruses, the respective 
primer has only 16-fold degeneracy and was predicted to give greater sensitivity 
than the VNLE primers. Clamp sequences were added to all primers, as described 
above. 
The assay was validated using a range of templates including the human viruses 
JC and BK, the non-human primate virus SV40, hamster polyomavirus and bovine 
polyomavirus (Wilson et al., submitted). Primer sets had the expected specificities. 
In addition, sequences from a rabbit polyomavirus, a virus for which no sequence 
information was available, were amplified (Wilson et al., submitted). Using the 
KVNLE and PVNLE primers we were able to detect 103 - 5x103 viral genomes in a 
background of 1 µg DNA; as predicted, the assay using the TMNEY primer was 
more sensitive, detecting <103 viral genomes in a 1 µg sample. 
Detection of polyomavirus sequences in human lymphoma: The detection of 
SV40 in samples of non-Hodgkin lymphoma has become a controversial issue with 
some groups detecting viral genomes in >40% of cases (Vilchez et al., 2002), while 
others have failed to detect evidence of the virus (Brousset et al., 2004). We 
screened DNA samples from 152 cases of non-Hodgkin lymphoma and 35 cases 
of Hodgkin lymphoma for the presence of SV40, BK virus and JC virus genomes 
using specific TaqMan™ assays with negative results (MacKenzie et al., 2003). A 
previously described consensus PCR assay, based on nucleotide sequences 
conserved between JC, BK and SV40 genomes, was also used to screen 128 of 
the non-Hodgkin's lymphoma samples and 18 of the Hodgkin lymphoma samples; 
again only negative results were obtained. The degenerate assays described 
above were used to investigate 35 cases of Hodgkin lymphoma but we found no 
evidence of polyomavirus genomes (Wilson et al., submitted). These results 
suggest that it is unlikely that SV40 is involved in the pathogenesis of commonly 
occurring non-Hodgkin lymphomas, and polyomaviruses are unlikely to play a 
direct role in Hodgkin lymphoma. 112 
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The above description provides examples of degenerate PCR assays designed to 
search for novel DNA tumour viruses. However, these assays can be used to 
detect a wide range of viruses including RNA and DNA viruses, viruses causing 
lytic and latent infections, and viruses with circular and linear genomes. For 
example, degenerate PCR was used to successfully identify a new hantavirus 
associated with an acute respiratory distress syndrome (Nichol et al., 1993). 
These assays are sensitive, versatile, robust and relatively easy to perform and 
can therefore be used for screening purposes. The main disadvantage is that they 
require knowledge of the viral agent that is likely to be involved and can only be 
used where sufficient sequence information, from related viruses, is available. 
Assays will be most reliable when primer design is based on alignment of a large 
number of viral genomes, as is the case with the herpesvirus assays. 
Subtractive hybridisation techniques: Subtractive hybridisation is used to isolate 
differences between two nucleic acid species. Since viral infection constitutes 
addition of exogenous nucleic acid sequences to a cell, this methodology can be 
used to detect RNA or DNA viruses. These assays are more difficult and 
cumbersome to perform than degenerate PCR assays but have the advantage that 
no a priori knowledge of the potential viral agent is required. 
Subtractive hybridisation involves two samples of nucleic acid - the tester sample, 
which includes the target sequence of interest, and the driver sample. The tester 
and driver samples are hybridised, allowing complementary strands of nucleic acid 
to anneal, and then various strategies are used to rescue either single-stranded 
tester molecules or tester :tester hybrids. The driver and tester samples must be as 
closely matched as possible in order to minimise differences in nucleic acid 
composition. For subtractive hybridisations using DNA samples, the driver sample 
should be derived from a non-affected sample from the same individual, whereas in 
cDNA subtractions the driver should be from the same cell type (at the same stage 
of differentiation) as the tester sample. Driver samples are always used in excess 
in the hybridisation reaction. 1 13 
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Subtractive hybridisation works best when nucleic acid complexity is low and the 
hybridisation reaction approaches completion. Body fluids, such as serum, and cell 
culture supernatants probably represent the least complex samples for virus 
hunting. RNA is considerably less complex than genomic DNA; RNA/cDNA 
subtractions are therefore simpler to perform than DNA subtractions and a wider 
choice of methodologies is available. Strategies for subtractive hybridisation using 
genomic DNA samples generally lack sensitivity because the complexity of the 
DNA prevents the hybridisation from reaching completion. The representational 
difference analysis (RDA) protocol circumvents this problem by using only a 
representation, or defined part, of the human genome in each hybridisation 
reaction (Lisitsyn et al., 1993). Representations are defined by digestion with a 
restriction enzyme and subsequent size selection. This results in a reduction of 
complexity of the DNA sample, which varies depending on the enzyme used. 
Following the generation of tester and driver representations, adaptor sequences 
are ligated to the 5' ends of the tester sample. The tester and driver samples are 
then hybridised and a 'fill-in reaction' is performed. This results in the addition of 
nucleotides, complementary to the adaptor molecule, to the 3' ends of all 
molecules that have hybridised to tester molecules. As a result, tester molecules 
that hybridised to other tester molecules (tester:tester hybrids) will have adaptor 
sequences, or their complements, on each end and will therefore be amplified 
exponentially using the adaptor as primer. Molecules that formed driver:driver 
hybrids will not have adaptor sequences on either end and will not be amplifiable 
using the adaptor primer, whereas molecules that were part of tester:driver hybrids 
will have an adaptor sequence at only one end and will be amplified linearly. 
Similarly, single stranded tester molecules will be amplified linearly. Each 
hybridisation and 'fill-in' is therefore followed by a PCR reaction, using the adaptor 
as primer, which results in the selective enrichment of double-stranded tester 
molecules. Following amplification, the adaptor sequence is changed and further 
rounds of hybridisation and amplification are performed. The first round of RDA is 114 
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largely subtractive but, as a result of the second order kinetics of reassociation, 
subsequent rounds have an increased kinetic component. 
The chance of detecting a viral genome using RDA increases with genome size 
since there is a greater chance of fragments from larger genomes being present in 
the representation. We have estimated that there is a 99% probability of detecting 
the presence of a herpesvirus genome in a single representation, but two 
independent representations are required to have a 95% probability of detecting an 
adenovirus genome and three to four are required for detection of a retrovirus 
genome. 
The RDA protocol requires meticulous bench work but, in our experience, the 
technique can reliably detect viral genomes present at single copy level. By 
monitoring the procedure using quantitative PCR, we have shown that fragments of 
the EBV genome can be amplified > 1 million-fold using three rounds of RDA. In 
our hands the technique does not work reliably when the target fragment is present 
at lower levels and when the starting DNA samples are not of good quality. 
The main advantage of RDA is that no a priori knowledge of the infectious agent is 
required. It is also versatile in that it can be used to detect linear and circular 
genomes and modified protocols can be used for the detection of RNA viruses and 
viruses present in body fluids. The need for matched samples, multiple 
representations and experienced lab workers are the main disadvantages. The 
technique is not ideal for screening samples and a high index of suspicion is 
required before embarking on RDA. Nevertheless, RDA has a good track record 
for virus discovery including the identification of human herpesvirus 8 (Chang et al., 
1994), the elusive agent in Kaposi's sarcoma, and the circovirus TTV (Nishizawa et 
al., 1997). 
Rolling circle amplification: Rolling circle amplification (RCA) is a technique used 
to exponentially amplify single or double-stranded circular DNA templates. It is 1 15 
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widely used as a laboratory method for amplifying small circular molecules, such as 
plasmids, and has only recently been described as a method for virus discovery 
(Rector et al., 2004b). RCA utilises bacteriophage cp29 DNA polymerase, a high­
fidelity enzyme with a strong strand-displacing capability, high processivity and 
proofreading activity. The processivity, coupled with the strand-displacing 
capability, enables the generation of tandem-repeat concatemers of circular DNA 
molecules. Elongation of displaced single-stranded products results in exponential 
amplification of the template DNA. Random hexamers are used to prime the 
reaction, eliminating the requirement for custom primers. RCA can be therefore be 
used to amplify complete, circular DNA genomes without any knowledge of viral 
genomic sequence. 
Rector et al (2004) first reported the use of the RCA technique in virus discovery. 
Using a commercially available kit (TempliPhi 100, Amersham Biosciences, 
Amersham, UK) they were able to selectively amplify complete genomes from 
human papillomavirus 16 DNA. Assay sensitivity was improved by increasing the 
concentration of nucleotides in the reaction. Optimised conditions were then used 
to isolate and sequence a novel variant of bovine papillomavirus type 1 and a novel 
papillomavirus from a Florida manatee (Rector et al., 2004a;Rector et al., 2004b) 
We have used this protocol to successfully amplify complete papillomavirus 
genomes from equine sarcoid tumours (Fig. 3) and complete polyomavirus 
genomes, including the genome of the rabbit polyomavirus metioned above. The 
technique is relatively simple to perform and is suitable for screening purposes. 
The major disadvantages of RCA are first, it can only be used to selectively amplify 
circular genomes and secondly, assay sensitivity is decreased when genomic DNA 
samples are used as template, since the background DNA is also amplified, albeit 
with lesser efficiency, during the multiple displacement amplification reaction. 116 
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Conclusions 
The last fifteen years have witnessed the dawn of the molecular era of virus 
discovery. Several complementary methods for the identification of novel viruses 
have been developed, each with its own pros and cons. Degenerate PCR has the 
advantage of sensitivity and simplicity but can only be used to detect related 
members of known virus families. Subtractive hybridisation techniques, such as 
RDA, are technically more complex and time-consuming and are less sensitive but 
do not require any knowledge of the potential infectious agent. The recently 
described RCA technique can only be used to amplify circular DNA genomes but, 
like RDA, does not depend on any a priori knowledge of the sequence of the 
potential virus. Both degenerate PCR assays and RDA have a proven track record 
and RCA holds promise for the future. 
The choice of method for use in virus hunting will depend on: the evidence 
suggesting involvement of a particular virus family or type; the index of suspicion; 
the reagents or samples that are available; and the predicted level of infection and 
therefore the required assay sensitivity. Of the assays described above, 
degenerate PCR assays are the most straightforward to perform and have the 
most applicability to screening vaccine cell substrates. These assays may prove 
useful in the investigation of novel cell substrates, such as clonal cell lines that are 
potentially tumourigenic. 
Acknowledgements 
We would like to thank Freda Alexander for performing the power calculations used 
to determine the required number of RDA representations for virus discovery and 
David Onions for helpful discussion. Work in our laboratory is supported by a 
Leukaemia Research Fund specialist programme grant. 117 
1 18 
Molecular methods for virus discovery 
Table 1. Primers used in degenerate PCR assays 
Number Sequence 
Herpesvirus 
1A  GACTTTCCAAGTTTCTAYCCNAGYATHAT 









Primer numbers refer to those used in Figures 1 and 2. Clamp sequences are shown in italics. 
N= A+C+G+T; Y=A+T; R=A+G; D=G+A+T; H=A+T+C. 119 
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Figure 1 .  Degenerate PCR assay for detection of herpesviruses. Panel a: Amino acid sequences 
of the herpesvirus polymerase proteins were aligned and blocks of conserved sequence identified - the 
alignment of the human herpesviruses is shown but these sequences were well conserved across 
herpesviruses of all species except fish. Pentapeptides were then selected (boxed sequences) on the 
basis of codon usage, to minimise degeneracy of the corresponding primer. Panel b: Three outer 
primers and two inner primers were synthesised; primer 1 was split into two syntheses, which differed in 
their codon usage for serine, and primer 3 was split in two syntheses with primer 3A including all 
nucleotide sequences encoding phenylalanine (F) and 3B including those encoding valine (V). The 
assay is run in a semi-nested format using the indicated primers. Panel c: GeneScan analysis showing 
amplification of Epstein-Barr virus (EBV) specific pol gene sequences using outer primers 1 A and 2. • 
indicates size markers. Panel d: GeneScan analysis of products of semi-nested assay showing 
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Figure 2. Degenerate PCR assay for detection of polyomaviruses: Panel a: Amino acid sequences 
of the polyomavirus large T antigen were aligned and blocks of conserved sequence identified (boxed 
areas). Panel b: One 5' primer and three 3' primers were synthesised; primer 5A covers all possible 
codons for KVNLE and primer 5B covers all possible codon usage for PVNLE. Primer 6 is derived from 
the sequence TMNEY; this sequence is not conserved across all polyomaviruses but the corresponding 
primer has a degeneracy of only 1 6-fold, resulting in a sensitive PCR reaction. Panel c (upper 
electropherogram): GeneScan analysis showing detection of bovine polyomavirus (BPyV) using primers 
4 and 5B. Panel c (lower electropherogram):  GeneScan analysis showing detection of SV40 sequences 
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Figure 3. Analysis of equine sarcoid tumour samples using rolling circle 
amplification: DNA samples were subjected to rolling circle amplification followed by 
restriction enzyme digestion with Hindl l l  and agarose gel electrophoresis. Solid arrow 
indicates the band representing the complete papillomavirus genome; dashed arrow 
indicates non-specific products. Lane M, Hindl l l-digested lambda phage DNA size marker; 
lanes 1 -5 ,  samples from equine sarcoid tumour samples - full length papillomavirus 
genomes are detected in four of the samples; lane 6, equine DNA; lane 7, cloned genome 
of bovine papillomavirus type 1 in a DNA background; lane 8, plasmid ; lane 9, water. 
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Classical Hodgkin lymphoma (cHL) is one of the commonest lymphomas in the 
Western world. The aetiology of cHL is not completely understood largely because 
the malignant cells, the Hodgkin and Reed-Sternberg (HRS) constitute only 1 % of 
the tumour mass, and this has hindered their characterisation. Epstein-Barr virus 
(EBV) is causally associated with a proportion of cHL cases and epidemiological 
data suggest that an infectious agent may be involved in the remaining cases, 
although this agent remains elusive. The generation of gene expression libraries 
from primary HRS cells may enable identification of genes involved in the disease 
pathogenesis. The primary aim of this study was to identify genes that are 
differentially expressed in HRS cells and their 'normal' counterpart. Serial Analysis 
of Gene Expression (SAGE) libraries were generated from CD30-positive cells 
enriched from an EBV-positive and EBV-negative case of cHL, as well as CD77-
positive cells from a reactive lymph node. Among the genes that had increased 
expression in the cHL cases compared with the "normal" counterpart were Protein 
Kinase C eta and Galectin 2. Results from specific relative quantitative PCR for 
these genes showed that both Protein Kinase C eta and Galectin 2 were indeed 
present at higher levels in the cDNA from the cHL samples used to generate these 
libraries. Although these data are prel iminary, further investigation of cHL cases is 
warranted to determine whether these genes are involved in the pathogenesis of 
cHL. 126 
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Introduction 
Hodgkin lymphoma (HL) is a malignant disease which accounts for around 30% of 
all lymphomas. It is subdivided into classical Hodgkin lymphoma (cHL) which 
accounts for around 95% of all cases, and noduar lymphocyte predominance HL 
(NLPHL) which makes up the remainder (WHO 2001 ). NLPHL is recognised as a 
distinct disease entity (Harris 1999) and the focus of this work is on cHL. cHL is 
characterised by the presence of Hodgkin and Reed-Sternberg (HRS) cells, the 
proposed malignant cells of the disease, in a polymorphous cellular background. A 
striking feature of cHL is the scarcity of the malignant cells, which usually constitute 
less than 1 % of the cells within the tumour mass. The rarity of these cells has 
hindered their characterisation and our understanding of this disease. Advances in 
molecular techniques over the last decade have established that the HRS cells are 
of 8-cell origin in the majority of cHL cases as evidenced by the detection of 
immunoglobulin (lg) gene rearrangements in isolated HRS cells (Kuppers et al., 
1994;Kanzler et al., 1996b;Marafioti et al., 2000). The majority of cHL cases show 
evidence of somatic hypermutation of variable (V) regions of lg genes indicating 
that they have participated in a germinal centre (GC) reaction; however, all HRS 
cells from an individual case show the same hypermutation pattern, therefore 
somatic hypermutation has ceased (Brauninger et al., 2006). In about 25% of 
cases crippling mutations which render the lg rearrangements non functional are 
detected (Kanzler et al., 1996b;Kuppers 2002). Even in the absence of crippling 
mutation, there is down-regulation of lg expression thus suggesting that the HRS 
cells in most cases are derived from pre-apoptotic GC B cells. 
The aetiology of cHL is unknown although EBV is causally associated with a 
proportion of cHL cases (IARC 1997). Epidemiological data suggest that an 
infectious agent may be involved in EBV-negative cHL cases particularly those 
aged 15-34 years and of nodular sclerosis (NS) subtype. It has been suggested 
that EBV may be using a hit and run mechanism in these cases although the 
available data do not support this idea (Gallagher et al., 2003). We, and others, 
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have looked for genomes of lymphotropic and/or oncogenic viruses other than EBV 
in HL biopsies with negative results (Jarrett et al., 1988;Khan et al., 1993;Secchiero 
et al., 1998;Berneman et al., 1998;Armstrong et al., 1998b;Gallagher et al., 
2002;MacKenzie et al., 2003;Wilson et al., 2006). 
A number of studies have attempted to determine the overall gene expression 
profile of HRS cells, the majority of which have used cHL-derived cell lines (Kapp 
et al., 1999;van den Berg et al., 1999;van den Berg et al., 2000;Kuppers et al., 
2003;van den Berg et al., 2003;Schwering et al., 2003a;Schwering et al., 
2003b;Janz et al., 2006;Staber et al., 2006) or whole cHL tissue (Devilard et al., 
2002;Sanchez-Aguilera et al., 2006). An advantage of using HL-derived cell lines 
for investigative studies is that the material is abundant and readily available; 
however, all of the cell lines have been derived from patients with end-stage 
disease and may not, therefore, be truly representative of primary HRS cells. In 
addition, only the L 1236 cell line has actually been shown to be clonally related to 
original tumour material (Kanzler et al., 1996a). 
The use of Serial Analysis of Gene Expression (SAGE) demonstrated the 
extremely high expression of the chemokine TARC (CCL17) in HL-derived cell 
lines and suggested a possible role in attracting Th2 cells to the surrounding 
infiltrate (van den Berg et al., 1999). In a subsequent SAGE study, expression of 
the B-cell receptor inducible gene BIC was identified in all subtypes of HL (van den 
Berg et al., 2003) and this led to the investigation and detection of the mature 
microRNA-155 in HL-derived cell lines and tissue samples (Kluiver et al., 2005). In 
comprehensive studies using SAGE and cDNA microarrays, the loss of the B­
lineage specific gene expression program was demonstrated in HL-derived cell 
lines (Kuppers et al., 2003;Schwering et al., 2003a;Schwering et al., 2003b). 
The first study to use primary HRS cells for global gene expression profiling 
generated cDNA libraries from micromanipulated HRS cells from a case of nodular 
sclerosis (NS) HL and a case of NLPHL (Gossman et al., 1999). In addition, 128 
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libraries were generated from two HL-derived cell lines, L428 and KMH2. For final 
analysis of the libraries, the authors combined the sequences obtained from both 
HL cases and the HL-derived cell lines. The expression profile supported a 8-cell 
lineage for HRS cells , but subsequent studies have shed doubt on whether the 
'primary tumour' cells were bona fide HRS cells. Further global gene expression 
studies on primary HRS cells are therefore necessary . 
The aim of the present study was to generate SAGE libraries from HRS cells away 
from the reactive infiltrate of the tumour , in order to identify known or novel genes 
that are involved in the pathogenesis of cHL. The primary aim was to determine 
differences in gene expression between HRS cells and a "normal" counterpart for 
further investigative analyses. Secondary aims were to compare expression 
differences between EBV-positive and negative HRS cells and also to identify 
novel viral transcripts. 
Material and Methods 
Sample selection and processing: Excess material from diagnostic lymph node 
biopsies was mechanically disrupted and mononuclear cells enriched by gradient 
centrifugation using Lymphoprep™ (Life Technologies, Paisley , UK). Analytical 
flow cytometry was performed using antibodies to a panel of markers including 
CD30 and the remaining cell suspension was stored viably in liquid nitrogen. Two 
cases of cHL were selected for inclusion in this study on the basis of availability of 
sufficient cells and the presence of an identifiable population of CD30-positive cells 
on flow cytometry. Case 6656 was a 15 year old female with a non-EBV­
associated tumour and a diagnosis of NSHL. Case 587 4 was a 70 year old male 
with an EBV-associated tumour , also of the NS subtype. Case 6333 was a 26 year 
old male with benign lymphadenopathy. The HL-derived cell line L428 was 
included for subsequent comparison. 
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Cell sorting: Cell sorting was performed using an EPICS Elite flow cytometer 
(Beckman Coulter, High Wycombe, UK). Single cell suspensions from cHL 
samples were stained with the BerH2 anti-CD30 murine monoclonal antibody 
(Dako UK Ltd, Cambridgeshire, UK) followed by a phycoerythrin-conjugated 
polyclonal goat anti-mouse lg/F(ab')2 (Dako UK Ltd). HRS cell fractions were 
selected on the basis of CD30-positivity and forward and side scatter 
characteristics (Figure 1 ). Following cell sorting, a small aliquot of cells from the 
positive fraction was analysed by flow cytometry to assess purity. In the positive 
fraction from case 6656, 86.2% of events in the total ungated population were 
CD30-positive and 3 x 105 cells were available for downstream analysis. For 587 4, 
86.8% of the events in the ungated positive fraction were CD30-positive and 1 .2 x 
105 cells were recovered. 
GC B-cells were chosen as the 'normal' counterpart of HRS cells for comparison, 
as HRS cells are thought to be derived from pre-apoptotic GC B-cells (Kuppers 
2002). In order to enrich GC B-cells, a single cell suspension from a reactive 
lymph node was stained sequentially with an anti-CD77 monoclonal antibody 
(lmmunotech, Buckinghamshire, UK) and a phycoerythrin-conjugated goat anti-rat 
secondary antibody (lmmunotech). Following sorting of CD77-positive events 
falling within the 'lymphoid' gate, the positive fraction contained 3.1 x 105 cells with 
a purity of 93%. 
RNA extraction : RNA extraction was performed immediately following cell sorting 
to preserve the quality of RNA. Total RNA was isolated using the RNAqueous™ kit 
(Ambion, Cambridgeshire, UK) according to the manufacturers protocol, and RNA 
was eluted in a total volume of 25 µI. 
cDNA synthesis: cDNA synthesis was performed using 3 µI of eluted RNA, 
roughly equivalent to 180 ng. Since insufficient RNA was available for the 
conventional SAGE protocol (Velculescu et al., 1995), the SMART cDNA kit (BD 130 
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Clontech, Oxford, UK) was used for cDNA amplification prior to SAGE. This 
methodology affords amplification of cDNA whilst maximising the length of mRNA 
transcripts. In conventional SMART the first strand cDNA is synthesised by using 
an oligo dT SMART CDS primer and a SMART IIA oligonucleotide that facilitates a 
switch mechanism at the 5' end of the mRNA sequence and enables longer 
transcripts to be synthesised. The amplification PCR which follows uses a single 
primer which is homologous to common sequences in both the oligo dT SMART 
CDS primer and SMART IIA oligonucleotide. SAGE requires the identification of a 
1 O bp specific gene tag which lies immediately 3' to the most 3' Nia Ill site in the 
cDNA derived from poly (A) mRNA; thus, primers used in any prior amplification 
step must distinguish the 5' and 3' ends of the cDNA. The SMART primers were 
therefore modified, as shown below, and for long-distance (LD) PCR the 3' LD 
primer was biotinylated to allow capture on immobilised streptavidin. The number 
of PCR cycles was optimised for each sample to ensure maximum yield of cDNA 
whilst not over-amplifying the samples. 
1st Strand CDNA synthesis: 
Modified SMART 1 1  A oligonucleotide 
5-'AAGCAGTGGTATCAACGCAGAGATCGCGGG-3' 
Modified 3' SMART CDS Primer II A 
5' -GAGTCCAGAAGAGTGCGATGAGT ACT(3o) VN-3' 
cDNA Amplification by LD PCR: 
Modified 5' PCR Primer 1 1  A 
5' -AAGCAGTGGT ATCAACGCAGAGA-3' 
Biotinylated 3' primer for capture of polyA RNA (5' label) 
5' -GAGTCCAGAAGAGTGCGATGAG-3' 131 
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SAGE: Amplified cDNA samples were double purified by resin binding and column 
purification using the QuickStep ™ 2 PCR Purification kit (Edge BioSystems, 
Gaithersburg, USA). The biotinylated cDNA was bound to DYNAL M-280 
streptavidin beads (lnvitrogen, Paisley, UK) and SAGE libraries were generated 
using the I SAGE kit (lnvitrogen), essentially as described by the manufacturer. 
Nucleotide sequencing: Cloned libraries were transformed into DH5a cells 
(lnvitrogen) and individual bacterial colonies diluted in 20 µI of H20. Two µI of this 
diluent was used as template in a Rolling Circle Amplification reaction (Templiphi™ 
kit, Amersham pie, Buckinghamshire, UK) prior to sequencing. Nucleotide 
sequencing was performed using the Big Dye Terminator™ cycle sequencing 
reaction kit V3.1 (Applied Biosystems, Warrington, UK). Excess dye terminators 
were removed using Perform a™ v3-96 Well Short Plates (Edge BioSystems) and 
products resuspended in 25 µI of Hi-di Formamide (Applied Biosystems). 
Sequencing reactions were analysed on an Applied Biosystems 3100 Genetic 
Analyzer using DNA sequencing Analysis software™ (Applied Biosystems). 
SAGE Tag Analysis: Sequencing files were analysed using the SAGE 2000 
software v4.5 kindly provided by Dr KW Kinzler (Johns Hopkins Oncology Center, 
Baltimore, Maryland, USA). Tags were normalised to 29898 (tag count of 6333) 
with duplicate di-tags and linker tags removed. Results were linked to the 
SAGEmap human database (http://www.ncbi.nlm.nih.gov/projects/SAGE/) and the 
CGAP best gene for a tag map (http://cgap.nci.nih.gov/SAGE) to identify the 
corresponding genes. The CGAP best gene was chosen for subsequent analysis 
because this designates one gene hit per SAGE tag. Tags with no gene match 
were also checked on the Tag mapper database 
(http://tagmapper.ibioinformatics.org/). Further comparisons were performed using 
Microsoft Access and Excel programmes. Genes that were up and down regulated 
in the cHL cases compared to the GC sample were analysed. We also looked for 
expression differences in the EBV-negative cHL case compared to the EBV­
positive case. Genes were considered differentially expressed if either the tag 132 
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count showed a � 5-fold increase or decrease, or there was a tag count of � 5 in 
one normalised library but no tags in another. 
Relative Quantitative PCR:  The biotinylated SMART cDNA used to generate the 
SAGE libraries was also used as template for quantitative reverse transcriptase 
(qRT) PCR in order to validate the SAGE results. SMART cDNA previously 
generated from cHL case 6656 using the conventional SMART protocol was also 
assessed for comparison. In addition, SMART cDNA was available from a similarly 
enriched HRS cell population from another EBV-negative case (6214). A '3-actin 
MGB PDAR TM assay was used as an endogenous control and cDNA samples were 
diluted to bring them into the dynamic range for this assay. Two genes chosen for 
investigation were Protein kinase C (PKG) eta and Galectin 2. All assays were 
commercially available (Applied Biosystems, Warrington, UK). Amplification and 
relative quantitation were performed using an Applied Biosystems 7500 Real Time 
PCR system (Applied Biosystems). Results were calibrated to the GC (6333) 
result and relative quantitation calculated by comparison to the '3-actin endogenous 
control and a standard MCt method. Relative expression differences were then 
calculated using the formula zMct calculation. 
Results 
SAGE analysis: Table 1 shows the number of SAGE tags generated from each of 
the samples and the corresponding duplicate di-tag count. 
Table 1 :  Total Tag counts 
Case Total tags Dupl icate di-tags 
6656 (EBV-ve HL) 5282 6025 
5874 (EBV+ve HL  45568 21 64 
6333 (GC 8-cells) 29898 1 51 8  
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The libraries from both 6333 (GC) and 5874 (EBV-positive HL case) are 
satisfactory with a low number of duplicate di-tags. This is an indication that further 
sequencing will provide additional information; however, the 6656 library (EBV­
negative HL case) yielded relatively few tags before the duplicate di-tag number 
indicated that further sequencing would not yield additional informative data. 
Although the 6656 library is included in some of the comparisons, this rather small 
library will only contribute information on highly expressed transcripts. The 6656 
library was not included in the analyses of down-regulated genes. The unique tags 
identified are shown in Table 2. 
Table 2: Unique tags identified 
Case Unique tags Gene h its No match 
6656 (EBV-ve HL) 725 58 1 1 44 
5874 (EBV+ve HL) 3580 2894 686 
6333 (GC B-cel ls) 2404 1 893 5 1 1 
Differential expression: Analysis of the normalised result revealed that forty nine 
tags were increased � 5-fold in 5874 compared to 6333. Twenty five of these were 
also increased in 6656. Thirty three tags were present with a count of � 5 in 5874 
but not present in 6333. Twenty of these were also present in 6656. One hundred 
and seven tags were decreased � 5-fold in 587 4 compared to 6333. Seventy eight 
tags had a count of � 5 tags in 6333 but were absent in 5874. 
One of the genes highly expressed in both cHL cases when compared to the GC 
library was the gene for the chemokine CCL 17, which has previously been shown 
to be highly expressed in HL-derived cell lines by the SAGE technique (van den 
Berg et al., 1999). Other genes with increased expression in one or both libraries 
were: CD44; Fascin; Neuron-specific enolase 2; Cathepsin B and Survivin. A list of 134 
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the 1 0  genes most highly expressed in case 587 4 compared to 6333 are shown in 
Table 3. The 1 O most highly expressed genes in 6656 compared with 6333 are 
shown in Table 4 and the genes most highly expressed in 5874 with no gene tags 
present in 6333 are shown in Table 5 along with the corresponding tags for 6656. 
Primary analysis was focussed on the validation of known genes that were 
differentially expressed in these libraries. Two genes chosen for further analysis 
from the list shown in Table 4 were PKC eta and Galectin 2 because they were 
present at greater than 5 tags in both cHL cases following normalisation and not 
present at all in 6333 (GC). From what is known about these genes, they may 
have a plausible function in HL. 
No EBV tags were detected in the library from the EBV-positive case 5874, despite 
the demonstration that EBV latent gene products were easily detectable in the 
starting cDNA sample (data not shown). A number of tags had no gene hits and 
may therefore be novel gene/viral sequences or splice variants. 
Relative Quantitative PCR :  Following qRT-PCR on the biotinylated cDNA, which 
was also used to generate the SAGE libraries, the relative quantitation between the 
cHL samples (587 4 and 6656) and GC sample (6333) as calibrator were assessed 
using the MCt method. Relative expression differences were then calculated 
using the formula 2-Mct calculation. The results shown in Figure 2 indicate that 
both cHL cases have increased expression of PKC eta and Galectin 2 compared to 
6333 (GC) . 
Discussion 
This study describes the generation of the first SAGE libraries from primary HRS 
cells. To date we have focused on analysing and validating gene expression 
differences between the cHL and GC libraries. One of the genes that was most 
highly differentially expressed in both cHL samples when compared to the GC 135 
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library was CCL 17, which had been shown previously to be highly expressed in HL 
cell lines and HL tissue samples (van den Berg et al. , 1999). Similar to other gene 
expression studies of cHL, fewer genes were up-regulated than down-regulated in 
HRS cells compared to GC 8-cells (Schwering et al., 2003a;Kluiver et al., 2006). A 
number of gene transcripts were up-regulated that had previously been shown to 
be expressed in HL by SAGE (Schwering et al., 2003a). These included: CD44; 
Fascin; Neuron-specific enolase 2 and Cathepsin B. Survivin, which has also been 
shown to be highly expressed in HL using tissue microarrays, was also increased 
in our EBV-negative cHL library (Garcia et al., 2003). Initial comparisons with 
previous studies therefore suggest that these libraries are representative of bona 
fide HRS cells. 
Although the above results indicate that these libraries will be a useful resource for 
further analyses, they have certain limitations. HRS cells are notoriously difficult to 
enrich as they are extremely fragile and the purity of our enriched fractions was 
only ~86%. In addition, the small amounts of RNA generated from these purified 
cell populations necessitated the inclusion of the SMART amplification procedure 
prior to generation of the SAGE libraries. It is possible that this could result in a 
bias towards small transcripts; however, libraries showed no obvious over­
representation of tags from small transcripts (data not shown). A previous study, 
also using a SMART based methodology for amplification of cDNA prior to SAGE, 
showed that the amplification by PCR had not distorted the representation of their 
library (Neilson et al., 2000). A comparative evaluation of amplification techniques 
for expression profiling at the single-cell level concluded that SMART PCR 
amplification correlated best with non-amplified cDNA at a global level compared to 
T7-based in vitro transcription and global PCR amplification (Subkhankulova and 
Livesey 2006). The literature therefore supports the use of the SMART 
amplification method for this type of analysis. To determine whether the use of the 
SMART amplification has biased the representation of our libraries, we constructed 
a SMART-amplified SAGE library from the HL-derived cell line L428. We are 
currently constructing a library using non-amplified cDNA from L428 for 136 
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comparison. This will enable us to validate the amplification procedure and further 
extend our investigations of the chosen genes of interest if the libraries are 
comparable. 
Initial analysis identified differential expression of Galectin 2 and PKC eta, both of 
which had increased expression in the cHL SAGE libraries compared to the GC 
library. qRT PCR assays performed using the original cDNA from these cases as 
template confirmed these findings. At present we are optimising 
immunohistochemical assays for Galectin 2 and PKC eta to determine if the 
encoded proteins are expressed by HRS cells in other diagnostic samples. In 
addition, we will perform qRT PCR on cDNA samples from HRS cells obtained by 
either laser microdissection or enrichment, and also on various B-cell populations. 
Galectins, which are a family of carbohydrate-binding proteins, are novel regulators 
of immune cell homeostasis (Rabinovich et al., 2002;Sturm et al., 2004;Liu and 
Rabinovich 2005;Toscano et al ., 2006). Galectins influence the development of 
the T-cell immune response including cytokine secretion, T-cell survival and 
activation (Bianco et al., 2006). Galectin 1 has been shown to counteract the 
pathogenic effect of Th1 cells in autoimmune retinal disease and skew the immune 
response towards a Th2 and T-regulatory profile in vivo (Toscano et al., 2006). 
This is of interest in cHL as the reactive infiltrate surrounding the HRS cells 
contains T cells that are primarily Th2 and T-regulatory cells. It is postulated that 
the Th2 cells may be attracted to the surrounding infiltrate in cHL by secretion of 
the chemokine TARC by HRS cells (van den Berg et al ., 1999). Increased 
expression of Galectin 1 has been demonstrated previously in HL-derived cell lines 
(Schwering et al., 2003a;Kluiver et al ., 2006) but increased expression of Galectin 
1 was not detected in our SAGE libraries from enriched HRS cells. Although 
structurally similar to Galectin 1, Galectin 2 expression is mainly confined to the 
gastrointestinal tract. Galectin 2 has also been shown to shift the cytokine 
secretion pattern of activated T cells to a Th2 profile and is also an inducer of T cell 
apoptosis (Sturm et al ., 2004). It is possible that Galectin 2 expression by the HRS 137 
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cells is contributing to the phenotype of the T cells within the reactive infiltrate of 
the HL tumour and is creating a favourable environment for HRS cell survival. 
PKG is a family of 12 serine/threonine kinases and several of its isoforms have 
been implicated in the regulation of apoptosis. Inactivation of PKCs sensitises 
tumour cells to drug-induced apoptosis while overexpression confers protection 
(Cartee and Kucera 2000). PKG eta, a novel PKG, has been shown to be involved 
in drug resistance and regulation of apoptosis in a number of human cancers 
including breast cancer (Beck et al ., 1998a);(Masso-Welch et al., 2001 ), ovarian 
cancer (Beck et al., 1998b) and colon cancer (Doi et al., 1994). Many studies have 
also shown that PKG eta is an effective inhibitor of apoptosis. In human 
keratinocytes PKG eta inhibits UV-induced activation of caspase 3 (Matsumura et 
al., 2003) and in prostate cancer cells down-regulation of PKG eta potentiates the 
cytotoxic effects of tumour necrosis factor-related apoptosis-inducing ligand 
(Sonnemann et al., 2004b). In addition, the down-regulation of PKG eta by 
antisense oligonucleotides sensitised lung cancer cells to the effects of anti­
neoplastic drugs (Sonnemann et al., 2004a). 
The exact mechanism responsible for the survival of HRS cells in cHL is still 
unclear, although a number of factors are known to be involved in their rescue from 
apoptosis, including expression of nuclear factor-KB (NF-KB). NF-KB is a 
transcription factor that regulates the expression of many effector molecules 
including growth factors, cytokines and anti-apoptotic proteins in response to 
ligation of surface receptors (Bonizzi and Karin 2004). It is now widely accepted 
that constitutive activation of NF-KB in HRS cells plays a critical role in escape from 
apoptosis (Bargou et al., 1997). Both cFLIP and XIAP are NF-KB target genes and 
therefore constitutive NF-KB activity in HRS cells may well be responsible for the 
anti-apoptotic phenotype of the HRS cells (Re et al., 2005). There are several 
mechanisms of activation of NF-KB in cHL which include EBV LMP-1 expression, c­
rel amplification, IKBa mutation/deletion and constitutive CD30 signalling 
(Emmerich et al ., 1999;Cabannes et al., 1999;Horie et al., 2002;Joos et al., 138 
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2003;Emmerich et al., 2003;Grimm et al., 2005;Osborne et al., 2005;Uchihara et 
al., 2006). In addition to CD30, CD40 (Gruss et al., 1 994) and RANK (Fiumara et 
al., 2001 )  are two other members of the TNF receptor family that are expressed on 
HRS cells and may contribute to HRS cell suNival by activating NF-KB. 
Overexpression of PKC eta may also contribute to HRS cell suNival and could 
represent a novel therapeutic target. 
A secondary aim of the present study was to compare the libraries generated from 
the EBV-positive and EBV-negative cHL cases in order to identify viral transcripts 
present in the EBV-negative HRS cells. EBV tags were not detected in the SAGE 
library from case 5874 (EBV-positive case). EBV latent gene transcripts were 
detected in cDNA from this case using quantitative PCR; this indicates that very 
large numbers of tags must be sequenced in order to detect EBV viral transcripts. 
The library generated from 587 4 is far from exhausted and we intend to increase 
the tag numbers on this case by continuing sequencing analysis. Larger SAGE 
libraries are certainly preferable for the identification of genes present at low copy 
number. Indeed, it has been shown that increasing the number of sequenced tags, 
not only enhances the reproducibility of the SAGE technique for the detection of 
known genes, but also increases its power for the possible detection of novel 
transcripts (Dinel et al., 2005). The library generated from case 6656 (EBV­
negative case) was small although this library will add data on highly expressed 
genes. A number of transcripts were detected in the SAGE library from this case 
that had previously been shown to be highly expressed in HRS cells. In both cHL 
libraries a number of tags had no gene hits and could represent novel splice 
variants, novel genes or viral sequences. 
Further analyses on these SAGE libraries from sorted HRS cells are required to 
maximise the potential of this valuable material for the discovery of known or novel 
genes that may be involved in the pathogenesis of cHL. 139 
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Table 3. Tags increased i:!: 5-fold in SAGE library from case 5874 (cHL) 
compared to 6333 (GC). 
Tag Sequence 5874/6333 Symbol Description 
GGCACAAAGG 70 CCL17  Chemokine (C-C motif) ligand 17  
GTGCACTGAG 28.5 HLA-A Major histocompatibility complex, class I, A 
GCAAAAAAAA 24 PDXK Pvridoxal {ovridoxine, vitamin 86) kinase 
TTTGAAATGA 23 SAT Spermidine/spermine N 1 -acetvltransferase 
TCTACACGTG 1 9  PFC Properdin P factor, complement 
TGGGTGAGCC 1 4  CTSB Cathepsin B 
CTCTTCGAGA 1 0  GPX1 Glutathione peroxidase 1 
Proteasome (prosome, macropain) activator 
GTGCTGGACC 9 PSME2 subunit 2 (PA28 beta) 
GGGGCTGGAG 9 PLXND1 Plexin D1 
GAAGAACAAG 8.5 SAT Soermidine/soermine N1 -acetyltransferase 
Column 5874/6333 shows the fold increase in 5874 compared to 6333. SAGE tags and 
corresponding gene hits are shown for the top 10 differentially represented genes. 
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Table 4. Tags increased � 5-fold in SAGE library from case 6656 (cHL) 
compared to 6333 (GC). 
Taa Seauence 6656/6333 Symbol Description 
Eukaryotic translation elongation factor 1 
GCCCAGCTGG 82 EEF1 D delta 
GGCACAAAGG 67 CCL1 7 Chemokine (C-C motif) ligand 1 7  
TTTGAAATGA 50 SAT Sperm idine/spermine N 1 -acetyltransferase 
GAAGAACAAG 45 SAT Spermidine/spermine N1 -acetvltransferase 
TGGGTGAGCC 39 CTSB Cathepsin B 
ATCACGAAGG 39 VAV2 Vav 2 oncoQene 
SET translocation (myeloid leukemia-
TATCTGTCTA 33 SET associated) 
TGCCCTTCGG 28 ZNF342 Zinc finger protein 342 
Transcribed locus, moderately similar to 
TCTCTATTAA 28 XP 371 398.2 mvosin 
TCTGCAAAGG 23 HMGB2 High-mobil ity group box 2 
Column 6656/6333 shows the fold increase in 6656 compared to 6333. SAGE tags and corresponding 
gene hits are shown for the top 1 O differentially represented genes. 141 
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Table 5. Tags present � 5-fold in SAGE library from case 5874 (cHL) and not 
present in 6333 (GC) library. 
Tag Seauence 5874 6333 6656 Symbol Description 
TCAGTGACCA 32 0 5 PRKCH Protein kinase C, eta 
TCCTCTTTCA 26 0 62 LGALS2 Galectin 2 
CCCACAACCT 26 0 1 6  FCN1 Ficolin 1 
CCCGTCCGGA 1 8  0 39 RPL1 3 Ribosomal protein L 1 3  
Neural proliferation, 
GAGAACCGTA 1 3  0 0 NPDC1 differentiation and control, 1 
GTGTGCGCCT 1 1  0 0 CARDS Caspase 8 
Phosphatidylinositol 3,4,5-
AAATCTCTGG 9 0 1 6  PREX1 trisphosphate- exchanger 1 
TTCAATAAAA 8 0 1 1  RPLP1 Ribosomal protein, lan::ie, P1 
GGACCTGCGC 7 0 1 6  RNASET2 Ribonuclease T2 
Endothelial differentiation, 
sphingolipid G-protein-coupled 
GGAGGTTGAA 7 0 5 EDG8 receptor, 8 
SAGE tags and corresponding gene hits are shown for the top 1 O differentially represented genes in 
5874 and not expressed in 6333. The corresponding tags for the 6656 library are also shown. 
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Figure 1. Enrichment of Hodgkin and Reed-Sternberg cells from case 5874. (A) Scatter plot 
of original sample showing gate used in subsequent sort. (B) Scatter plot following cell sorting. (C) 















Figure 2. Relative quantitative expression differences between cHL cDNA (5874 
and 6656) compared with the GC cDNA (6333). (A) PKC eta gene expression 
assay. (B) Galectin 2 gene expression assay. 
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Discussion and Future Plans 
The mechanism of transformation of the HRS cells of cHL is not completely 
understood. EBV is detectable in HRS cells, the tumour cells of cHL, in around 
one third of HL cases in western countries and is thought to play a role in the 
disease pathogenesis in these cases (Long et al., 1 97 4;Armstrong et al., 
1 992;Jarrett et al., 1 996;IARC 1 997). The ability to detect EBV DNA in serum 
samples from patients with EBV-associated HL could prove useful in both clinical 
and epidemiological studies. Overall, the results obtained in chapter 2 suggest that 
EBV DNA is detectable in serum of most, if not all, patients with EBV-associated 
HL. In contrast, EBV DNA is infrequently found in serum from non-EBV-associated 
cases and, in this study, was never detected in samples from healthy individuals. 
Results obtained from the post-treatment samples analysed suggests that 
detection of EBV may be a useful prognostic marker. In a small comparative study 
the results also suggested that serum is superior to plasma as a source of DNA. 
These results add to a growing body of data indicating that serum samples from 
cancer patients provide a useful source of DNA suitable for molecular analyses 
(Leon et al., 1 977;Steinman 1 979;Vasioukhin et al., 1 994;Nawroz et al., 
1 996;Anker et al., 1 997). We demonstrated that EBV DNA is present as naked 
DNA and not in virions in the serum of HL patients. A study of the molecular 
characterisation of circulating EBV DNA in the plasma of nasopharyngeal 
carcinoma and lymphoma patients confirmed our findings (Chan et al., 2003). We 
suggested that this assay could prove useful in epidemiological studies and in the 
clinical follow-up of patients with EBV-associated HL and other EBV-associated 
malignancies. The monitoring of EBV DNA levels in blood has now been shown to 
be useful in the management of post-transplant lymphoproliferative disease 
(Wagner et al., 2002). In addition, rising serum EBV DNA levels preceded the 
clinical detection of NHL by months in a HIV-infected patient (Fleisch et al., 2005). 
Wagner and colleagues reported EBV DNA detection in the plasma of paediatric 
HL patients and suggested this might be of value for non-invasive diagnostic, 146 
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prognostic and follow-up tests for HL (Wagner et al., 2001 ). A recent study 
questioned the sensitivity of the EBV assay employed by Wagner and colleagues, 
although stated that results obtained in our study were in broad agreement with 
their own (Gandhi et al., 2006). Preliminary results from small numbers in our 
study showed that serum was perhaps a better source of DNA than plasma. 
Gandhi and colleagues used plasma as a DNA source in their study and correctly 
commented that no large scale study had compared the relative sensitivities 
between EBV detection in serum and plasma. They conclude that EBV-DNA from 
plasma is a sensitive and reliable biomarker for disease evaluation in EBV-positive 
HL patients (Gandhi et al., 2006). 
Since EBV is associated with only a proportion of cHL cases it has been suggested 
that perhaps EBV has been involved in a hit-and-run scenario with respect to EBV­
negative cases (Ambinder 2000). In chapter 3 we addressed this issue using a 
comprehensive combined serological and molecular approach. Analysis of EBV 
seroprevalence rates in an epidemiological study of young adult HL  revealed that 
cases with EBV HRS-ve HL were more likely to be EBV seronegative than controls. 
Furthermore, additional studies clearly showed that some HL patients have never 
been infected by EBV. Quantitative PCR was used to look for the presence of 
deleted EBV genomes in a series of adult cases with EBV HRS+ve and EBV HRS­
ve HL. Subgenomic fragments were detected in equimolar proportions. This 
study, therefore , found no evidence to support the idea that a hit-and-run 
mechanism involving EBV plays a role in the pathogenesis of HL. 
Epidemiological studies suggest that an infectious agent is involved in the aetiology 
of young adult cHL although cases in this age group are less likely to have EBV­
associated disease than cases diagnosed in early childhood or older adulthood. 
Since previous molecular studies had failed to find a consistent association 
between cHL and other candidate viruses (Jarrett et al., 1988;Torelli et al., 
1991 ;Secchiero et al., 1998;Berneman et al., 1998;Cozen et al., 1998;Armstrong et 
al., 1998b;MacKenzie et al., 2003), we investigated whether novel herpesviruses 
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were detectable in EBV-negative HL using a highly sensitive degenerate PCR 
assay as discussed in chapter 4. Despite exhaustive sequencing no novel 
herpesviruses were detected. Chapter 5 describes the use of both conventional 
and degenerate PCR strategies for the investigation of possible polyomavirus 
involvement in HL. No direct association between polyomaviruses and EBV­
negative HL was found. It therefore appears highly unlikely that members of these 
two virus families are directly involved in HL disease pathogenesis. More recently 
measles virus has been implicated as a candidate in a proportion of HL cases 
(Benharroch et al., 2003). These results, however, remain controversial and have 
not been confirmed (our unpublished data and personal communication R. 
Kuppers). Zur Hausen and de Villiers have put forward a hypothesis suggesting a 
link between TT viruses and HL. The hypothesis leaves many questions 
unanswered and further investigative studies on the role of TTVs in HL are required 
to confirm or refute this suggestion (zur Hausen and de Villiers 2005). 
Chapter 6 describes currently used molecular methods for virus discovery, 
including degenerate PCR assays, RDA and RCA, and summarises the 
advantages and disadvantages of each technique. We have used RCA to 
successfully amplify complete papillomavirus genomes from equine sarcoid 
tumours (Yuan et al., 2006) and complete polyomavirus genomes, including the 
genome of the rabbit polyomavirus. The technique is relatively simple to perform, 
requires no a prio ri knowledge of the likely agent, and is suitable for screening 
purposes. An assay such as this may be useful for the investigation of HL samples 
for the presence of circular viral genomes such as TT viruses. 
The putative virus remains elusive but complementary techniques for virus 
discovery need to be explored before a direct role for viruses other than EBV in this 
disease can be excluded. Using available sequence data from more than 140 
sequenced viral genomes, Wang and colleagues designed a DNA microarray that 
could potentially simultaneously detect hundreds of viruses (Wang et al., 2002). 
The array was further expanded with the objective of creating a microarray that 
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could detect a wide range of known viruses and also unknown viruses (Wang et al., 
2003). Using this strategy a novel coronavirus associated with severe acute 
respiratory syndrome was identified (Ksiazek et al., 2003). This "Virochip" has also 
been used to identify a novel gammaretrovirus in prostate tumours (Urisman et al., 
2006) and to detect Human parainfluenzavirus 4 infection associated with 
respiratory failure in an immunocompetent adult (Chiu et al., 2006). The possible 
use of a "Virochip" for the investigation of HL samples would be an exciting 
prospect. Such a study may provide a definitive answer to the question of whether 
another virus is involved in the EBV-negative cases of HL. 
In search of gene expression differences between EBV-positive and EBV-negative 
HL we generated SAGE libraries from enriched HRS cell populations f rom HL 
patients as described in Chapter 7.  As we have a long standing interest in virus 
hunting in HL, one of our aims in this study was the detection of other infectious 
agents in non-EBV associated HL. It appears at present that the tag counts in our 
libraries are not sufficiently large to detect viral sequences but sequencing of tags 
is ongoing. The library generated from the EBV-negative case was small and 
exhausted at a low tag count number. A number of the genes shown to have 
increased expression in this case when compared to the GC B-cell library had, 
however, been shown previously to be upregulated in HL. This is consistent with 
the observation that highly abundant transcripts come through early on in the 
SAGE analysis. A larger library is required from an EBV-negative case for the 
investigation of lower abundance transcripts. 
At present the libraries are suitable for the investigation of gene expression 
differences between HRS cells and GC 8-cells. In comprehensive studies using 
SAGE and DNA microarrays the loss of the 8-lineage specific gene expression 
program has been demonstrated in the HRS cells of cHL (Kuppers et al., 
2003 ;Schwering et al., 2003a ;Schwering et al., 2003b). Down regulation of these 
genes affects multiple pathways in 8-cells including BCR signalling. Gene 
expression studies using primary HRS cell material will help in the characterisation 149 
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of HRS cells and perhaps identify critical genes involved in the disease 
pathogenesis. Preliminary results from the study presented in Chapter 7 have 
highlighted a number of genes that appear to show increased expression in cHL. 
Among the genes that had increased expression in the cHL cases compared with 
the GC 8-cells were Protein Kinase C eta and Galectin 2. Results from specific 
relative quantitative PCR for these genes showed that both Protein Kinase C eta 
and Galectin 2 were indeed present at higher levels in the cDNA from the cHL 
samples used to generate these libraries. We are at present performing 
confirmatory analyses of these findings, and continuing the analysis of other genes 
of interest that show increased expression in HRS cells. 
As discussed in Chapter 7 the conventional SAGE technique has been used 
previously as a useful tool for the characterisation of gene expression profiles in HL 
cell lines and HL-derived tissue. Our study aimed to look at the gene expression 
profile of the HRS cells themselves and identify known and perhaps novel 
transcripts that may be involved in the disease process. The LongSAGE technique 
(Saha et al., 2002) releases a larger tag from each transcript which is 21 bp in 
length. Studies have shown that longer tags were much more efficient for the 
identification of novel genes in comparison with conventional SAGE tags (Saha et 
al., 2002;Chen et al., 2002). A robust LongSAGE protocol has since been 
described which states that as little as 50 ng of mRNA was sufficient for library 
construction (Gowda et al., 2004). Techniques using small amounts of starting 
material are attractive when dealing with HRS cells, which are scarce within the HL 
tumour mass. Certainly LongSAGE would be advantageous for the possibility of 
identifying viral transcripts in HRS cells as the longer tags can be compared to 
genomic databases (Saha et al., 2002). 
The transforming event in cHL is still unknown. Additional gene expression studies 
are required using primary HRS cell material to clarify the complex gene 
expression profile of HRS cells in cHL and identify candidates involved in the 
disease pathogenesis. Involvement of a transforming virus in EBV-negative cases 
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has not been excluded and future studies, using state-of-the-art molecular 
techniques for virus discovery, are warranted. 15 1 
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Classical Hodgkin lymphoma (cHL) is a malignant disease characterised by the 
presence of Hodgkin and Reed-Sternberg (HRS) cells, the proposed malignant 
cells of the disease, in a polymorphous cellular background. The scarcity of the 
HRS cells within the tumour mass has hindered the complete characterisation of 
these cells although they are now considered to be derived from pre-apoptotic 
germinal centre B cells. The aetiology of cHL is still unknown although Epstein­
Barr virus (EBV) is associated with a proportion of cases and it is now accepted 
that EBV is involved in the pathogenesis of these cases. EBV association rates 
vary with age, histological subtype and geographical locale. 
Results from a number of studies have indicated that the DNA present in the 
serum/plasma of cancer patients is largely derived from tumour cells . We 
speculated that the ability to detect EBV DNA in serum samples from patients with 
EBV-associated HL could prove useful in both clinical and epidemiological studies. 
EBV DNA was detected in serum from 30/33 patients with EBV-associated 
Hodgkin's disease but only in 6/26 patients with non-EBV-associated disease 
(p<0.001 ). Samples from healthy individuals were negative and only 5/12 
infectious mononucleosis samples were positive. Copy number of EBV was 
variable. Analysis of a small group of cases suggested that EBV-positivity in post­
treatment samples correlates with risk factors indicative of a poor prognosis. 
Overall, the results are consistent with the idea that DNA from HRS cells is present 
in the serum of HL patients, and further suggest that serum EBV should be 
evaluated as a prognostic marker . 
There is strong epidemiological evidence that an infectious agent may also be 
involved in the pathogenesis of young adult EBV-negative cHL cases from 
developed countries. It has been suggested that EBV may also cause these 
tumours by using a hit-and-run mechanism. Support for this idea comes from the 171 
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finding that most young adult patients, who are likely to have a good immune 
response to EBV, have EBV-negative HL. Analysis of EBV seroprevalence rates in 
an epidemiological study of young adult HL revealed that cases with EBV-negative 
HL were more likely to be EBV seronegative than controls. Additional studies 
clearly showed that some HL patients have never been infected by EBV. 
Quantitative PCR was used to look for the presence of deleted EBV genomes in a 
series of adult cases with both EBV-positive and negative HL. Subgenomic 
fragments were detected in equimolar proportions. This study found no evidence 
to support the idea that a hit-and-run mechanism involving EBV plays a role in the 
pathogenesis of HL. 
In search of another infectious agent that may be involved in the transformation 
process of the young adult EBV-negative cases we looked for the presence of both 
herpesviruses and polyomaviruses using degenerate PCR strategies. Although 
sensitive, the assays were negative for novel viruses of these families. Future 
studies will therefore utilise other molecular techniques for virus discovery, as 
discussed in chapter 6, to search for a virus. 
Serial Analysis of Gene Expression (SAGE) was used to investigate the gene 
expression profile in primary HRS cells from an EBV-positive and an EBV-negative 
case of cHL and also normal germinal centre (GC) B-cells. We looked for gene 
expression differences in the cHL libraries compared with the GC library to identify 
genes that may be involved in the disease pathogenesis. Protein Kinase C and 
Galectin 2 were two genes chosen for further investigation because of their 
plausible gene function and the apparent increased expression in the cHL cases. 
These genes may be involved in the disease pathogenesis; however, validation of 
the libraries is still ongoing and the results obtained require additional verification 
before any finite conclusions can be drawn. An additional aim of this study was to 
identify viral sequences that may be present in the EBV-negative case of cHL. We 
aim to increase the size of our libraries and also investigate SAGE tags generated 
that are not linked to known genes in the common databases. The use of primary 
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cHL material for global gene expression studies should help characterise the HRS 
cells and increase our understanding of the disease pathogenesis. 
At present the aetiology of HL is still unknown and any infectious agent/s present in 
the EBV-negative cases remains elusive. Further studies using state-of-the-art 
molecular techniques for virus discovery are warranted. 173 
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De klassieke variant van het Hodgkin lymfoom (cHL) is een vorm van kanker die 
wordt gekenmerkt door de aanwezigheid van een minderheid van tumor cellen, de 
zogenaamde Hodgkin en Reed-Sternberg (HRS) cellen, en een polymorfe 
cellulaire achtergrond van andere niet maligne infiltrerende cellen. Het lage 
percentage tumor cellen in het aangedane weefsel is gedurende lange tijd een 
belangrijke beperkende factor geweest voor de verdere karakterisering van deze 
cellen. Gedurende de laatste jaren is het duidelijk geworden dat de tumor cellen 
afkomstig zijn van pre-apoptotische kiemcentrum B cellen. De etiologie van het 
cHL is op dit moment nog niet bekend, we weten echter wel dat het Epstein-Barr 
virus (EBV) betrokken is bij de pathogenese in een deel van de gevallen. Het 
percentage EBV positieve gevallen varieert op basis van leeftijd, histologisch 
subtype en geografische locatie. 
Op basis van de resultaten van een aantal studies is het duidelijk geworden dat 
DNA aanwezig in serum / plasma van patienten vooral afkomstig is van de tumor 
cellen. Naar aanleiding van deze bevindingen hebben wij de hypothese 
geformuleerd dat de mogelijkheid om EBV DNA in serum van patienten met EBV 
positieve cHL aan te kunnen tonen een belangrijk middel zou kunnen zijn voor 
klinische en epidemiologische studies. EBV DNA kon inderdaad aangetoond 
worden in 30 van de 33 patienten met een EBV positief cHL en bij slechts 6 van de 
26 patienten met EBV negatief cHL (p<0.001 ). Sera van gezonde individuen waren 
altijd negatief en EBV DNA kon slechts bij 5 van de 12 patienten met de ziekte van 
Pfeiffer worden aangetoond. Het aantal kopieen EBV dat kon worden aangetoond 
was variabel in de drie patienten populaties. Op basis van een studie met een 
beperkt aantal patienten bleek dat de aanwezigheid van EBV DNA in het serum 
correleerde met risicofactoren voor een slechte prognose. Deze resultaten 
bevestigen de hypothese dat DNA afkomstig van HRS cellen aanwezig is in het 
serum van cHL patienten en suggereren dat aanvullende studies m.b.t. de 
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aanwezigheid van EBV DNA in het serum van patienten als mogelijke 
prognostische marker zinvol zijn. 
Er zijn duidelijke epidemiologische aanwijzingen dat ook bij EBV negatieve HL 
patienten in de westerse landen een infectieuze factor betrokken is bij de 
pathogenese. Er is onderzoek gedaan of EBV oak in deze tumoren betrokken kan 
zijn geweest volgens het 'hit-and-run' mechanisme. Jong volwassenen die een 
goed werkend immuunsysteem hebben en waarschijnlijk oak een effectieve 
immuunrespons tegen EBV kunnen induceren, hebben vaak een EBV negatief HL. 
Serum analyse in het kader van een epidemiologische studie bij jong volwassenen 
toonde aan dat patienten met een EBV negatief HL vaker negatief waren voor EBV 
dan gezonde controles. Aanvullende studies toonden bovendien aan dat sommige 
HL patienten nog nooit ge"infecteerd waren geweest met EBV. Vergelijking van 
volwassen patienten met EBV negatieve en positieve HL op basis van 
kwantitatieve PCR voor EBV DNA resulteerde in gelijke hoeveelheden in beide 
groepen. Op basis van deze studie kon geen bewijs warden gevonden voor het 'hit 
and run' mechanisme voor EBV in EBV negatieve HL patienten. Het is dus 
aannemelijk dat EBV geen rol speelt bij de pathogenese van EBV negatieve HL. 
Om een mogelijke andere infectieuze factor op te sporen die betrokken zou 
kunnen zijn bij de ontwikkeling van HL werd met behulp van gedegenereerde 
primers een PCR gedaan voor herpes virus en polyoma virus in EBV negatieve HL 
patienten. Op basis van deze experimenten konden geen aanwijzingen gevonden 
warden voor de aanwezigheid van eventuele nieuwe varianten van deze virussen 
ondanks de hoge sensitiviteit van deze aanpak. Voor het aantonen van nieuwe of 
andere virussen in EBV negatieve HL zijn alternatieve screenings strategieen 
gewenst. 
Gen expressie profielen van primaire HRS cellen van een EBV positieve en een 
EBV negatieve HL patient warden gemaakt met de 'Serial Analysis of Gene 
Expression' (SAGE) techniek. Ter controle werd ook een genexpressie profiel 176 
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gemaakt van normale kiemcentrum B cellen (CB). De expressie profielen van de 
HRS cellen werden vergeleken met het profiel van de CB om genen betrokken bij 
de pathogenese van HL  te identificeren . Twee genen , Protein Kinase C en 
Galectin 2, werden geselecteerd voor verdere analyse vanwege hun functie en de 
verhoogde expressie in HRS cellen ten opzichte van CB. Deze genen zouden 
betrokken kunnen zijn bij de pathogenese van HL. De SAGE banken en de 
differentieel tot expressie komende genen zullen nog verder worden gevalideerd. 
Naast het identificeren van genen betrokken bij de pathogenese van HL,  kunnen 
de expressie profielen ook worden gebruikt om eventueel aanwezige virale 
sequenties aan te tonen in de EBV negatieve HRS cellen, en op deze manier het 
mogelijk nu nog onbekende virus betrokken bij de pathogenese van H L  op sporen. 
Hiervoor zullen in eerste instantie de SAGE banken van de HRS cellen en de CB 
nog verder worden uitgebreid. Door gen expressie profielen te maken van primair 
HL  materiaal kunnen we de HRS cellen karakteriseren en zal onze kennis over de 
pathogenese van HL toenemen. 
Op dit moment is de etiologie van cHL nog steeds niet opgehelderd en is met 
name nog onduidelijk of er wel of niet een andere infectieuze factor betrokken is bij 
de pathogenese van EBV negatieve cHL gevallen. Verdere studies met state-of­
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